

Annual Report 2006

OOA



Address

Oncology Graduate School Amsterdam OOA
VU medisch centrum
Kamer CCA 3.36
De Boelelaan 1117
1081 HV Amsterdam

phone : 020-4444054
e-mail : p.keblusek@vumc.nl
website : www.ooa-graduateschool.nl

Contents

Preface		5
1	Board and organization	9
2	General report	13
3	Educational activities	19
4	PhD research program	25
5	Awards	43
Annex 1	Faculty and staff	47
Annex 2	International visitors	59
Annex 3	PhD theses completed	63
Annex 4	Scientific publications	71



preface

Preface

The mission of the Oncology Graduate School Amsterdam (Onderzoekschool Oncologie Amsterdam - OOA) is to educate graduate students in basic and clinical cancer research, and to ensure proper supervision and mentoring of graduate students in the Amsterdam region. OOA's graduate students are scientist-in-training who receive additional theoretical and practical education on various subjects related to cancer.

OOA is a joint venture of the Netherlands Cancer Institute (Nederlands Kanker Instituut - NKI) and the medical faculties VU Medical Center (VUmc) and Amsterdam Medical Center (AMC) of the Free University Amsterdam (Vrije Universiteit - VU) and the University of Amsterdam (Universiteit van Amsterdam- UvA), respectively. These organizations strive for excellence in research and education in oncology, the realization of which is promoted by their participation in OOA.

The OOA research program ranges from basic molecular biology to clinical bedside research. It includes, for instance, fundamental studies on cellular signal transduction and the control of gene expression, but also clinical trials of new immunotherapeutic approaches and the development

of new tools to evaluate the quality of life in cancer patients. OOA organizes a range of educational activities, including specialized training courses, meet-the-expert sessions and an annual graduate student retreat.

This report describes the activities and scientific output of OOA in 2006. It includes detailed listings of our educational activities, such as training programs, and an overview of the scientific output, including listings of PhD theses completed and scientific papers published throughout the year 2006.

Executive Directors,

Prof.dr. G.A. Meijer (VU)
Prof.dr. T.K. Sixma. (NKI)
Prof.dr. J.P. Medema (UvA)

board and organization

1

1. Board and organization

Board

Prof.dr. A. Berns, chairman
Prof.dr. S. Rodenhuis
Prof.dr. H.M. Pinedo
Prof.dr. P. Postmus
Prof.dr. C.E.E. Konings
Prof.dr. D.J. Richel

Executive directors

Prof.dr. G.A. Meijer, chairman
Prof.dr. T.K. Sixma
Prof.dr. J.P. Medema

Founding institutes

Free University Amsterdam (VU)/ VU Medical Center (VUmc)
Administrative center
Contact / secretariat: dr. P. Keblusek
De Boelelaan 1117
1081 HV Amsterdam
phone : 020-4444054
fax : 020-4442964
email : p.keblusek@vumc.nl

University of Amsterdam (UvA)/ Academic Medical Center (AMC)
Contact / secretariat: dr. Y. Donselaar
Meibergdreef 15
1105 AZ Amsterdam
phone : 020-5668502
fax : 020-5669165
email : y.e.donselaar@amc.uva.nl

Netherlands Cancer Institute. (NKI)
Contact / secretariat: Ms. M. van der Velde
Plesmanlaan 121
1066 CX Amsterdam
phone : 020-5122015
fax : 020-5122029
email : m.vd.velde@nki.nl

Faculty and staff

The complete list of founding institutes' faculty and staff involved in educational activities and research projects conducted by OOA is provide in Annex 1.

general report

2

2. General report

Educational activities

The core activity of OOA is training PhD students in conducting cancer research. For this purpose, OOA has developed a high-quality curriculum. In 2006, OOA organized various graduate training courses and also the Annual Graduate Student Retreat.

All courses were evaluated by means of standard evaluation procedures. In this way, OOA carefully monitors the quality of its courses. Based on the outcome of these evaluations, the training programs are being improved continuously.

A detailed description of all training courses offered in 2006 is provided in chapter 3 of this Annual Report.

Research program

Research projects at OOA's institutes can be clustered under two main themes. The theme 'Experimental biology' covers 'Oncogenesis' and 'Tumor cell biology' as the main lines of research. The second main theme is 'Experimental clinical research' and covers 'Diagnosis of cancer' and 'Prevention and therapy of cancer'. Chapter 4 provides listings of all individual PhD projects conducted within these main themes. More detailed descriptions of these research programs and their output are provided in the annual reports of the founding institutes.

Theme 1: Experimental biology

The development of cancer is frequently associated with aberrations in cell signaling and signal transduction pathways. Transformation of a normal cell into a fully malignant cell requires multiple (sequential) genetic alterations affecting key genes controlling essential cellular pathways involved in cell division, proliferation, and apoptosis. Studying the genes and proteins involved in these pathways should result in a better understanding of the processes of tumorigenesis and tumor progression and should contribute to the development of novel diagnostic tools and better treatment strategies.

By applying innovative research tools, novel components of the major cancer-relevant pathways may be discovered. Tools applied in research projects include high-throughput methods for genetic, epigenetic, transcriptomic and proteomic analyses. Examples are gain-of-function

genetic screens with retroviral cDNA expression libraries, and loss-of-function genetic screens with RNA interference libraries. In addition, advanced mouse models have been developed for the genetic dissection of cancer.

At the cellular level, processes like cell-cell communication, cell-cell adhesion, cell migration and proliferation are being studied. Metastasis, the spread of tumor cells to distant sites in the body, is the main cause of cancer lethality. The mechanisms of metastasis of lymphomas and carcinomas are being investigated in the research projects.

The 'viral oncogenesis projects' focus the role of human papilloma viruses (HPVs) and Epstein-Barr virus (EBV) in the development of human cancers, like anogenital cancers (i.e. cervical cancer), head and neck cancer and lymphomas. Virus-induced oncogenesis is investigated using both in vitro models and clinically well-defined patient tumor samples. Viral and host markers are being tested in screening and clinical trials for their capability to assess the risk associated with the development of cancer. These markers have increased sensitivity and specificity compared to currently used methods.

Theme 2: Experimental clinical research

This theme focuses on the identification of new methods for the diagnosis, prognosis and individualized treatment of cancer. Early detection of cancer greatly increases the chance of a favorable outcome.

The emerging and rapidly growing fields of molecular imaging and genomics provide new opportunities to study the unique biology of a specific malignant disease in an individual patient. Combining an integrated research approach with clinical data collection and evaluation allows for the development of highly valuable indicators for the diagnosis and prediction of disease outcome in the individual patient. In our research, modern state-of-the-art CT and MRI machines enable imaging of anatomical details with high precision. In addition, imaging techniques like SPECT, PET, PET-CT and MRI, provide non-invasive methods to obtain unique molecular and biological information at the tissue level in vivo. For the purpose of molecular imaging studies, novel reporter probes are being developed and evaluated in (pre)clinical studies. In addition, by using the (advanced) mouse models available at the OOA institutes, new

clinical strategies for molecular imaging are being developed.

High-throughput tools are being applied to measure genetic variation and improve the criteria for disease classification. These tools include expression micro-arrays and CGH arrays for human and mouse studies. Quantitative mass spectrometry is being applied in the search for proteins capable of distinguishing between diseased and disease-free states with high sensitivity and specificity. The newly identified proteins may be used as specific cancer markers for routine non-invasive tests.

Cancer therapy is another important focus within this theme. This program includes research lines focused on targeted therapy, both by medical and radiotherapeutic means. Patient-tailored therapy should ensure that the benefits of a treatment are optimized and that patients who are unlikely to benefit, are spared the side-effects of treatment. The research projects include preclinical evaluation and clinical application of the new generation of molecular targeted therapies and anti-angiogenic agents against novel cellular targets in the tumor and its environment. The pharmacological optimization of conventional cytotoxic drugs is another line of research that is being studied.

The theme "Experimental clinical research" also focuses on passage of the blood-brain barrier by drugs. Inadequate passage of the blood-brain barrier is generally considered a major cause of the lack of efficacy of systemic chemotherapy against intracranial malignancies.

Yet another research line is focused on immune therapy. New immunotherapeutic approaches for the treatment of malignant disorders are being investigated. The impact of vaccination in the adjuvant and primary treatment settings is being explored.

Projects focused on radiotherapy and surgery is directed at the clinical implementation and optimization of 4-dimensional, image-guided approaches to improve local disease control by radiation treatment and to reduce toxicity to normal tissue.

In the gene therapy area, clinical trials are evaluating gene therapy in malignancy with the current focus on optimal targeting of tumors and improving viral vector efficacy.

PhD projects and students

Overall, 314 PhD projects were actively elaborated throughout 2006. A total number of 47 PhD students obtained their PhD degree in 2006. The names of the PhD students at the three OOA institutes and the projects in which they participated are listed in chapter 4. Of all PhD projects, 20% was funded by the participating institutes themselves (primary funding ; 'eerste geldstroom'); 20% was financed by public funds (secondary funding; 'tweede geldstroom') and 61% by private (including cancer charity) and industrial

funds (tertiary/quaternary funding; 'derde / vierde geldstroom').

International visitors

Training of PhD students can be stimulated and enhanced by having scientific interactions between students and foreign experts operating in the field of the students' research projects. OOA is part of a large international network of cancer researchers and, therefore, international guests from other research institutes visit OOA's institutes frequently to interact with OOA students and staff.

Throughout 2006, we welcomed 70 international experts in various settings (Annex 2).

Awards

Several PhD students and staff of the OOA institutes won prestigious awards and honors - scientific or otherwise - in 2006. Chapter 5 provides a listing of these awards and honors.

Scientific publications

Scientific output of OOA's research efforts takes shape mainly as scientific papers published in the literature and PhD theses produced by PhD students at the end of their training. A total of 47 students completed and defended their PhD thesis and obtained their PhD degree in 2006. Annex 3 provides the complete list of PhD students who obtained their degree in 2006 with details of their theses and graduation.

In 2006, the scientific output of the three institutes participating in OOA was again very impressive. It was a productive year with important new findings and scientific publications that received widespread recognition and were published in top scientific journals. A total of 950 publications have been published (with participation) by researchers from the three institutes combined. Of these, 31 papers were published jointly by researchers from different participating institutes in OOA. Annex 4 provides the complete list of scientific publications in 2006.

Facilities

Several events at the founding institutes have affected the activities of OOA in a positive way in 2006. Early in the year, the VUmc Institute for Cancer and Immunology (V-ICI) and the Cancer Center Amsterdam (CCA) merged into CCA/V-ICI. CCA/V-ICI is now one of the five research institutes within the VU University Medical Center. CCA/V-ICI was established to integrate all research efforts in oncology and immunology. Many researchers of this institute are based in the CCA research building that was opened officially on June 19, 2006. It

provides state-of-the-art facilities which will enhance the conduct of modern cancer research and improve scientific output, both in qualitative and quantitative terms. The new research facilities bring together under one roof several oncology research groups, promoting collaboration and cross-fertilization. One of the aims of CCA-V-ICI is to build bridges between clinical and preclinical research and thus promote the conduct of translational cancer research.

In 2006 at the AMC, a major effort has been the integration of seven individual research institutes into one combined institute, the AMC Research Institute, enabling closer cooperation between research groups. On April 13, 2006, the Executive Board of AMC installed the AMC Research Council / AMC Research Institute.

At the NKI, the renovated auditorium was opened. The auditorium, which seats 300, provides the NKI with a state-of-the-art facility for seminars, courses and scientific meetings. In addition, the former clinical building will be completely renovated and transformed into a modern research building in the course of 2007.



educational activities

3

3. Educational activities

In line with its mission, i.e. providing graduate students education in oncology research, OOA organizes several advanced courses in the field of oncology annually. The educational program is drawn up by the Board of Directors based upon evaluations of previous courses, contemporary developments in cancer research, and educational needs expressed by PhD students as well as initiatives from the OOA faculty. OOA offers courses focused on a wide variety of topics. As a follow-up to the recommendations by the site visit committee in 2002, the number of clinically oriented courses has been increased since.

In 2006, eight courses were organized. Courses are usually restricted to about 15-20 graduate students to ensure optimal interaction between students and faculty. Courses are advertised on the OOA website and announced by e-mail to the PhD students.

Focus of the courses ranged from anatomy and microscopy to histopathology of mouse and human tumors, and from discovery and expression regulation of cancer genes to proteomics. Courses included lectures given by (inter)national experts, demonstrations and practical training. In addition, the Annual Graduate Student Retreat was organized again in 2006.

Besides the specialized oncological courses mentioned below, the graduate students followed several general courses such as courses on biostatistics and epidemiology, on laboratory animal technology and on writing and (poster)presentations techniques in scientific English. These courses were organized by the AMC, VUmc and NKI.

Discovery of cancer genes and networks in model organisms

Organization: Dr. F. van Leeuwen
Dr. J. Jonker
Date: 31 January - 10 February
Location: NKI

The aim of the course 'discovery of cancer genes and networks in model organisms' is to give an in-depth view of how model organisms are invaluable for understanding problems involved in human disease. The course will consist of presentations by 9 or 10 national and international speakers who will discuss their work with you after the seminar. Papers selected by the speakers were studied in detail and discussed the papers in literature discussions groups before the seminars.

A total of 14 OOA PhD students participated in the course. The evaluation rate of the course was very good (8.3, scale 1-10).

Stem cell differentiation

Organization: Dr. G.J. Schuurhuis
Dr. F.J. van Millegen
Date: 16 - 18 January
Location: VUmc

Stem cell research and its applications in patient care are a rapidly emerging field. In this first course on stem cells, both the normal stem cell, its prevalence in different tissues and its application in both tissue engineering and anticancer therapy, and the malignant stem cell were covered. Theoretical backgrounds and practical implications were taught, and therefore demonstrations, practical work and lectures were all part of course

A total number of 16 PhD students (15 OOA PhD students) participated in the course. The overall evaluation rate was 7.5 (scale 1-10).

Anatomy of the mouse

Organization: Prof.dr. R. van Noorden
Prof.dr. W. Lamers
Date: 21 - 24 March
Location: AMC

Most biomedical PhD students perform animal experiments at some stage of their research career, but most students have never received practical instructions with respect to the anatomy, histology and pathological anatomy of experimental animals. For this reason, experimental animals are usually not subjected to a thorough and systematic inspection to assess whether, besides the local (expected) effects in the organ(s) under study, other organs are affected as well.

This annual course aims at providing insight(s) into the anatomy and histology of the mouse, presently the most frequently used animal species in cancer research. In addition, the course focused on the recognition of pathological changes in the mouse. During the course each student dissected either a male or a female mouse, to become acquainted with the topographic anatomy of this species. The microscopy part of the course focused on studying the architecture of normal and pathologically altered mouse tissues. During the practical part, recognition of cell and tissue types, and changes in architecture of tissues as a result of pathological processes, were studied microscopically. In addition to standard staining techniques, functional staining techniques were demonstrated.

A total of 31 students participated in the course (23 PhD students from the OOA, and 8 Master Oncology students). The evaluation rate of the course was a 7.9 (scale 1-10).

In the footsteps of Antoni van Leeuwenhoek

Organization: Prof.dr. C.J.F. van Noorden
Prof.dr. G.A. Meijer
Prof.dr. P. Peters
Date: 6 - 16 June
Location: AMC, NKI, VUmc

This six-day course covered a wide range of aspects of microscopy, starting with the basic principles of microscopy, preparation and staining methods of microscopic specimens, quantitative analysis of microscopic images, electron microscopy techniques and confocal laser scanning microscopy.

Lectures were given by international experts in the various fields of microscopy. Hands-on sessions related to all aspects of microscopy were also part of the course.

A total of 20 PhD students participated in the course. The overall evaluation rate was 4.1 (scale 1-5)

Protein structure and function

Organization: Prof.dr. T. Sixma
Dr. A Perrakis
Date: 29 September - 6 October
Location: NKI

Understanding the function of macromolecules - proteins, nucleic acids, et cetera - in the cell and deregulation that is the cause of cancer, is significantly enhanced by studying of the structure of macromolecules and their complexes in detail. The ability to map interactions back to atomic detail, to describe the effect of mutations, and to provide mechanistic insight are unique to this field.

The overall aim of this course was to teach molecular biologists how to use available structural information in their own research. This course provided an understanding of the principles of protein structure determination and an overview of complementary biophysical techniques that aid in studying protein mechanisms. This was presented in a series of lectures by experts, with introductory technical lectures and time to discuss issues afterwards. The course included a number of practical and literature session in which each student concentrated on known protein structures that are of relevance to their own research.

A total of 15 students participated in the course. The overall evaluation rate was 8.0 (scale 1-10).

Annual Graduate Student Retreat

Organization: Prof.dr. T. Sixma

M. Van der Velde
S. Boonen

Time: 11 - 13 October
Location: Texel

A highlight of the educational program is the Annual Graduate Student Retreat. This three-day retreat focuses entirely on research conducted by the graduate students themselves. At the retreat, students not only present their work as a poster in the first year of their participation and as an oral presentation in subsequent years, they are also in charge of chairing sessions, discussions. In recent years, students participated in peer review of presentations given by others in order to award the prize for the best poster and best presentation. In this manner, the retreat trains important skills in presentation and interaction but it also provides an overview of research conducted within OOA at an early stage of the student's career, contributing significantly to the interaction between different groups.

A total of 81 students participated this retreat.

Oncogenomics and proteomics: A sampler dish of techniques and applications

Organization: Dr. B. Ylstra
Dr. C. Jimenez
Time: 6 - 9 September
Location: VUmc

With the advent of high-throughput genome and proteome analysis including array and mass spectrometry technologies we are now able to study the human genome at a higher resolution than ever before and on a high-throughput manner. Research in this field is rapidly expanding and will have a large impact on our understanding of the prognosis and diagnosis of cancer. The course is designed to survey the development and application of post-genomic techniques for investigations of the human genome in relation to cancer from three elementary perspectives: DNA, RNA and protein.

PhD students could sign up for the theoretical and/or practical course.

A total of 84 students participated the theoretical part and 20 students the practical part of the course. The overall evaluation rate was 7.5 (scale 1-10).

Histopathology of tumors

Organization: Dr. N. van Grieken
Dr. E. Thunissen
Date: 21 and 27 November, 4 December
Location: VUmc

Many research projects focus on tumor biology in order to predict survival or therapy response, using DNA-, RNA- or protein-based tests. Also,

understanding biological mechanisms of a tumor may reveal new targets for future treatment. For this reason many PhD students in cancer research have a background of molecular biology and often little knowledge of clinical behavior of tumors or histological tumor characteristics. Although the number of clinical applications of molecular tests are rapidly increasing, in daily practice histopathological examination of tissue (together with imaging) still is the gold standard for diagnosis and staging of most tumors. In addition, the choice of treatment largely depends on clinicopathological variables.

Aim of the course was to give a basic introduction in the diverse histology of malignant tumors and their precursor lesions. Microscopical structures, growth patterns, grading and staging systems, and different cell types present in selected tumor types were explained and discussed by 6 pathologists each specialized in the particular field of interest.

A total of 15 OOA PhD students participated in the course. The overall evaluation rate was 4.5 (scale 1-5)

Biology of colorectal cancer risk

Organization: Dr. R. Fijneman
Prof.dr. G.A. Meijer
Time: 11 and 12 December
Location: VUmc

Colorectal cancer (CRC) is the second leading cause of cancer death in the Netherlands, as in most of the western world. Colon adenomas, the precursor lesions of CRC, have a high prevalence (30%) in the population over 60 years of age, while only 5% of these adenomas progress to carcinomas. Early diagnosis of non-malignant lesions is one realistic approach to reduce CRC mortality rates. Current developments in colon cancer research broaden our view on colon tumor development, and improve our capabilities to estimate an individual's colon cancer risk. In this course, we discussed: (i) what molecular mechanisms affect colon tumor development? (ii) what genetic factors increase colorectal cancer risk?

A total of 14 students participated in the course. The overall evaluation rate was 8.1 (scale 1-10).

PhD research program

4

4. PhD research program

This chapter describes the PhD projects conducted within the two main themes of the OOA research programs, with the names of the PhD students involved and their supervisor(s). Graduate students who obtained their PhD degree in 2006 are marked by means of an asterisk added to their name.

Funding

- 1 Financed by OOA institute (“eerste geldstroom”)
- 2 Financed by public funds (“tweede geldstroom”)
- 3-4 Financed by private funds (“derde / vierde geldstroom”)

Theme 1 Experimental Biology

<i>Name</i>	<i>Title of the project</i>	<i>Supervisor(s)</i>	<i>Start</i>	<i>Funding</i>
Cell Biology (NKI)				
J.I. van den Bout	The role of $\alpha 3 \beta 1$ integrin in the development and pathophysiology of the glomerulus	Sonnenberg	2000	3
S. Ellenbroek	Tiam1/Rac signaling and wnt/beta-catenin-induced tumorigenicity	Collard	2004	3
A. Hajdo-Milasinovic	Ras en Rho signaling networks and epithelial-mesenchymal transition	Collard	2001	3
S. Huveneers	Cooperation between the SRC oncogene and integrin $\alpha v \beta 3$ in oncogenic transformations of epithelial cells	Danen	2003	3
M. Ketema	Analysis of the function of a novel nuclear envelope protein, nesprin 3 in anchoring the nucleus to the intermediate filament system	Sonnenberg	2005	2
M. Langeslag*	Signalling function of membrane potential	Jalink	2000	1
S. Litjens*	The role of the integrin $\alpha 6 \beta 4$ in signal transduction controlling cell proliferation	Sonnenberg	1999	1
C. Margadant	Generation of a mouse model for EBS-MD	Sonnenberg	2006	4
J. Meijer	Role of the chemokine SDF-1 and its receptor CXCR4 in carcinoma and melanoma metastasis	Roos	2003	3
S. Mertens	Initiation and progression of lymphomas and skin carcinogenesis in Tiam1 mutant mice	Collard	2001	3
J. van Rheenen*	Localized phosphoinositide signals	Jalink	2000	2
T. Rygiel	Function based screening for genes involved in invasion of epithelial tumor cells	Collard	2002	3
N. Sachs	Function of integrin-CD151 complexes in tumor cell invasion and metastasis	Sonnenberg	2004	3
Cellular Biochemistry (NKI)				
C. Berkers	Chemistry-based functional proteomics, new tools for cancer biology	Oova	2004	1
F. Frederiks	The role of histone methylation in the regulation of gene expression	van Leeuwen	2004	4

<i>Name</i>	<i>Title of the project</i>	<i>Supervisor(s)</i>	<i>Start</i>	<i>Funding</i>
A. Houben	Autotaxin, a secreted lyso PLD: role in tumor progression	Moolenaar	2006	3
A. Los	Role of diacylglycerol kinases in cell cycle progression and cytoskeletal organisation	van Blitterswijk/ Moolenaar	2000	3
L. van Meeteren	LPA receptors: signaling, migration and proliferation	Moolenaar	2001	3
B. Ponsioen	LPA receptor signaling	Moolenaar	2003	3
A. van Rossum*	Contactin couples dynamic actin networks to cell migration and breast cancer	Moolenaar	1998	3
K. Verzijlbergen	The role of histone methylation in gene silencing and transcriptional memory	van Leeuwen	2005	2
L. van Zeijl	Cell-cell connexin signalling: suppression of cell transformation	Moolenaar	2000	3

Immunology (NKI)

A.H. Bakker	Analysis and manipulation of tumor specific T cell immunity	Schumacher	2002	2
A.D. Bins	Melanoma-specific Tcell immunity in advanced-stage melanoma patients	Borst	2001	1
M. Coccoris	Dissecting virus-specific cytotoxic T cell immunity	Kruisbeek	2000	2
C. Gerlach	Cellular barcoding and dissection of T cell differentiation	Schumacher	2005	1
M. Heideman	Role of translesion DNA synthesis in Immunity and Cancer Development	Borst	2005	2
J. van Heijst	Tracing lineage relationships by cellular barcoding	Schumacher	2004	3
A. Jorritsma	Analysis of vaccine-induced melanoma specific T-cell immunity: a combined human + mouse study	Haanen	2002	3
A.M. Keller	Cellular and molecular basis of effector and memory T cell responses	Borst	2002	1
P. Krijger	The role of post replication repair in lymphoma development an somatic hypermutation	Jacobs	2006	2
P. Langerak	Complementation tagging and lymphocyte development	Borst	2003	4
C. Maas	Apoptosis signalling of BH3-only protein Bid, mechanisms of action and modes	Borst	2004	3
K. Oosterhuis	Treatment of HPB positive penicle and cervical cancer by introduction of NPV7 special TCI	Schumacher	2006	2
V. Peperzak	The role of CD27/CD70-retulated cell survival in shaping effector and memory T cell responses	Borst	2004	2
K. Schepers*	Molecular analysis of the cytotoxic T cell response	Kruisbeek/ Schumacher	1999	1
S. Schnell*	Control of T-cell differentiation	Berns	2003	4
E. Veraar	TNF ligands in cancer: CD70	Borst	2006	4
I. Verbrugge	Tumor therapy with ionizing radiation and death ligand Trail efficacy and key mol. determinants	Borst/ Verheij	2004	3
M. Witte	Induction of T-cell immunity through adoptive transfer of T cell receptors	Borst	2003	2

Molecular Biology (NKI)

M. Aarts	High-throughput gene modification by single-stranded DNA oligonucleotides	Te Riele	2004	4
----------	---	----------	------	---

<i>Name</i>	<i>Title of the project</i>	<i>Supervisor(s)</i>	<i>Start</i>	<i>Funding</i>
R. Drost	Therapy responses of BRCA-mutated tumors and role of PALB2 in mammary tumorigenesis	Jonkers	2005	3
B. Evers	Mammary tumorigenesis in conditional tumor suppressor gene knockout mice	Berns	2003	2
F. Foijer*	Specific and redundant functions of the retinoblastoma suppressor gene family in growth control and differentiation	Te Riele	2000	3
P.-A. Genest	Function of a new modified base in DNA, β -D-glucosyl-hydroxymethyluracil (J) and its interaction with proteins	Borst	2001	2
T. Vormer	The identification of oncogenic events collaborating with loss of function of the retinoblastoma gene family in tumor development and progression	Te Riele	2003	3
B. van de Weerd*	Checkpoint function in mitosis	Medema	2001	2
E. Wielders	Subtle gene modification to study the role of the mismatch repair complex Msh2/Msh5 in mutation avoid	Te Riele	2004	3
Z.-J. Yu	Function of a new modified base in DNA, β -D-glucosyl-hydroxymethyluracil (J) and its interaction with proteins	Borst	2001	2
W. van Zon	Control of Mitosis by regulated protein destruction	Wolthuis	2004	1
Molecular Carcinogenesis (NKI)				
M. Epping	Molecular basis of anti-cancer activity of HDAC inhibitors	Bernards	2002	4
A. Fabius	Molecular barcode screens to identify genetic interactions with protein kinases in mammalian cells	Beijersbergen	2004	3
A.C. Faesen	3D repertoire	Sixma	2005	2
M. Creyghton*	Dephosphorylations of retinoblastoma family proteins by PP2A	Bernards	2000	3
E. Geutjes	The role of deubiquitinating enzymes in apoptotic signalling pathways	Bernards	2006	2
P. Knipscheer	Crystal structure determination of the components of an E2/E3 ligase ubiquitination system involved in cell cycle control	Sixma	1999	2
R. Kortlever	Senescence rescue screens	Bernards	2002	1
H.J. Kuiken	HCD/HT using RNAi technology	Bernards	2005	4
J. Mullenders	High throughput functional screens for stable loss-of-function phenotypes	Bernards	2003	3
F. Mattioli	Structural and functional analysis of a novel E3 ubiquitin ligase consisting of the pcp's BMI1 and ING1B	Sixma	2006	3
G. Natrajan*	Structural studies of DNA Mismatch repair	Sixma	1999	2
J. Nijwening	Development & application of shRNA in cell based screening technologies	Bernards	2005	4
K. Repanas	Function structure studies of components of the lines retroposition machinery	Perrakis	2001	2
A. Reumer	LI & Alu elements: Structural and functional analysis of human non-LTR retrotransposons	Sixma	2005	2
M. Vargas	Structural analysis of the mechanism of ubiquitin conjugation	Sixma	2004	2

Molecular Genetics (NKI)

<i>Name</i>	<i>Title of the project</i>	<i>Supervisor(s)</i>	<i>Start</i>	<i>Funding</i>
A. Alendar	Identificaiton of the PIM regulatory network by micro array analysis and high through put retroviral tagging	Berns	2002	3
E. Boutsma	Functional analysis of BMI-ring finger interacting proteins and application of microarray technology to identify BMI-1 response genes	Bernards	2000	3
U. Braunschweig	Genome-wide analysis of chromatin structure	van Lohuizen	2005	2
S. Bruggeman	Characterisation of oncogenic potential and mechanism of gene repression of TBX2	van Lohuizen	2003	3
T.Geiger	Oncogenic function of human DRIL1	Berns	2003	3
T. Kuilman	Novel functional genomic screens to identify pathways that protect mouse & human cells against oncogenic transformation by mutant RAS	Berns	2003	2
C. Michaloglou	Senescence-like replicative arrest in melanocytic naevi: a melanoma-suppressive mechanism?	Peeper	2003	1
E.H.M. van Montfort	Development of a mouse model to study the genetic basis of malignant mesothelioma	Berns	2000	3
M. Smit	The role of the neurotrophic tyrosine kinase receptor	Berns	2005	3
P. Taghavi	Functional analysis of MBI1-ring finger interacting proteins and application of microarray technology to identify BMI1-responsive genes	van Lohuizen	2000	3
V. Theodorou	Cloning of novel mammary tumor progression and metastasis genes	Hilkens	2001	2
J. van der Torre	Novel factors involved in chromosome end protection by telomeres	Berns	2006	3
Y. van der Velden	The role of Ikb1 in tissue morphogenesis and cancer zebrafish	Haramis	2006	2
J. Vissers	Regulation of histone H2A monoubiquitination by Ring 1b/Bmi1 and USP3 in DNA damage respons	van Lohuizen	2006	4
L. Vredeveld	The role and mechanism of escape from Ras induced senescence in oncogenesis	Peeper	2002	3
Tumor Biology (NKI)				
R. Bernad*	Identification of specific transport pathways through the nuclear pore complex	Fornerod	2001	2
J. Drost	Identification and characterization of human tumor suppressor genes in the p53 pathway	Agami	2005	3
J. van Duijse	Genome wide screens for DNA-damage check point in human cells	Agami	2005	4
A. Duursma	Activated proteolysis in response to DNA damage	Agami	2001	1
D. Engelsma	Synthetic transport signals to predict and regulate nucleocytoplasmic transport	Fornerod	2002	1
A. Griekspoor*	The peptide transport TAP inhibitor US6 as a lead to generate novel drug transporter inhibitors	Neefjes	2000	1
T. Groothuis*	Characterization of SNARES involved in degranulation of human CTLs	Peters	2000	2
J. Hendriksen	Role of the nuclear pore complex in B-type catenin nuclear signalling	Fornerod	2001	2
T. van den Hoorn	Defining the MHC class II microdomain to understand immune responses	Neefjes	2004	3

<i>Name</i>	<i>Title of the project</i>	<i>Supervisor(s)</i>	<i>Start</i>	<i>Funding</i>
D. Houben	Pathways of antigen presentation by CD1 a,b and c	Peters	2006	2
B. Kalverda	The role of RamBP3 in beta cetenin dependent nuclear signaling and oncogenesis	Fornerod	2004	3
M. Kedde	Studying tumorigenesi using RNAi	Neefjes	2003	3
R. Nagel	Genome wide search for DNA damage checkpoint functions in humans	Neefjes	2005	4
J. Neijssen	Peptidases and improving the MHC class I response	Neefjes	2002	2/1
B. Pang	Manipulation of phagosomal pathways	Neefjes	2006	2
P. Paul	Drugs for therapy	Neefjes	2006	2
J. Pierson	EG immunopriion immunological and structural studies of prion diversities	Peters	2006	4
N. Rocha	Structure elucidation of cord7 and complexe	Neefjes	2001	1
C. le Sage	Activated proteolysis, a novel rapid resopnse to DNA damage	Agami	2002	2
I. Salomon	Microban	Neefjes	2005	4
Y. Souwer	The role of HLA-DO and HLA-DM in effective MHC class II mediated immune activation	van Ham/ Neefjes	2001	2
A. Zwaagstra	Identification of novel mammary tumor progressions genes	Hilkens	2005	3
W. Zwart	Molecular basis of resistance to anti-estrogens	Michalides	2003	1
Clinical Genetics (VUmc)				
N. Ameziane	Role of Fanconi anemia genes in familial and sporadic breast cancer	Joenje/Pals	2004	2
S. Bakker	The Achillesheel of tumours with the Fanconi anemia phenotype	Joenje/te Riele	2005	1
E. Blom*	Structuur en functie van Fanconi anemie genen	Arwert / Joenje	2000	1
C.J. Dommering	Retinoblastoom en erfelijkheid	Meijers	2006	1
F. Léveillé*	Cloning and characterization of the Fanconi anemia genes FANCE and/or FANCF	de Winter / Joenje	1999	3
P. van der Lelij	The role of sister chromatid cohesion in the maintenance of genetic stability	Joenje / de Winter	2006	1
Medical Oncology (VUmc)				
B.G. Molenkamp	Immunomodulation of the melanoma sentinel lymph node	de Gruijl	2004	3
J.J. Lindenberg	Adenovirus-based and CD40-targeted in vivo tumor vaccination	de Gruijl	2006	2
Molecular Cellbiology and Immunology (VUmc)				
E.M. van Beek	SIRP-alpha-CD47 interactions in viral and tumor immunity	van den Berg	2003	1
G. van der Bij	Role of macrophages in peritoneal and liver metastasis	van Egmond / Beelen	2003	1
S.J. Oosterling*	Prevention of metastases outgrowth after surgery of primary colon carcinoma	Meijer/Beelen/ van Egmond	2006	1 / 3

<i>Name</i>	<i>Title of the project</i>	<i>Supervisor(s)</i>	<i>Start</i>	<i>Funding</i>
Obstetrics and Gynaecology (VUmc)				
B. Hermsen	Risk assessment and preventive measures in women at high risk of developing breast and ovarian cancer	von Mensdorff-Pouilly / Kenemans	2002	4
M.E. Nowee	Oncogenic factors in ovarian and tubal carcinoma	Verheijen	2002	4
Oral and Maxillofacial Surgery and Pathology (VUmc)				
J.F. Bremmer	Diagnosis and therapy of genetically altered mucosal lesions in the oral cavity and oropharynx	van der Waal / Brakenhoff	2002	1
P.K.E. Börjesson	Detection and therapy of head and neck cancer with radiolabeled anti-CD44v6 monoclonal antibodies	van Dongen / de Bree	2000	1
A.P. Graveland	Molecular diagnosis of head and neck squamous cell carcinoma (HNSCC)	Brakenhoff	2005	3
M. Moreno	Study of MUC1 as a target for the immunotherapy of patients with breast and ovarian carcinomas	Von Mensdorff-Pouilly / Scheper	2004	1
S. Smeets	Multi-step head and neck carcinogenesis	Brakenhoff	2003	1
B.M. Schaaij-Visser	A quantitative proteome progression model for squamous cell cancer	Brakenhoff	2004	4
H.J.T. van Zeeburg	Innovative therapies of precancerous lesions in the oral cavity and oropharynx	Brakenhoff	2004	1
Pathology (VUmc)				
L.J.W. Bosch	Methylation for Early Colorectal Cancer Detection	Meijer	2005	4
N.W.J. Bulkman	HPV-BOB	Snijders / Meijer	2001	2
S.A.G.M. Cillessen	Functional analysis of apoptosis signaling pathways in B-cell lymphomas	Oudejans / Meijer	2003	3
J. van Galen	Polycomb expression in normal human lymphocyte development	Meijer / Oudejans	2002	4
A. Hardebol	Functional characterization of chromosome 20q amplified genes suitable for CRC screening	Meijer	2005	4
F.E. Henken	Defining the essential molecular pathways involved in cervical carcinogenesis	Snijders	2005	1
A.T. Hesselink	HPV quantification in cervical smears: consequences for screening and management of women with equivocal cervical smears	Snijders / Meijer	2002	1
P.A.J. Krijnen	Epstein-Barr virus LMP1,2 specific immunoreactivity and immunotherapy in Hodgkin's Disease	Middeldorp	2005	3
D. Rijkaart	Stratifying high-risk HPV positive women for risk of CIN 3 and cervical carcinoma by HPV transcript analysis	Snijders / Meijer	2006	3
R.M. Overmeer	TSLC1 silencing, a marker for risk assessment of cervical cancer	Meijer	2005	3
R. van de Ven	ABC Transporters in dendritic cell function	Scheffer / de Gruijl	2003	3
J. de Wilde	Cervical carcinogenesis: unraveling of the multistep pathways using well-defined clinical material and in vitro cell culture model systems	Snijders / Steenbergen	2002	1
M. de Wit	Molecular imaging of colorectal cancer	Meijer / Fijneman	2006	4

<i>Name</i>	<i>Title of the project</i>	<i>Supervisor(s)</i>	<i>Start</i>	<i>Funding</i>
Cell Biology & Histology (AMC-UvA)				
J.M.E.D.Gillis	When protein degradation fails	Reits/ van Noorden	2005	2
H.A.G. Krol	Role of peptidases in polyglutamine disorders	Reits/ van Noorden	2004	1
P. Krawczyk	Double strands DNA breaks and their repair	Aten/ van Noorden	2003	3
Center for Experimental Molecular Medicine (AMC-UvA)				
J.W. van Baal*	Proteomics and expression-arrays for solving molecular mechanisms involved in the metaplastic transformation of inflamed squamous epithelium into Barrett's oesophagus	Peppelenbosch/ van Deventer	2002	3
S.A. Bleumink	Morphostasis of the adult gastrointestinal tract	Peppelenbosch/ van Deventer	2002	1
T. Borovski	Chromosomal aberrations and cancer stem cells	Medema	2006	3
H. Braat	Innovative feedingintervention in patients with chronic inflammation	van Deventer	1999	3
S.H. Diks	Tissue factor-dependent signalling	van Deventer	1999	2
F.F. van Doormaal	The association between hemostasis and cancer	Buller/ Richel	2006	1
K. Kemper	The role of cancer stem cells in tumorigenesis and metastasis in colon cancer	Medema	2006	1
L. Kodach	Early detection of colorectal cancer using proteomic technology	van Deventer	2003	3
A.M. Rygiel	Follow-up study of a cohort of Barrett's oesophagus patients by brush cytology and fish	van Deventer	2003	2
J.B. Tuynman	A phase II study on the effects of celecoxib on several pharmacodynamic endpoints, including activity of the Wnt/b-catenin pathway, apoptosis, proliferation, and angiogenesis in sporadic colorectal polyps and colorectal cancer in human	Richel/ van Deventer	2002	3
I. Vermeulen	Wnt signalling and cancer stem cells	Medema	2006	2
G. Hardenberg	The role of APRIL and its receptors in tumour growth and immune regulation	Medema	2003	3
F.B. Mullauer	Inventory of the anti-cancer efficacy of the plant-derived compound Betulinic acid and the clarification of the mechanisms underlying its induction of tumor-specific apoptosis	Medema	2005	3
Gastroenterology & Hepatology (AMC-UvA)				
W.A. Marsman*	Gene therapy for adenocarcinoma in esophagus	Oude Elferink	2000	2
N. van Til	Development of a method for hepatocyte transplantation and repopulation	Oude Elferink	2001	1

<i>Name</i>	<i>Title of the project</i>	<i>Supervisor(s)</i>	<i>Start</i>	<i>Funding</i>
F. Milano	Developing novel strategies for treating oesophageal cancer: dendritic cells immunotherapy	Krishnadath	2003	3

Development, Aging and Genetic Diseases / The Netherlands Ophthalmic Research Institute Amsterdam (AMC/UvA)

A.V. Kantardzhieva*	Crumbs and MAGUK proteins, from interaction to function	Berns/ de Jong/ Wijnholds	2001	2 / 3
---------------------	---	---------------------------	------	-------

Human Genetics (AMC-UvA)

A.C.J. Ammerlaan	Genetic profiling of gliomas and their recurrences for improvement of diagnosis and prognosis	Hulsebos / Versteeg	2002	3
J. Bunt	The role of OTX2 in medulloblastoma	Versteeg/ Kool	2005	1
H.J. Gierman	The human genome: understanding functional nuclear organisation from landmarks in the human transcriptome	Versteeg	2003	1
A. Koppen	Gene silencing by Myc-oncogenes	Versteeg	2001	3
I.M. Revet	The role of the MEIS homeobox genes in neuroblastoma pathogenesis	Versteeg	2003	3

Pathology (AMC-UvA)

E.M.J. Boon*	Regulation of cell adhesion and migration with inflammation and tumor metastasis; adhesion molecule CD44, growth factors, and receptor tyrosine kinases in the regulation of invasivity, metastases, proliferation and apoptosis of colon carcinomas	Pals	2000	3
D. Gorter	Functional and molecular analysis of HGF/Met signaling in germinal center B cells and B cell neoplasia	Pals	2000	3
R. Groen	Heparan sulfate proteoglycans and HGF activator in HGF/MeT-signaling and lymphomagenesis	Pals/ Spaargaren	2003	2
R.M. Reijmers	The role of heparan sulphate proteoglycans in B cells and multiple myeloma	Pals/ Spaargaren	2003	2

Pediatric Surgical Center, Emma Children's Hospital (AMC / UvA)

J.M. Schnater*	The way forward in hepatoblastoma. A study of epidemiology, gene expression patterns, and the development of a tumor model	Lamer/ Heij/ Aronson	1999	3
----------------	--	----------------------	------	---

Theme 2: Experimental Clinical Research

<i>Name</i>	<i>Title of the project</i>	<i>Supervisor(s)</i>	<i>Start</i>	<i>Funding</i>
Clinical Oncology (NKI)				
B. Kroon jr.*	Dynamic sentinel node biopsy & predictive factors for regional metastases in penile cancer	Horenblas	2003	1
S. Mook	Prognostic profiling in breast cancer	Van 't Veer	2006	2
Experimental therapy (NKI)				
F. Greil*	Chromatin Profiling	van Steensel	2002	1
J. Hannemann	Micro array analysis of breast cancer as a diagnostic tool to guide optimal treatment	van de Vijver	2002	3
A.E. van Herwaarden	Generation and validation of cytochrome 450 3A k-o and transgenic mice as tools for improved DDR	Schinkel	2001	3
H. Horlings	Genetic classification of breast cancer	van de Vijver	2006	2
H. Janssen*	Hypoxia and perfusion in human tumors: quantification and implications for treatment outcome	Begg/ Hausterman	2000	3
M. Joerger	Pharmacogenetics in solid tumor patients	Schellens/Beijnen	2003	3
M. Kok	Molecular prediction of therapy outcome in breast cancer	Van 't Veer	2004	4
J. Lagas	Impact of the multidrug transporters p-glycoprot., MRP2 and BCRP on the behaviour of anti-cancer drugs	Schinkel	2004	4
S. Neijenhuis	Determinants of radiosensitivity	Begg	2003	3
R. Oostendorp	Preclinical and clinical pharmacology of oral drugs	Schellens/Beijnen	2004	4
D. Peric-Hupkes	Chromatin Profiling of Human gene silencing complexes	van Lohuizen	2004	3
J. Prama	Gene expression profiling to predict outcome after chemoradiation in head and neck cancer	Begg	2005	3
E. van der Steeg	The impact of OATP drug carriers on in vivo pharmacology toxicology & physiology	Beijnen	2004	4
M.L. Triesscheijn*	mTHPC-mediated photodynamic therapy (PDT): how do drug uptake and distribution influence tumor and normal tissue respons?	Stewart/Baas	2001	3
S. Veltkamp	Clinical Pharmacology of oral gemcitabine and other (oral) anti-cancer agents	Schellens/Beijnen	2003	4
C. Vermeulen	Determinants of radiosensitivity	Begg	2002	3
M. Vlaming	Compound Mrp2 (Abcc2) and other drug transporter knockout mice to study determinants ...	Schinkel	2003	3
M. Vogel	Functional Genomics of Gene Regulation by heterochromatin proteins	van Steensel	2002	3
A. Vrieling	The IGF system in breast and colorectal carcinogenesis: dietary intervention and mol. studies	van Leeuwen	2002	3
R. van Waterschoot	Generation and validation of cytochrome P450 3A knockout and transgenic mice as tools for...	Beijnen	2005	2
E. de Wit	Bioinformatics of transcription regulation	van Steensel	2003	1

Medical Oncology (NKI)

D. Boss	Clinical pharmacology of anticancer drugs	Schellens	2005	4
J. Bueno de Mesquita	Predictive and prognostic factors in breast cancer	Linn/v.d. Vijver	2003	4
M. Deenen	Clinical pharmacology and pharmacogenetics of fluoropyrimidine anti-cancer agents	Schellens/Beijnen	2006	4
R. Keizer	Population pharmacokinetics and pharmacodynamics of investigational anti-cancer agents	Schellens/Beijnen	2006	4

Pharmacy and Pharmacology (NKI)

T. Bosch*	PK/PD and pharmacogenetics of anticancer drugs	Beijnen	2002	4
E. Brouwers	Bioanalyse van metalen (i.h.b. Platina) in biologische matrices m.b.v. ICP-MS	Beijnen	2003	4
C. Ekhart	Genotyping as tool for dose individualization in high-dose chemotherapy	Huitema	2006	3
J. Engwegen	Clinical proteomics	Beijnen	2003	4
M.C. Gast	Proteomics in Oncology	Beijnen	2003	4
M. Klous	Pharmaceutical development of diacetylmorphine formulations	Beijnen	2001	4
S. Koolen	Oral administration of anti-cancer agents	Schellens/ Beijnen	2006	4
S. van der Schoot	Pharmaceutical development of anti cancer agents	Beijnen	2002	1
L. Tran	High-dose 121I-labelled rituximab in the treatment of non-Hodgkin lymphomas	Beijnen	2006	4
A. Zandvliet	Population pharmacokinetics & pharmacodynamics of investigational anticancer drugs	Beijnen	2003	4

Psychosocial Research and Epidemiology (NKI)

S. v.d. Belt-Dusebout	Risk of second malignancy and cardiovascular disease after treatment for testicular cancer	van Leeuwen	2003	3
K. Douma	Long-term psychosocial impact of genetic testing among familial adenomatous polyposis families	Aaronson	2004	3
M. Hooning	Long term risk of second cancers following treatment of Hodgkin's disease, testicular cancer and breast cancer	van Leeuwen	2000	3
B. Kreukels*	Effects of chemotherapy on cognitive skills and evoked potentials in women receiving adjuva treatment for breast cancer	van Leeuwen	2000	3
C. Lammens	LFS-VHI-study -> Psychosocial aspects of genetic testing in families at high risk of multiple tumors	Aaronson	2005	3
V. Retèl	Constructive technology assessment in an early stage of clinical implementation of microarray testing for node-negative breast cancer patients	van Harten	2006	4
A. van Rosmalen	The role of early life-style factors in the etiology of breast cancer	Rookus	2001	4
C. Schilder	Assessment of neuropsych. sequelae of tamoxifen & exemestane in postmenopausal women with EBC	van Dam/ Schagen	2003	4
J. Verloop	Physical activity and breast cancer risk	Van Leeuwen	1997	3

Radiotherapy (NKI)

G. Borst	Optimization of conformal radiation therapy of non-small cell lung cancer by advanced 3-D planning	Lebesque	2003	3
L. McDermottt	Dose verification and dose optimization of radiotherapy using portal imaging	Mijnheer/ van Herk	2001	1
M. Smitsmans	On-line tomographic guidance for RT of the prostate	Bartelink	2003	4
S. Vink	Improvement of tumor response by combined modality treatment: a translational approach	Verheij	2001	3
J. Wolthaus	Optimization of conformal RT of nonsmall cell lung cancer by advanced 3-D planning	Bartelink	2003	3

Gastroenterology (VUmc)

J.S. Terhaar sive Droste	Colorectal polyps and cancer in Amsterdam	Craanen	2005	3
--------------------------	---	---------	------	---

Obstetrics and Gynaecology (Vumc)

E.M. Davelaar	Serum tumour markers in cervical carcinoma	Verstraeten	2004	2
M. Verbruggen	Clinical and molecular aspects of borderline ovarian tumours	Dorsman	2002	1

Hematology (VUmc)

N. Feller*	Detection and eradication of minimal residual disease in acute myeloid leukaemia	Ossenkoppele / Schuurhuis	2002	2
C. Hess	The nature of minimal residual disease in acute myeloid leukemia	Schuurhuis / Ossenkoppele	2002	3
I. Houtenbos*	Leukemic dendritic cell vaccination in minimal residual disease in acute myeloid leukemia	Ossenkoppele / v d Loosdrecht / Scheper	2001	1
M. Terwijn	Detection of residual leukemic stem cells during minimal residual disease in AML	Schuurhuis / Ossenkoppele	2006	3
W. van den Ancker	Optimizing strategies in dendritic cell vaccination in myeloid leukaemia	v.d. Loosdrecht / Ossenkoppele	2006	1
M. van Luijn	Regulation of MHC class-II in acute myeloid leukemia and its impact on immunoserveillance	v.d Loosdrecht / Ossenkoppele	2006	3
A. van Rhenen	The nature of primitive clonogenic aml cells and the role in emergence of minimal residual disease in AML	Schuurhuis / Ossenkoppele	2002	4
J. Zijlstra-Baalbergen	Response monitoring in non-Hodgkin's lymphoma using Positron Emmission Tomography	Huijgens / Lammertsma	2003	1

Medical Oncology (VUmc)

A. Adema	Development of novel strategies to optimize cytotoxic and targeted therapy	Peters	2003	4
J.H. Augustijn-Savonije*	Effects of erythropoietin in cancer patients	Giaccone/ Marx	1999	4
M.N.A. Bijman	Docetaxel: its role in the inhibition of angiogenesis and the mechanism for induction of apoptosis	Boven / Hoekman	2001	3

I. Bijnsdorp	Enhancement of trifluorothymidine cytotoxicity by docetaxel	Peters	2005	3
A. Checinska	The role of caspases in the sensitivity of lung cancer cells to chemotherapy	Kruyt / Rodriguez	2002	3
H. van Cruijsen	Clinical trials with receptor tyrosine kinase inhibitors in patients with advanced cancer	Hoekman	2004	3
M.L. Janmaat*	Mechanisms of cytotoxicity of EGFR pathway inhibitors in epithelial cancers	Rodriguez / Kruyt	2000	4
M.I. Gallegos Ruiz	Mutational and functional analysis of the EGFR pathway in NSCLC patients: correlation with prognosis and response to small molecule EGFR inhibitors	Giaccone	2005	3
C. Lemos	Folate supplementation in chemotherapy: increase of efficacy versus induction of drug resistance	Peters	2005	3
J. Sigmond	Interaction of gemcitabine with novel molecular targets	Peters	2002	4
B. Vischioni*	Nuclear/cytoplasmic shuttling of inhibitor of apoptosis proteins (IAP) as a regulatory mechanism for tumor progression	Rodriguez / Giaccone	2001	3
J. Voortman	Efficacy and mechanism of combination therapy with proteasome inhibitor PS-341 (Velcade(tm)) in NSCLC	Kruyt / Giaccone	2003	4
L. Vroling	Circulating endothelial cells as markers for anti-angiogenic therapy	Broxterman	2005	3
T. Würdinger*	The development of tumor-selective coronaviruses as anti-cancer agents	Rottier / Gerritsen / van Beusechem	2001	3
Medical Psychology (VUmc)				
J. van Dijk	Psychosocial functioning and quality of life of retinoblastoma survivors and parents in the Netherlands	Imhof	2004	3
Neurology (VUmc)				
I. Bosma	Health-related quality of life and neurocognitive functioning of long-term surviving high-grade glioma patients / Synchronized brain activity and neurocognitive function in brain tumor patients: a MEG study / Efficacy and toxicity of cerebral glioma treatment	Klein / Stam / Postma	2004	4
Neurosurgery (VUmc)				
S. Idema	Improving oncolytic viral therapy for glioma	Dirven / Lamfers	2003	4
Nuclear Medicine (VUmc)				
W. Direcks	Experimental and clinical studies using positron emission tomography (PET) for monitoring response to chemotherapy in (locally) advanced breast cancer	Molthoff / v.d. Wall	2003	3
J. Emmering	Towards a rational use of PET in breast cancer patients	Teule	2003	1
G.J.M. Herder*	The introduction of PET in clinical oncology: evaluation in non-small cell lung cancer	Teule	2003	2
A.J. de Langen	Restaging the mediastinum after induction chemotherapy for stage IIIA-N@ NSCLC: biological determinants of FDG-PET results	Hoekstra	2005	1

Orthopedics (Vumc)

M.A. Witlox*	Gene therapy of osteosarcoma. Preclinical studies with adenoviral vectors and adenoviral oncolysis	Wuisman / van Beusechem / Gerritsen	2000	2
--------------	--	-------------------------------------	------	---

Otolaryngology / Head and Neck Surgery (VUmc)

J. Brouwer	Investigation into cost-effectiveness of diagnostic algorithms of patients with head and neck cancer to prevent unnecessary treatments	Leemans	2000	1
C.D.L. van Gogh	Voice therapy for patients with voice problems after treatment for early glottic cancer / Voice after laryngectomy by means of a sound-producing tracheoesophageal shunt valve	Mahieu	2002	2
A.M. Lo Galbo	Hypothyroidism after treatment for laryngeal cancer	Leemans	2005	1
I.M. Oskam	Health related quality of life in head and neck cancer patients	Leemans	2004	1
L.R. Perk	Molecular imaging with PET using long-lived positron emitters	van Dongen	2003	2
L. van der Putten	FDG-PET for avoidance of futile direct laryngoscopies under general anesthesia with taking of biopsies in patients with suspicion on recurrent laryngeal carcinoma after radiotherapy	Leemans	2005	3
A. Senft	Screening for distant metastases and second primary tumors with FDG-PET (the school study)	Leemans	2002	2
B.M. Tjink	Antibody-based therapy with emphasis on head and neck cancer	Van Dongen / de Bree / Leemans	2003	3

Pathology (VUmc)

T. Buffart	Predicting lymph node status in gastric cancer by DNA-based genomic profiling for stratifying surgical therapy	vd Velde / Meijer	2004	3
E.A. Greijer	Early pathogenesis and intervention in Epstein-Barr virus (EBV) driven post-transplant lymphoproliferative disease (PTLD) in stem cell (SCT) and solid organ transplant (SOT) recipients	Middeldorp	2005	3
A. Hardebol	CRC screening by faeces DNA based testing using chromosome 20q genes	G.A. Meijer	2005	4
I. van Houdt	Involvement of resistance to apoptotic cell death in the response to immunotherapy	Kummer / van den Eertwegh	2003	1
J. Molling	Anti-tumor effector functions of skewed natural killer T cells	Scheper / von Blomberg	2002	3
J.F.M. Muris*	Expression profiling and clinical outcome in primary nodal diffuse large B-cell lymphomas	Meijer / Oudejans	2000	1
D. Purnomosari*	Molecular analysis of early onset Indonesian breast cancer	Van Diest / Pals	2003	3
S. Santegoets	Dendritic and T cell functions in patients with metastatic hormone-refractory prostate cancer treated with Prostate GVAX cancer immunotherapy and Ipilimumab	de Gruijl	2002	3
Q.J.M. Voorham	Increasing sensitivity for detection of high risk flat adenomas in population screening for colorectal cancer	G.A. Meijer	2006	3

S.M. Wilting	Distinction of early, intermediate and late cervical intraepithelial neoplasia grade III (CIN III) lesions by micro-array analysis	Snijders / Steenbergen	2003	3
Pediatrics (VUmc)				
N. Franke	Drug resistance in childhood leukemia	Cloos / Kaspers	2006	4
B.F. Goemans	Cellular resistance to conventional and targeted anticancer agents in relation to molecular biological features in childhood relapsed and refractory acute myeloid leukemia	Kaspers / Zwaan	2002	4
I. Hubeek	Tyrosine phosphatases as new targets in childhood cancer	Cloos	2005	3
M. Luttjeboer	Ex vivo radiosensitivity and modification by anticancer agents in pediatric brain tumors	Kaspers / Sminia	2002	4
S. Mostert	Compliance with chemotherapy in childhood acute lymphoblastic leukemia in a developing country	Veerman	2003	4
J. Vink	Glucocorticoid-induced apoptosis and glucocorticoid resistance in lymphoid malignancies and autoimmune diseases	Kaspers	2001	3/4
D.G. van Vuurden	Targeted therapy in pediatric brain tumors	Kaspers	2005	1
Pulmonology (Vumc)				
S.A. Smulders*	Patients with resectable lung cancer: preoperative selection and postoperative function	Postmus	2002	4
R. van den Berg	The use of molecular biomarkers in early lung cancer	Snijders / Smit	2003	2
H. van Tinteren*	Assessing the value of FDG-PET in lung cancer: from theory to practice	Boers / Teule / Hoekstra	2000	1
Radiology (VUmc)				
P. de Graaf	Clinical and experimental high resolution ocular MR Imaging: towards improved detection of retinoblastoma tumor extent	Castelijns	2006	3
R. Ljumanovic	Prognostic value of MRI-determined lymph node parameters in development of distant metastases in head and neck carcinoma	Castelijns	2003	3
J.H. Weijs	Optimization of US selection criteria of lymph nodes (size, laterality, aspect and behaviour) to perform USgFNAC in follow-up of patients's oral cavity or oropharyngeal carcinoma	Castelijns	2005	2
Radiotherapy (VUmc)				
R.W.M. Underberg*	Clinical implication of 4-dimensional radiotherapy for treatment of lung cancer	Senan / Slotman	2003	1
K.A. van Nifterik	Malignant glioma genetics and related chemo-radiosensitivity as guidance for individualized therapy	Sminia / Hulsebos	2002	1/3
Surgery (VUmc)				
R.P.M. Brosens	Tumor profiling for prediction of clinical outcome in colorectal cancer patients	Cuesta / G.A. Meijer	2006	3

H. Fabry	Strategy and results in early breast cancer	Meijer	2003	1
G. Melis	Quantifications of the generation of arginine in the kidney during liver surgery	Van Leeuwen	2001	2
M.P.C. Siroen	ADMA clearing after liverresection for metastatic cancer	Van Leeuwen/ van der Sijp	2002	2
H. Torrença	Sentinel node procedure in breast cancer as a routine in daily practice	Pijpers	2002	3
R.J.C.L.M. Vuylsteke*	Clinical and immunological aspects of the sentinel lymph node procedure in melanoma	Van Leeuwen / Meijer / Scheper	2000	3
M. Westerterp	The role of FDG PET in esophageal cancer staging and monitoring the response to neoadjuvant therapy	Molthoff	2005	2
Urology (Vumc)				
A. Mol	New experimental markers for early detection of high-risk prostate cancer	Van Moorselaar / Geldoff	2006	3
Gastro-enterology & Hepatology (AMC-UvA)				
M.A. van Geer	Development of infectivity enhanced conditionally replicating adenovirus vectors for gene therapy of pancreatic cancer	Oude Elferink	2002	3
Hematology (AMC - UvA)				
D. Hallaert	Novel therapeutic approaches to attack the microenvironment in Chronic Lymphocytic Leukemia	Van Oers/ Eldering	2004	3
A.P. Kater*	Novel apoptosis inducing strategies in chronic lymphocytic leukemia	Van Oers/ Kipps/ Eldering	2002	2
M.J. Wondergem	Can transformation of indolent lymphoma be detected at an early stage by PET scanning?	Huijgens / Hoekstra	2006	1
Medical Oncology (AMC-UvA)				
S.J. de Kort	Ethical aspects of palliative cancer chemotherapy	Willems/ Richel	2003	3
Pathology (UvA/AMC)				
R. Carvalho*	Molecular genetic changes during gastric carcinogenesis	Offerhaus	2002	1
W.W.J. de Leng	Carcinogenesis in het Peutz-Jehgers syndroom	Offerhaus	2002	3
Pediatric Oncology (AMC-UvA)				
E.J. Aukema	Late consequences and needs of young survivors of a brain tumor and their parents	Last/Schouten/ Grootenhuis	2006	1
R. Cuperus	Modulation of fentetinide induced cell death in neuroblastoma	Caron/ Kuilenburg	2004	3
V. Engelen	QLIC-ON quality of life in childhood oncology	Versteeg/ van Nes	2005	3
J.J. Molenaar	Delineating the biological and clinical importance of CyclinD1 in neuroblastoma	Caron	2000	1
E.C. van Dalen	Anthracycline-induced cardiotoxicity in childhood cancer	Caron	2002	3

J. Stutterheim	MRD monitoring at children with neuroblastoma	Caron/ Tytgat	2006	3
Radiotherapy (UvA/AMC)				
J. Bergs	Aberrations in premature condensed chromosomes(PCC) as a predictive assay for the response of human cervical carcinomas after radiotherapy combined with hyperthermia	Haveman/ Konings	2002	1
H.P. Kok	Development of an new dual modality heating technique form treatment of cancer at the esophagus and other intracavitary locations	Crezee/Konings	2002	3
A.L.J. Uitterhoeve	Results of radiotherapy alone or in combination with chemotherapy in non small cell lung cancer	Gonzalez	1998	1
Surgery (AMC/UvA)				
R. Bakx	Pouch versus STE-anastomoses bij rectum-carcinoom	Van Lanschot	2001	3
S. Dinant*	Strategies to improve outcome after partial liver resection	van Gulik/ Gouma	2001	4
M.C. Janssen	Locale ablatie van levertumoren: het effect van radiofrequente thermoablatie, interstitiele lasercoagulatie en cryoablatie op de acute fase immuunreactie en stollingsactivatie in de rat	Van Gulik	2001	3
M. Westerterp*	Improving and simplifying diagnostic evaluation of oesophageal cancer with a combination of EUS-FNA and PET	van Lanschot	2002	2
Urology (AMC-UvA)				
C.A. Mochtar*	Prognostic factors for clinical progression after treatment of BPH	De la Rosette/ Debruyne/ Kiemerney/ Laguna-Pes	2000	4
P. Beemster	Cryosurgery of small renal tumors	De la Rosette/ Laguna/ Wijkstra	2005	1

awards

5

5. Awards

This chapter lists awards and honors won by staff and students involved in OOA throughout 2006. The lists are in alphabetical order of the recipients' last name.

Scientific awards and honors

H. Bartelink. (NKI) was the recipient of the bi-annual Regaud Medal Award of the European Society of Therapeutic Radiation and Oncology (ESTRO). He also received the Kilroe Award at the meeting of the Coloprotology Section of the Royal Medicine Society.

A. Berns. (NKI) received the first Massachusetts General Hospital Award in Cancer Research.

K. Borensztajn (AMC) received a poster prize at the 46th Annual Scientific meeting of the British Society of Haematology, Edinburgh, for the abstract: Borensztajn KS, Bijlsma MF, Groot AP, Brüggemann LW, Versteeg HH, Reitsma PH, Peppelenbosch MP and Spek CA. Coagulation factor Xa drives tumour cells into apoptosis through BH3-only protein Bim upregulation.

B. Goeman (VUmc) received the Chris Meijer Award at the V-ICI annual plenary meeting.

J. van der Heijden (VUmc) received the AGIKO Rheumatology Grant of the "Nederlandse Vereniging voor Reumatologie" (Euro 15,000).

A. Kater (AMC) won the Van Vlissingen Award for best thesis on lymphoproliferative diseases over the last 3 years.

A. van de Loosdrecht (VUmc) won the Young Investigators Award of the MDS Foundation, Atlanta, for his work on "Multicolour Flow Cytometry in Myelodysplastic Syndromes" (USD 40,000).

S. Mostert (VUmc) won the poster prize in the section psychosocial research at the International Society of Paediatric Oncology Meeting, Geneva.

M. Sitaresmi (VUmc) won the poster prize in the section health care and economic research at the International Society of Paediatric Oncology Meeting, Geneva.

S. Slofstra (AMC) won a poster prize at the 46th Annual Scientific meeting of the British Society of Haematology, Edinburgh, for the abstract: Slofstra SH, Groot AP, Aberson HL and Spek CA. Microarray analysis points towards C/EBPdelta as a novel mediator in endotoxin-induced DIC.

H. Vékony (VUmc) won the 1st prize for an oral presentation at the "Pathologendagen", Ede, and the 2nd prize for the oral presentation at the OOA Annual Graduate Student Retreat, Texel.

I. van der Waal (VUmc) was appointed Honorary Member of the International Association of Oral Pathologists, Brisbane, Australia.

General awards and honors

P. Borst. (NKI) was awarded the honor of "Commander of the Order of the British Empire".

A.J.P. Veerman (VUmc) was awarded the honor of "Officier in de Orde van Oranje Nassau" during the International Congress on Childhood Leukemia, Noordwijkerhout.

J. van der Heijden (VUmc) was awarded the honor of "Ridder in de Orde van de Nederlandse Leeuw".

faculty and staff

annex

1

Annex 1.

Faculty and staff of OOA

Faculty

Prof.dr. N.K. Aaronson (Theme 2)
Department of Psychosocial Research and
Epidemiology
Netherlands Cancer Institute

Dr. R. Agami (Theme 1)
Department of Tumor Biology
Netherlands Cancer Institute

Dr. J.A. Aten (Theme 1)
Department of Cell Biology and Histology
Academic Medical Centre / Universiteit van
Amsterdam

Prof.dr. G.M.M. Bartelink (Theme 2)
Department of Radiotherapy
Netherlands Cancer Institute

Prof.dr. A. Begg (Theme 2)
Department of Experimental Therapy
Netherlands Cancer Institute

Dr. R. Beijersbergen (Theme 1)
Department of Molecular Carcinogenesis
Netherlands Cancer Institute

Prof.dr. R. Bernards (Theme 1)
Department of Molecular Carcinogenesis
Netherlands Cancer Institute

Prof.dr. A.J.M. Berns (Theme 1)
Department of Molecular Genetics
Netherlands Cancer Institute

Prof.dr. J.H. Beijnen (Theme 2)
Division of Pharmacology
Netherlands Cancer Institute

Prof.dr. J.G. Borst (Theme 1)
Department of Immunology
Netherlands Cancer Institute

Prof.dr. P. Borst (Theme 1)
Department of Molecular Biology
Netherlands Cancer Institute

Prof.dr. R.H. Brakenhoff (Theme 1 and 2)
Department of Otolaryngology-Head & Neck
Surgery
VU University Medical Center

Prof.dr. H. N. Caron (Theme 1 and 2)

Pediatric Oncology
Academic Medical Centre / Universiteit van
Amsterdam

Dr. J.G.N.M. Collard (Theme 1)
Department of Cell Biology
Netherlands Cancer Institute

Dr. J. Crezee (Theme 2)
Department of Department of Radiation Oncology
Academic Medical Centre / Universiteit van
Amsterdam

Prof.dr. G.A.M.S. van Dongen (Theme 1 and 2)
Department of Otolaryngology-Head & Neck
Surgery
VU University Medical Center

Dr. E.F. Eldering (Theme 1)
Department of Experimental Immunology
Academic Medical Centre / Universiteit van
Amsterdam

Dr. D. Geerts (Theme 1)
Department of Human Genetics
Academic Medical Centre / Universiteit van
Amsterdam

Dr. W.R. Gerritsen (Theme 2)
Department of Medical Oncology
VU University Medical Center

Prof.dr. D.J. Gouma (Theme 2)
Department of Surgery
Academic Medical Centre / Universiteit van
Amsterdam

Prof.dr. G. Giaccone (Theme 2)
Department of Medical Oncology
VU University Medical Center

Dr M. A. Grootenhuys (Theme 2)
Department of Pediatrics
Academic Medical Centre / Universiteit van
Amsterdam

Prof.dr. T.M. van Gulik (Theme 2)
Department of Experimental Surgery
Academic Medical Centre / Universiteit van
Amsterdam

Prof. Dr. A. Hagenbeek (Theme 1 and 2)

Department of Hematology
Academic Medical Centre / Universiteit van
Amsterdam

Dr. J. Haanen (Theme 1 and 2)
Department of Immunology
Netherlands Cancer Institute

Prof. Dr. M. van Herk (Theme 2)
Department of Radiotherapy
Netherlands Cancer Institute

Prof.dr. O.S. Hoekstra (Theme 2)
Department of Nuclear Medicine
VU University Medical Center

Prof.dr. P.C. Huijgens (Theme 1 and 2)
Department of Haematology
VU University Medical Center

Dr T.J.M. Hulsebos (Theme 1)
Department of Neurogenetics
Academic Medical Centre / Universiteit van
Amsterdam

Dr. K. Jalink (Theme 1)
Department of Cell Biology
Netherlands Cancer Institute

Prof.dr. H. Joenje (Theme 1)
Department of Human Genetics
VU University Medical Center

Dr. J. Jonkers (Theme 1)
Department of Molecular Biology
Netherlands Cancer Institute

Dr. G.J. Kaspers (Theme 2)
Department of Paediatrics
VU University Medical Center

Prof.dr. C.C.E. Koning (Theme 2)
Department of Radiotherapy
Academic Medical Centre / Universiteit van
Amsterdam

Dr. M. Kool (Theme 1)
Department of Human Genetics
Academic Medical Centre / Universiteit van
Amsterdam

Prof.dr. Y. van Kooyk (Theme 1 and 2)
Department of Molecular Biology and Immunology
VU University Medical Center

Dr. K.K. Krishnadath (Theme 1)
Department of Gastroenterology and Hepatology
Academic Medical Centre / Universiteit van
Amsterdam

Dr. A. B.P. van Kuilenburg (Theme 1 and 2)
Department of Clinical Chemistry
Academic Medical Centre / Universiteit van
Amsterdam

Prof.dr. A.A. Lammertsma (Theme 2)

Department of Nuclear Medicine
VU University Medical Center

Prof.dr. Ch.R. Leemans (Theme 2)
Department of Otolaryngology-Head & Neck
Surgery
VU University Medical Center

Prof. dr. A.G.J.M. van Leeuwen (Theme 2)
LaserCenter
Academic Medical Centre / Universiteit van
Amsterdam

Prof.dr. F.E. van Leeuwen (Theme 2)
Psychosocial Research and Epidemiology
Netherlands Cancer Institute

Dr. F. van Leeuwen (Theme 1)
Department of Cellular Biochemistry
Netherlands Cancer Institute

Prof.dr. M. van Lohuizen (Theme 1)
Department of Molecular Genetics
Netherlands Cancer Institute

Dr. R.M. Luiten (Theme 2)
Department of Immunology
Academic Medical Centre / Universiteit van
Amsterdam

Prof.dr. J.P. Medema (Theme 1)
Laboratory of Experimental Oncology and
Radiotherapy
Academic Medical Centre / Universiteit van
Amsterdam

Prof.dr. C.J.L.M. Meijer (Theme 1 and 2)
Department of Pathology
VU University Medical Center

Prof.dr. G.A. Meijer (Theme 1 and 2)
Department of Pathology
VU University Medical Center

Prof.dr. S. Meijer (Theme 2)
Department of Surgical oncology
VU University Medical Center

Prof.dr. H. Meijers-Heijboer (Theme 1)
Department of Clinical Genetics
VU University Medical Center

Prof. dr. W.H. Moolenaar (Theme 1)
Department of Cellular Biochemistry
Netherlands Cancer Institute

Prof.dr. J.M. Middeldorp (Theme 1 and 2)
Department of Pathology
VU University Medical Center

Prof.dr. J.J.C. Neefjes (Theme 1)
Department of Tumor Biology
Netherlands Cancer Institute

Prof. dr. C.J.M. van Noesel (Theme 1)
Department of Pathology

Academic Medical Centre / Universiteit van Amsterdam

Prof.dr. C.J.F. van Noorden (Theme 1 and 2)
Department of Cell Biology & Histology
Academic Medical Centre / Universiteit van Amsterdam

Prof. dr. M.H.J. van Oers (Theme 1 and 2)
Department of Hematology
Academic Medical Centre / Universiteit van Amsterdam

Prof.dr. G.J. Ossenkoppele (Theme 1 and 2)
Department of Haematology
VU University Medical Center

Prof.dr. S.T. Pals (Theme 1 and 2)
Department of Pathology
Academic Medical Centre / Universiteit van Amsterdam

Dr. A. Perrakis (Theme 1)
Department of Molecular Carcinogenesis
Netherlands Cancer Institute

Dr. D. Peeper (Theme 1)
Department of Molecular Genetics
Netherlands Cancer Institute

Prof.dr. G.J. Peters (Theme 2)
Department of Clinical Oncology
VU University Medical Center

Prof.dr. P.J. Peters (Theme 1)
Department of Tumor Biology
Netherlands Cancer Institute

Prof.dr. H.M. Pinedo (Theme 2)
Department of Clinical Oncology
VU University Medical Center

Prof.dr. P. Postmus (Theme 2)
Department of Pulmonology
VU University Medical Center

Prof.dr. D.J. Richel (Theme 1 and 2)
Department of Medical Oncology
Academic Medical Centre / Universiteit van Amsterdam

Prof.dr. H.P.J. te Riele (Theme 1)
Department of Molecular Biology
Netherlands Cancer Institute

Prof.dr. S. Rodenhuis (Theme 2)
Department of Internal Medicine
Netherlands Cancer Institute

Dr. E. Roos (Theme 1)
Department of Cell Biology
Netherlands Cancer Institute

Prof.dr. J.J.M.C.H. de la Rosette (Theme 2)
Department of Urology

Academic Medical Centre / Universiteit van Amsterdam

Prof.dr. J.H.M. Schellens (Theme 2)
Department of Internal Medicine
Netherlands Cancer Institute

Prof.dr. R.J. Scheper (Theme 1 and 2)
Department of Pathology
VU University Medical Center

Dr. A. Schinkel (Theme 1)
Department of Experimental Therapy
Netherlands Cancer Institute

Dr. J.H. Schornagel (Theme 2)
Department of Internal Medicine
Netherlands Cancer Institute

Prof. Dr. T. Schumacher (Theme 1)
Department of Immunology
Netherlands Cancer Institute

Prof.dr. S. Senan (Theme 2)
Department of Radiation Oncology
VU University Medical Center

Prof.dr. T.K. Sixma (Theme 1)
Department of Molecular Carcinogenesis
Netherlands Cancer Institute

Prof.dr. B.J. Slotman (Theme 1 and 2)
Department of Radiation Oncology
VU University Medical Center

Prof.dr. E.F. Smit (Theme 2)
Department of Pulmonology
VU University Medical Center

Dr. A. Sonnenberg (Theme 1)
Department of Cell Biology
Netherlands Cancer Institute

Dr. M. Spaargaren (Theme 1)
Department of Pathology
Academic Medical Centre / Universiteit van Amsterdam

Dr. C.A. Spek (Theme 1 and 2)
Department of Experimental and Molecular
Medicine
Academic Medical Centre / Universiteit van Amsterdam

Dr. B. van Steensel (Theme1)
Department of Molecular Biology
Netherlands Cancer Institute

Dr. L. van 't Veer (Theme 2)
Department of Experimental Therapy
Netherlands Cancer Institute

Dr. L.J. Valentijn (Theme1)
Department of Human Genetics
Academic Medical Centre / Universiteit van Amsterdam

Prof.dr. W.P. Vandertop (Theme 2)
Department of Neurosurgery
VU University Medical Center

Prof.dr. A.J.P. Veerman (Theme 2)
Department of Paediatrics
VU University Medical Center

Dr. M. Verheij (Theme 2)
Department of Radiotherapy
Netherlands Cancer Institute

Prof.dr. R.H.M. Verheijen (Theme 2)
Dept. of Obstetrics & Gynaecology
VU University Medical Center

Prof.dr. R. Versteeg (Theme 1 and 2)
Department of Antropogenetics
Academic Medical Centre / Universiteit van
Amsterdam

Dr. M. van de Vijver (Theme 2)
Department of Experimental Therapy
Netherlands Cancer Institute

Dr. H. Wijkstra (Theme 2)
Department of Urology
Academic Medical Centre / Universiteit van
Amsterdam

Staff

Netherlands Cancer Institute

Cell Biology

Dr. J.G. Collard
Dr. C. Jalink
Dr. E. Roos
Dr. A. Sonnenberg

Molecular Carcinogenesis

Prof.dr. R. Bernards
Dr. R. Beijersbergen
Dr. A. Perrakis
Prof.dr. T.K. Sixma

Cellular Biochemistry

Dr. W.J. van Blitterswijk
Dr. N. Divecha
Dr. F. van Leeuwen
Prof.dr. W.H. Moolenaar
Dr. H. Ovaa
Dr. M. Verheij

Immunology

Prof.dr. J. Borst
Dr. J.B.A.G. Haanen
Dr. H. Jacobs
Prof.dr. T.N.M. Schumacher
Dr. F.A. Vyth-Dreese

Molecular Biology

Prof.dr. P. Borst (honorary staff member)
Dr. J. Jonkers
Dr. H. van Luenen
Prof.dr. H. te Riele
Dr. B. van Steensel

Tumor Biology

Dr. R. Agami
Dr. M. Fornerod
Dr. R.J.A.M. Michalides
Prof.dr. J.J. Neefjes
Prof.dr. P.J. Peters

Molecular Genetics

Prof.dr. A.J.M. Berns
Dr. J. Hilkens
Dr. P. Krimpenfort
Prof.dr. M. van Lohuizen
Dr. M. Snoek
Dr. M.A. van der Valk

Experimental therapy

Prof.dr. A.C. Begg
Dr. A. Schinkel
Dr. F.A. Stewart
Prof.dr. M.J. van de Vijver
Dr. L.J. van 't Veer

Radiotherapy

B.M.P. Aleman
Prof.dr. G.M.M. Bartelink
Dr. J.S.A. Belderbos
Dr. R.W. de Boer

Dr. M. Boersma
Dr. I. Bruinvis
B.N.F.M. van Bunningen
Dr. E.M.F. Damen
Dr. L.G.H. Dewit
Dr. R.L.M. Haas
Dr. A.A.M. Hart
Dr. W. Heemsbergen
Dr. M. van Herk
Dr. E.P.M. Jansen
Dr. J.V. Lebesque
Dr. C.A.M. Marijnen
E.A.H. Masselink
Dr. B.J. Mijnheer
Dr. L.M.F. Moonen
Dr. C.R.N. Rasch
Dr. P. Remeijer
Dr. N.S. Russell
J.G. Salverda
Dr. C. Schneider
Dr. J. Stroom
Dr. J.C.M. Theuws
Dr. C. van Vliet-Vroegindeweyj
Dr. C. Vrieling
Dr. F.W. Wittkämper

Medical Oncology

Dr. J.W. Baars
Dr. P. Baas
Drs. E.M. Bais
Prof.dr. J.H. Beijnen
Dr. J.P. de Boer
Dr. W.W. ten Bokkel Huinink
Dr. W. Boogerd
Dr. H. Boot
Dr. J.A. Burgers
Dr. A. Cats
Prof.dr. G.C. de Gast
L. Gualthérie van Weezel
Dr. J.B.A.G. Haanen
Dr. A. Huitema
Dr. J.M. Kerst
Dr. S.C. Linn
Dr. A. Lukas
Dr. H. Neering
Prof.dr. S. Rodenhuis
Dr. J.H.M. Schellens
Dr. J.H. Schornagel
Dr. M. Smits
Dr. B.G. Taal
Dr. M. van der Weide
Dr. N. van Zandwijk

Surgical Oncology

Prof.dr. B.B.R. Kroon
Dr. A.J.M. Balm
Dr. A. Bex
Dr. M.W.M. van den Brekel
Dr. D.R. Buitelaar
Prof.dr. M.P.M. Burger
Dr. J. ten Cate

Dr. F. van Coevorden
Dr. M.P. Copper
Dr. W. van Driel
Dr. G. Fons
Dr. S. Gonggrijp
Dr. J.J. Hage
Prof.dr. F.J.M. Hilgers
Prof.dr. S. Horenblas
Dr. H. Huitink
Dr. C. Keijzer
H. Klomp
Dr. F.H.M. Kroon
Dr. P.J.F.M. Lohuis
Dr. M.A.C. Lubsen
Dr. W. Meinhardt
Dr. O.E. Nieweg
Dr. H.S.A. Oldenburg
Dr. H.G. van der Poel
Dr. M. de Rie
J.M. Ronday
Dr. E.J.Th. Rutgers
Dr. P.F.E. Schutte
Dr. M. Scramek
Dr. M. Slot
Dr. L.E. Smeele
Dr. T. Stoppa
Dr. I.B. Tan
Dr. A.P. Timmers
Dr. V.J. Verwaal
Dr. M.J. Vrancken Peeters
L.A.E. Woerdeman
Dr. F.A.N. Zoetmulder

Psychosocial Research and Epidemiology

Prof.dr. N.K. Aaronson
Prof.dr. F.S.A.M. van Dam
Prof.dr. W.J. van Harten

Prof.dr. F.E. van Leeuwen
Dr. M.A. Rookus

Pathology

Dr. T. Alderliesten
Dr. J.M. G. Bonfrer
Dr. H. van Boven
Dr. M.P.W. Gallee
Dr. K. Gilhuijs
Dr. C.A. Hoefnagel
Dr. F.B.L. Hogervorst
Dr. D. de Jong
Dr. J. Kluijt
Dr. W. Koops
Dr. R. Kröger
Dr. C. Loo
Dr. W.J. Mooi
S.H. Muller
Dr. P.M. Nederlof
Dr. W.J. Nooijen
F.A. Pameijer
Dr. R. van Pel
Dr. J.L. Peterse
Dr. W. Prevoo
Dr. M. Sinaasappel
Dr. F. Sivo
Dr. J. Teertstra
Dr. O. van Tellingen
Dr. R.A. Valdès Olmos
Dr. L. van 't Veer
Dr. M.L.F. van Velthuisen
Dr. S. Verhoef
Prof.Dr. M. van de Vijver
Dr. J. Wesseling

Radiology

A.P.E. Besnaard
W. Koops
Dr. R. Kröger

VU University Medical Center

Anaesthesiology

Prof.dr. W.W.A. Zuurmond

Clinical Genetics

Dr. S. Agarwal
Dr. F. Arwert
Prof.dr. H. Joenje
Dr. M. Levitus
Dr. F. Menko
Prof.dr. H. Meijers-Heijboer
Dr. G. Pals
Dr. J. de Winter

Clinical Chemistry

Dr. C.B.M. Oudejans
Prof.dr. M.A. Blankenstein

Gastro-enterology

Dr. M. Craanen
Prof.dr. C Mulder

Haematology

M.E.D. Chamuleau
Dr. A. Dräger
Prof.dr. P.C. Huijgens
Dr. J.J.W.M. Janssen
Prof. dr. G.J. Ossenkoppele
R. Roovers
Dr. G.J. Schuurhuis
Dr. A.A. van de Loosdrecht
Dr. O. Visser
Dr. Q. Waisfisz
Dr. S. Zweegman
Dr. J.M. Zijlstra

Medical Psychology

Prof dr.P.T. Cohen-Kettenis
Dr. J. Huisman
Dr. M. Klein
Prof.dr.H.M. Ploeg

Molecular Cell Biology

Prof.dr. R.H.J. Beelen
Prof.dr. G. Kraal
Prof.dr. Y. van Kooyk

Medical Oncology

Prof.dr. E. Boven
Dr. H.J.Broxterman
Dr. J. Buter
Dr. T.D. de Gruijl
Dr. R.J.A. Fijneman
Dr. W.R. Gerritsen
Prof.dr. G.G. Giaccone
Dr. A.E. Greijer
Dr. B.N. Hangalapura
Dr. K. Hoekman
Dr. R. Honeywell
Dr. M.L. Janmaat
Dr. C.R. Jimenez
Dr. F.A.E. Kruyt
Dr. B.C. Kuenen
Prof.dr. J. Lankelma
Dr. P. Noordhuis

Dr. D. Oosterhoff

Prof.dr. G.J. Peters
Dr. T.V. Pham
Dr. S. Piersma
Dr. J.A. Rodriguez
Dr. F.H.E. Schagen
Dr. C.H. Smorenburg
Dr. C.J. van Groeningen
Dr. V.W. van Beusechem
Dr. A.J.M. van den Eertwegh
Dr. Y. Yuana

Neurosurgery

Dr. J.C. Baaijen
Dr. C.M.F. Dirven
Dr. M.L.M. Lamfers
Dr. D.P. Noske
Prof.dr. W.P. Vandertop

Neurology

Prof.dr. J.J. Heimans
Dr. T. Postma
Dr. J.C. Reijneveld

Nuclear Medicine

Dr. R. Boellaard
Dr. E.F.I. Comans
Dr. N.H. Hendrikse
Dr. J.D.M. Herscheid
Prof.dr. O.S. Hoekstra
Prof.dr. A.A. Lammertsma
Dr. M. Lubberink
Dr. C.F.M. Molthoff
Dr. H.J. Pijpers
Dr. P. Raijmakers
E. van Tilburg
G.W.M. Visser
A.D. Windhorst

Obstetrics and Gynaecology

Dr. J.C. Dorsman
Prof.dr. P. Kenemans
Dr. S. von Mensdorff-Pouilly
Prof.dr. R.H.M. Verheijen
Dr. A.A. Verstraeten
Ophthalmology
Dr. S. Imhoff
Dr. A. Moll

Oral and maxillofacial surgery and pathology

Prof.dr. I. van der Waal

Orthopaedics

Prof.dr. P.I.J.M. Wuisman

Otolaryngology / Head and Neck Surgery

Dr. B.J.M. Braakhuis
Prof.dr. R.H. Brakenhoff
Dr. R. de Bree
Dr. F. Dijk
Prof.dr. G.A.M.S. van Dongen
Dr. D.J. Kuik
Prof.dr. Dr. Ch.R. Leemans
Prof.dr. H.F. Mahieu

Dr. I. Verdonck-de Leeuw
Dr. D. Vugts

Pathology

Dr. J. Beliën
Prof. dr. E. Bloemena
Dr. H.J. Bontkes
Dr. B. Carvalho
Dr. B. Diosdado
Dr. D.A.M. Heideman
Dr. E. Hooijberg
Dr. F.J. van Kemenade
Dr. P. Krijnen
Prof.dr. C.J.L.M. Meijer
Prof.dr. G.A. Meijer
Prof.dr. J.M. Middeldorp
Prof.dr. W.J. Mooi
Dr. J.J. Oudejans
Dr. G.L. Scheffer
Prof.dr. R.J. Scheper
Dr. P.J.F. Snijders
Dr. R. Steenbergen
Dr. S.J.C. Stevens
Dr. C. Svenson
Dr. M. van de Wiel
Prof.dr. P.J. van den Elsen
Dr. P. van den IJssel
Dr. B.M.E. von Blomberg-van der Flier
Dr. B. Ylstra

Paediatrics

Dr. C.J.M. Broers
Dr. J. Cloos
Dr. V. de Haas
Dr. I. Hubeek
Dr. G.J. Kaspers

Dr. M.H. van der Berg
Dr. E. van
Dr. A.M. van Furth
Prof. Dr. A.J.P. Veerman

Pulmonology

Dr. P.W.A. Kunst
Prof.dr. P.E. Postmus
Prof.dr. E.F. Smit
Dr. T.G. Sutedja

Radiology

Prof.dr. J.A. Castelijns
J. van Rijn

Radiation Oncology

Dr. G.K. Kuipers
Dr. F.J. Lagerwaard
Dr. M.V.M. Lafleur
Prof.dr. S. Senan
Prof.dr. B.J. Slotman
Dr. P. Sminia
Dr. B. van Triest

Surgical Oncology

Prof.dr. M.A. Cuesta
Dr. M. van Egmond
Prof.dr. P.A.M. van Leeuwen
Prof.dr. S. Meijer

Urology

Dr. E.C. de Boer
Dr. P.A.M.J. Frantzen
Dr. A.A. Geldof
Dr. R.J.A. Moorselaar

University of Amsterdam

Medical Biochemistry
Prof.dr. J.M.F.G. Aerts

Cell Biology & Histology
Dr. J.A. Aten
Prof. dr. C.J.F. van Noorden
Dr. A. Sonnenberg

Experimental Internal Medicine
Dr. C.A. Spek

Gastro-enterology & Hepatology
Prof.dr. R.P.J. Oude Elferink
Dr. K.K. Krishnadath

Genetic Metabolic Diseases
Dr. A.B.P. van Kuilenburg

Human Genetics
Dr. H.A.M. Geerts
Dr. L.J. Valentijn
Prof.dr. R. Versteeg
Dr. M. Kool

Hematology
Dr. M.J. Kersten
Dr. H. Koene
Prof. dr. M.H.J. van Oers

Immunology
Dr. E.F. Eldering
Dr. R.M. Luiten

LaserCenter
Dr. M.C. Aalders
Prof. dr. A.G.J.M. van Leeuwen

Medical Biochemistry
Prof. dr. J.M.F.G. Aerts

Medical Oncology
Dr. P.J.M. Bakker
Prof.dr. D.J. Richel
Dr. A.M. Westermann
Dr. H. Wilmink

Neurogenetics
Dr. Th.J.M. Hulsebos

Pathology
Prof.dr. S.T. Pals
Dr. M. Spaargaren
Prof. dr. C.J.M. van Noesel

Pediatric Oncology
Dr. H. van den Berg
Prof.dr. H.N. Caron
Dr. A.B.P. van Kuilenburg
Dr. J. de Kraker
Dr. J.H. Merks
Dr. A.Y.N. Schouten-van Meeteren
Prof. dr. G.A.M. Tytgat
Dr. A.C. Verschuur
Dr. M.D. van de Wetering
Dr. J. Zsiros

Radiotherapy
Dr. C. van Bree
Dr. N.A.P. Franken
Prof.dr. C.C.E. Koning
Prof.dr. J.P. Medema

Surgery
Prof.dr. D.J. Gouma
Prof.dr. T.M. van Gulik

Urology
Prof.dr. J.J.M.C.H. de la Rosette
Dr.Ir. H. Wijkstra

international visitors

annex **2**

Annex 2.

International visitors

Allison J.P., USA
Aloy P., Spain
Assaraf Y.G., Israel
Attikum H., Switzerland

Balkwill F., UK
Baumeister W., Germany
Becker P., Germany
Bickmore W., UK
Bjornsti M.A., USA
Breakefield X., USA
Bussemaker H., USA

Caldas C., UK
Carroll J., USA
Chabner B.A., USA
Clarke M., USA
Condeelis J., USA
Colot V., France
Cullen, UK

Davis I., UK
de Thé H., France
Dhillon H., Australia

Easton D., UK

Fagotto F., Canada
Fearon D., UK

Germain R., USA
Gottschling D., USA
Grinstein S., Canada

Hall P., Sweden
Heidenblad M., Sweden
Hornstein E., Israel

Tomlinson I., UK

Jacob S., Switzerland

Keller P., Germany
Kloetzel P.M., Germany
Krissinel E., UK

Lamers M., USA
Laurie G., UK
Look T., USA
Lowe S., USA
Luscombe N., UK

Madhani H., USA
Mahmood U., USA
McFadden G., Canada

Nasmyth K., UK
Niederhuber J.E., USA

Pearl L., UK
Pelkmans L., Switzerland
Pouysségur J., France
Praz F., France

Quackenbush J., USA

Ravdin P., USA
Raz E., Germany
Rebholz-Schuhmann D., UK
Reuter G., Germany
Reynolds A., USA
Rosen J., USA

Sharpe M., UK
Schubeler D., Switzerland
Skotheim R., Oslo
Schwartz M., USA
Shay J., USA
Soininen R., Finland
Slebos R.J.C., USA
Stappenbeck T., USA
Stark H., Germany

ten Berge, USA
Tuveson, USA

Van Waardenburg R., USA
van Tendeloo V., Belgium
Von Hoff D., USA

PhD theses completed

annex **3**

Annex 3.

Theses completed

In 2006, 47 graduate students completed their graduate training and obtained a PhD degree. Their names, thesis titles, supervisors and institutes are listed below. The institute at which the research described in the theses was carried out is mentioned between brackets and may differ from the university where the PhD graduation took place.

Name	:	Augustijn-Savonije J.H. (Vumc)
Title	:	Effects of erythropoietin in cancer patients
University	:	Vrije Universiteit Amsterdam
(co)Promotors	:	Giaccone G, Marx JMM
Date	:	7 May 2006
Name	:	Bernad R. (NKI)
Title	:	Molecular dissection of the nuclear pore complexes in relation to nuclear export pathways
University	:	Universiteit Leiden
(co)Promotors	:	Neefjes JJ
Date	:	20 June 2006
Name	:	Blom E. (Vumc)
Title	:	Evolutionary clues to the molecular function of Fanconi anemia genes
University	:	Vrije Universiteit Amsterdam
(co)Promotors	:	Joenje H, Arwert F, de Winter JP
Date	:	21 April 2006
Name	:	Boon E.M.J. (AMC)
Title	:	The HGF/MET pathway in colorectal cancer.
University	:	Universiteit van Amsterdam
(co)Promotors	:	Pals ST, van der Neut R
Date	:	09 March 2006
Name	:	Bos C.L. (AMC)
Title	:	Signal transduction & drug intervention in colon cancer.
university	:	Universiteit van Amsterdam
(co)Promotors	:	Richel DJ, Peppelenbosch MP.
Date	:	15 September 2006
Name	:	Bosch T. (NKI)
Title	:	Pharmacogenetic screening in anti-cancer therapy: focus on docetaxel, irinotecan and fluoropyrimidines
university	:	Universiteit Utrecht
(co)Promotors	:	Schellens JHM, Beijnen JH
Date	:	3 March 2006
Name	:	Carvalho R. (AMC)
Title	:	Gastric carcinoma profiling: investigating its molecular origin.
university	:	Universiteit van Amsterdam
(co)Promotors	:	Offerhaus GKA, Weterman MAJ
Date	:	02 November 2006
Name	:	Creyghton M. (NKI)
Title	:	Protein phosphatase type 2A regulatory subunits and cancer
university	:	Universiteit Utrecht
(co)Promotors	:	Bernards R
Date	:	11 Januari 2006

Name : **Dinant S. (AMC)**
Title : Strategies to improve outcome after partial liver resection
university : Universiteit van Amsterdam
(co)Promotors : van Gulik TM, Gouma DJ
Date : 10 October 2006

Name : **Feller N. (Vumc)**
Title : Detection and eradication of minimal residual disease in acute myeloid leukaemia
university : Vrije Universiteit Amsterdam
(co)Promotors : Ossenkuppele GJ, Schuurhuis GJ
Date : 24 March 2006

Name : **Foijer F. (NKI + VUmc)**
Title : Braking news: The G2 restriction point
university : Vrije Universiteit Amsterdam
(co)Promotors : te Riele HPJ
Date : 25 October 2006

Name : **Greil F. (NKI)**
Title : Hetrochromatin composition and function
university : Universiteit van Amsterdam
(co)Promotors : van Driel R
Date : 23 November 2006

Name : **Griekspoor A. (NKI)**
Title : Single cell biochemistry to visualize antigen presentation and drug resistance
university : Universiteit Leiden
(co)Promotors : Neefjes JJ
Date : 01 November 2006

Name : **Groothuis T. (NKI)**
Title : Manipulations of the ubiquitin proteasome system and their effects on antigen presentation
university : Universiteit Leiden
(co)Promotors : Neefjes JJ
Date : 01 November 2006

Name : **Herder C.J.M. (Vumc)**
Title : The use of 18FDG PET in NSCLC
university : Vrije Universiteit Amsterdam
(co)Promotors : Postmus PE, Teule GJJ, Hoekstra OS, Smit EF
Date : 26 April 2006

Name : **Houtenbos I. (Vumc)**
Title : Strategies to translate leukemia-derived dendritic cell vaccination into clinical practice
university : Vrije Universiteit Amsterdam
(co)Promotors : Ossenkuppele GJ, van de Loosdrecht AA
Date : 24 November 2006

Name : **Janmaat M.L. (Vumc)**
Title : Targeting ErbB receptors as anticancer therapy: Factors of sensitivity and resistance
university : Vrije Universiteit Amsterdam
(co)Promotors : Giaccone G, Rodriguez JA
Date : 10 November 2006

Name : **Janssen H. (NKI)**
Title : Hypoxia in head and neck cancers; measurements and importance
university : Begg AC
(co)Promotors : Radboud Universiteit Nijmegen
Date : 11 September 2006

Name : **Kantardzhieva A.V. (AMC)**
Title : Crumbs and MAGUK proteins, from interaction to function

university : Universiteit van Amsterdam
 (co)Promotors : Berns AJM, de Jong PTVM, Wijnholds J
 Date : 07 June 2006

Name : **Kater A.P. (AMC)**
 Title : Novel apoptosis inducing strategies in chronic lymphocytic leukemia
 university : Universiteit van Amsterdam
 (co)Promotors : van Oers MHJ, Kipps TJ, Eldering E
 Date : 02 February 2006

Name : **Kreukels B. (NKI)**
 Title : Information processing and brain activity after adjuvant chemotherapy in breast cancer patients
 university : Universiteit van Amsterdam
 (co)Promotors : van Dam FSAM
 Date : 05 July 2006

Name : **Kroon B.K. (NKI/Vumc)**
 Title : Dynamic sentinel node biopsy in penile carcinoma
 university : Vrije Universiteit Amsterdam
 (co)Promotors : Horenblas S
 Date : 24 February 2006

Name : **Langeslag M. (NKI)**
 Title : TRPM7, Calcium and the cytoskeleton
 university : Universiteit Leiden
 (co)Promotors : Moolenaar WH
 Date : 11 October 2006

Name : **Levielle F. (Vumc)**
 Title : The Fanconi anemia DNA maintenance pathway: focus on the FANCE and FANCF proteins
 university : Vrije universiteit Amsterdam
 (co)Promotors : Joenje H, de Winter JP
 Date : 27 October 2006

Name : **Litjens S.H.M. (NKI + AMC)**
 Title : Plectin's acting-binding domain: a versatile element
 university : Universiteit van Amsterdam
 (co)Promotors : Berns AJM, Sonnenberg A
 Date : 24 February 2006

Name : **Marsman (AMC)**
 Title : Barrett's battle gene therapy and diagnostic endoscopy
 university : Universiteit van Amsterdam
 (co)Promotors : van Lanschot JJB, Bosma PJ, Bergman JJGHM
 Date : 17 November 2006

Name : **Mochtar C.A. (AMC)**
 Title : Prognostic factors for clinical progression after treatment of BPH
 university : Universiteit van Amsterdam
 (co)Promotors : de la Rosette JJMCH, Debruyne FMJ, Kiemeneij LALM, Laguna-Pes MP
 Date : 04 April 2006

Name : **Muris J.F.M. (Vumc)**
 Title : Expression profiling and clinical outcome in primary nodal diffuse large B-cell lymphomas
 university : Vrije Universiteit Amsterdam
 (co)Promotors : Meijer CJLM, Oudejans JJ
 Date : 15 December 2006

Name : **Natrajan G. (NKI)**
 Title : MutS: Recognition of DNA mismatches and initiation of repair
 university : Erasmus Universiteit Rotterdam
 (co)Promotors : Sixma TK
 Date : 13 September 2006

Name : **Oosterling S.J. (Vumc)**
 Title : Surgical trauma and intra-abdominal tumor development
 university : Vrije Universiteit Amsterdam
 (co)Promotors : Meijer S, Beelen RHJ
 Date : 17 November 2006

Name : **Purnomosari D. (Vumc)**
 Title : Molecular analysis of early onset Indonesian breast cancer
 university : Universiteit van Utrecht
 (co)Promotors : van Diest PJ, Pals G
 Date : 29 November 2006

Name : **Smulders S.A. (Vumc)**
 Title : Patients with resectable lung cancer: preoperative selection and postoperative function
 university : Vrije Universiteit Amsterdam
 (co)Promotors : Postmus PE
 Date : 24 November 2006

Name : **Schepers K. (NKI)**
 Title : Dissection and manipulation of antigen-specific Tcell responses
 university : Universiteit Leiden
 (co)Promotors : Schumacher TNM
 Date : 19 October 2006

Name : **Schnater J.M. (AMC)**
 Title : The way forward in hepatoblastoma. A study of epidemiology, gene expression patterns, and the development of a tumor model
 university : Universiteit van Amsterdam
 (co)Promotors : Lamers WH, Heij HA, Aronson DC
 Date : 19 October 2006

Name : **Schnell S.A.C. (NKI + AMC)**
 Title : Further optimization of the diagnostic management of deep venous thrombosis
 university : Universiteit van Amsterdam
 (co)Promotors : Berns AJM, Jacobs H
 Date : 15 December 2006

Name : **Triesscheijn M. (NKI)**
 Title : mTHPC-mediated photodynamic therapy; from bed to bench and back again
 university : Universiteit Utrecht
 (co)Promotors : Schellens JHM
 Date : 20 September 2006

Name : **Underberg R.W.M. (Vumc)**
 Title : Clinical implication of 4-dimensional radiotherapy for treatment of lung cancer
 university : Vrije Universiteit Amsterdam
 (co)Promotors : Senan S, Slotman BJ
 Date : 11 January 2006

Name : **van Baal J.W.P.M. (AMC)**
 Title : Molecular mechanisms in the development of Barrett's esophagus.
 university : Universiteit van Amsterdam
 (co)Promotors : Peppelenbosch MP, Krishnadath KK.
 Date : 15 December 2006

Name : **van de Weerd B. (NKI)**
 Title : Separating the multiple roles of polo-like kinase-1 in mitosis
 university : Universiteit Utrecht
 (co)Promotors : Medema RH
 Date : 30 March 2006

Name : **van Rheenen (NKI)**
 Title : PIP2 as local second messenger: a critical re-evaluation
 university : Leiden

(co)Promotors : Prof.dr. J.J. Neefjes
Date : 11 January 2006

Name : **van Rossum A. (NKI)**
Title : Contactin couples dynamic actin networks to cell migration and breast cancer
university : Leiden
(co)Promotors : Moolenaar WH
Date : 29 March 2006

Name : **van Tinteren H. (Vumc)**
Title : Assessing the value of FDG-PET in lung cancer: from theory to practice
university : Vrije Universiteit Amsterdam
(co)Promotors : Boers M, Teule GJJ, Hoekstra OS
Date : 13 December 2006

Name : **Vischioni B. (Vumc)**
Title : Expression and subcellular localization of inhibitor of apoptosis (IAP) proteins in human tissues: mechanisms and clinical implications
university : Vrije Universiteit Amsterdam
(co)Promotors : Giaccone G, Rodriguez JA
Date : 14 November 2006

Name : **Vuylsteke R.J.C.L.M. (Vumc)**
Title : Clinical and immunological aspects of the sentinel lymph node procedure in melanoma
university : Vrije Universiteit Amsterdam
(co)Promotors : van Leeuwen PAM, Meijer S, Scheper RJ
Date : 29 September 2006

Name : **Westerterp M. (AMC)**
Title : Oesophageal cancer: novel diagnostic and therapeutic modalities
university : Universiteit van Amsterdam
(co)Promotors : van Lanschot JJB, Boellaard R, Plukker JT, Sloof GW
Date : 16 June 2006

Name : **Witlox M.A. (Vumc)**
Title : Gene Therapy of Osteosarcoma. Preclinical studies with adenoviral vectors and adenoviral oncolysis
university : Vrije Universiteit Amsterdam
(co)Promotors : Wuisman PIJM, van Beusechem VW, Gerritsen WR
Date : 15 December 2006

Name : **Wurdinger T. (Vumc)**
Title : The development of tumor-selective coronaviruses as anti-cancer agents
university : Universiteit van Utrecht
(co)Promotors : Rottier PJM, Gerritsen WR, van Beusechem VW, Verheije MH
Date : 2 January 2006

scientific publications

annex 4

Annex 4.

Scientific publications

1. Aalders MCG, Triesscheijn M, Ruevekamp M, de Bruin M, Baas P, Faber DJ, Stewart FA. Doppler optical coherence tomography to monitor the effect of photodynamic therapy on tissue morphology and perfusion. *J Biomed Optics* 2006; 11: 044011. (NKI)
2. Aarnoudse CA, Garcia-Vallejo JJ, Saeland E, van Kooyk Y. Recognition of tumor glycans by antigen-presenting cells. *Curr Opin Immunol* 2006; 18(1): 105-111. (VUmc)
3. Aarts M, Dekker M, de Vries S, van der Wal A, te Riele H. Generation of a mouse mutant by oligonucleotide-mediated gene modification in ES cells. *Nucleic Acids Res* 2006; 34: e147. (NKI)
4. Abdallah AM, Verboom T, Hannes F, Safi M, Strong M, Eisenberg D, Musters RJ, Vandenbroucke-Grauls CMJE, Appelmelk BJ, Luirink J, Bitter W. A specific secretion system mediates PPE41 transport in pathogenic mycobacteria. *Mol Microbiol* 2006; 62(3): 667-679. (VUmc)
5. Abdullah-Sayani A, Bueno-de-Mesquita JM, Van De Vijver MJ. Technology insight: Tuning into the genetic orchestra using microarrays - Limitations of DNA microarrays in clinical practice. *Nat Clin Pract Oncol* 2006; 3: 501-16. (NKI)
6. Abou El Hassan MA, Braam SR, Kruyt FAE. A real-time RT-PCR assay for the quantitative determination of adenoviral gene expression in tumor cells. *J Virol Methods* 2006; 133(1): 53-61. (VUmc)
7. Abou El Hassan MA, Braam SR, Kruyt FAE. Paclitaxel and vincristine potentiate adenoviral oncolysis that is associated with cell cycle and apoptosis modulation, whereas they differentially affect the viral life cycle in non-small-cell lung cancer cells. *Cancer Gene Ther* 2006; 13(12): 1105-1114. (VUmc)
8. Ackland SP, Clarke SJ, Beale P, Peters GJ. Thymidylate synthase inhibitors. Update on Cancer Therapeutics 2006; 1: 403-427. (VUmc)
9. Adam M, Pogacic V, Bendit M, Chappuis R, Nawijn MC, Duyster J, Fox CJ, Thompson CB, Cools J, Schwaller J. Targeting PIM kinases impairs survival of hematopoietic cells transformed by kinase inhibitor-sensitive and kinase inhibitor-resistant forms of Fms-like tyrosine kinase 3 and BCR/ABL. *Cancer Res* 2006; 66: 3828-35. (NKI)
10. Adema AD, Zuurbier L, Floor K, Hubeek I, Kaspers GJL, Albertoni F, Peters GJ. Cellular resistance against troxacitabine in human cell lines and pediatric patient acute myeloid leukemia blast cells. *Nucleos Nucleot Nucl Acids* 2006; 25(9-11): 981-986. (VUmc)
11. Adler AS, Lin M, Horlings H, Nuyten DSA, Van De Vijver MJ, Chang HY. Genetic regulators of large-scale transcriptional signatures in cancer. *Nat Genet* 2006; 38: 421-30. (NKI)
12. Aerts JGJV, Surmont V, van Klaveren RJ, Tan KY, Senan S, Van Wijhe G, Vernhout R, Verhoeven GT, Hoogsteden HC, van Meerbeeck JP. A phase II study of induction therapy with carboplatin and gemcitabine in patients with locally advanced non-small cell lung cancer. *Thoracic Oncology* 2006; 1: 532-536. (VUmc)
13. Agrawal S, Anderson P, Durbeek M, van Rooijen N, Ivars F, Opdenakker G, Sorokin LM. Dystroglycan is selectively cleaved at the parenchymal basement membrane at sites of leukocyte extravasation in experimental autoimmune encephalomyelitis. *J Exp Med* 2006; 203(4): 1007-1019. (VUmc)
14. al Naiemi N, Bart A, de Jong MD, Vandenbroucke-Grauls CMJE, Rietra PJ, Debets-Ossenkopp YJ, Wever PC, Spanjaard L, Bos AJ, Duim B. Widely distributed and predominant CTX-M extended-spectrum beta-lactamases in Amsterdam, The Netherlands. *J Clin Microbiol* 2006; 44(8): 3012-3014. (VUmc)
15. al Naiemi N, Heddema ER, Bart A, de Jonge E, Vandenbroucke-Grauls CMJE, Savelkoul PHM, Duim B. Emergence of multidrug-resistant Gram-negative bacteria during selective decontamination of the digestive tract on an intensive care unit. *J Antimicrob Chemother* 2006; 58(4): 853-856. (VUmc)
16. Al Toma A, Goerres MS, Meijer JW, Pena AS, Crusius JBA, Mulder CJ. Human leukocyte antigen-DQ2 homozygosity and the development of refractory celiac disease and enteropathy-associated T-cell lymphoma. *Clin Gastroenterol Hepatol* 2006; 4(3): 315-319. (VUmc)
17. Al Toma A, Goerres MS, Meijer JW, von Blomberg BME, Wahab PJ, Kerckhaert JA, Mulder CJ. Cladribine therapy in refractory celiac disease with aberrant T cells. *Clin Gastroenterol Hepatol* 2006; 4(11): 1322-1327. (VUmc)
18. Albeck S, Alzari P, Andreini C, Banci L, Berry IM, Bertini I, Cambillau C, Canard B, Carter L, Cohen SX, Diprose JM, Dym O, Esnouf RM, Felder C,

- Ferron F, Guillemot F, Hamer R, Ben Jelloul M, Laskowski RA, Laurent T, Longhi S, Lopez R, Luchinat C, Malet H, Mochel T, Morris RJ, Moulinier L, Oinn T, Pajon A, Peleg Y, Perrakis A, Poch O, Prilusky J, Rachedi A, Ripp R, Rosato A, Silman I, Stuart DI, Sussman JL, Thierry JC, Thompson JD, Thornton JM, Unger T, Vaughan B, Vranken W, Watson JD, Whamond G, Henrick K. SPINE bioinformatics and data-management aspects of high-throughput structural biology. *Acta Crystallogr D Biol Crystallogr* 2006; 62: 1184-95. (NKI)
19. Alberici P, Jagmohan-Changur S, De Pater E, Van Der Valk M, Smits R, Hohenstein P, Fodde R. Smad4 haploinsufficiency in mouse models for intestinal cancer. *Oncogene* 2006; 25: 1841-51. (NKI)
20. Aleksunes LM, Scheffer GL, Jakowski AB, Pruijboom-Brees IM, Manautou JE. Coordinated expression of multidrug resistance-associated proteins (Mrps) in mouse liver during toxicant-induced injury. *Toxicol Sci* 2006; 89(2): 370-379. (VUmc)
21. Alkureishi LW, de Bree R, Ross GL. RADPLAT: an alternative to surgery?. *Oncologist* 2006; 11(5): 469-480. (VUmc)
22. Allaart CF, Goekoop-Ruiterman YP, Vries-Bouwstra JK, Breedveld FC, Dijkmans BAC, Grop FS. Aiming at low disease activity in rheumatoid arthritis with initial combination therapy or initial monotherapy strategies: the BeSt study. *Clin Exp Rheumatol* 2006; 24(6 Suppl 43): S077-S082. (VUmc)
23. Altelaar AFM, Klinkert I, Jalink K, De Lange RPJ, Adan RAH, Heeren RMA, Piersma SR. Gold-enhanced biomolecular surface imaging of cells and tissue by SIMS and MALDI mass spectrometry. *Anal Chem* 2006; 78: 734-42 (NKI/VUmc)
24. Alzari P, Berglund H, Berrow NS, Blagova E, Busso D, Cambillau C, Campanacci V, Christodoulou E, Eiler S, Fogg MJ, Folkers G, Geerlof A, Hart D, Haouz A, Herman MD, Macieira S, Nordlund P, Perrakis A, Quevillon-Cheruel S, Tarandeu F, van Tilbeurgh H, Unger T, Luna-Vargas MPA, Velarde M, Willmanns M, Owens R. Implementation of semi-automated cloning and prokaryotic expression screening: the impact of SPINE. *Acta Crystallogr D Biol Crystallogr* 2006; 62: 1103-13. (NKI)
25. Andrieu N, Easton DF, Chang-Claude J, Rookus MA, Brohet R, Cardis E, Antoniou AC, Wagner T, Simard J, Evans G, Peock S, Fricker JP, Nogues C, van 't Veer L, van Leeuwen FE, Goldgar DE. Effect of chest X-rays on the risk of breast cancer among BRCA1/2 mutation carriers in the international BRCA1/2 carrier cohort study: a report from the EMBRACE, GENEPSO, GEO-HEBON, and IBCCS Collaborators' Group. *J Clin Oncol* 2006; 24: 3361-6. (NKI)
26. Andrieu N, Goldgar DE, Easton DF, Rookus M, Brohet R, Antoniou AC, Peock S, Evans G, Eccles D, Douglas F, Nogues C, Gauthier-Villars M, Chompret A, van Leeuwen FE, Kluijdt I, Benitez J, Arver B, Olah E, Chang-Claude J. Pregnancies, breast-feeding, and breast cancer risk in the International BRCA1/2 Carrier Cohort Study (IBCCS). *J Natl Cancer Inst* 2006; 98: 535-44. (NKI)
27. Andrieux A, Salin P, Schweitzer A, Begou M, Pachoud B, Brun P, Gory F, Kujala P, Saud-Chagny MF, Hofle G, Job D. Microtubule Stabilizer Ameliorates Synaptic Function and Behavior in a Mouse Model for Schizophrenia. *Biol Psychiatry* 2006; 60: 1224-30. (NKI)
28. Anthony RM, Urban JF, Alem F, Hamed HA, Roza CT, Boucher JL, van Rooijen N, Gause WC. Memory T(H)2 cells induce alternatively activated macrophages to mediate protection against nematode parasites. *Nat Med* 2006; 12(8): 955-960. (VUmc)
29. Appel IM, den Boer ML, Meijerink JP, Veerman AJP, Reniers NC, Pieters R. Up-regulation of asparagine synthetase expression is not linked to the clinical response L-asparaginase in pediatric acute lymphoblastic leukemia. *Blood* 2006; 107(11): 4244-4249. (VUmc)
30. Appels NMGM, Rosing H, Stephens TC, Hughes A, Schellens JHM, Beijnen JH. Absolute quantification of farnesylated Ras levels in complex samples using liquid chromatography fractionation combined with tryptic digestion and electrospray tandem mass spectrometry. *Anal Biochem* 2006; 352: 33-40. (NKI)
31. Appels NMGM, Rosing H, Stephens TC, Schellens JHM, Beijnen JH. Quantification of farnesylmethylcysteine in lysates of peripheral blood mononuclear cells using liquid chromatography coupled with electrospray tandem mass spectrometry: Pharmacodynamic assay for farnesyl transferase inhibitors. *Anal Chem* 2006; 78: 2617-22. (NKI)
32. Appels NMGM, Tung KO, Rosing H, Schellens JHM, Beijnen JH. A rapid and simple HPLC-UV method for the determination of inhibition characteristics of farnesyl transferase inhibitors. *Biomed Chromatogr* 2006; 20: 161-5. (NKI)
33. Arbyn M, Sasieni P, Meijer CJLM, Clavel C, Koliopoulos G, Dillner J. Chapter 9: Clinical applications of HPV testing. A summary of meta-analyses. *Vaccine* 2006; 24 Suppl 3: S78-S89. (VUmc)
34. Aricescu AR, Assenberg R, Bill RM, Busso D, Chang VT, Davis SJ, Dubrovsky A, Gustafsson L, Hedfalk K, Heinemann U, Jones IM, Ksiazek D, Lang C, Maskos K, Messerschmidt A, Macieira S, Peleg Y, Perrakis A, Poterszman A, Schneider G, Sixma TK, Sussman JL, Sutton G, Tarboureich N, Zeev-Ben-Mordehai T, Jones EY. Eukaryotic expression: Developments for structural proteomics. *Acta Crystallogr D Biol Crystallogr* 2006; 62: 1114-24. (NKI)
35. Armstrong NJ, Brodnicki TC, Speed TP. Mind the gap: Analysis of marker-assisted breeding strategies for inbred mouse strains. *Mamm Genome* 2006; 17: 273-87. (NKI)

36. Armstrong NJ, Mcpeek MS, Speed TP. Incorporating interference into linkage analysis for experimental crosses. *Biostatistics* 2006; 7: 374-86. (NKI)
37. Ateenyi-Agaba C, Weiderpass E, Tommasino M, Smet A, Arslan A, Dai M, Katongole-Mbidde E, Hainaut P, Snijders PJF, Franceschi S. Papillomavirus infection in the conjunctiva of individuals with and without AIDS: an autopsy series from Uganda. *Cancer Lett* 2006; 239(1): 98-102. (VUmc)
38. Aten JA, Kanaar R. Chromosomal organization: Mingling with the neighbors. *Plos Biol* 2006; 4(5): 689-691. (AMC)
39. Aulwurm S, Wischhusen J, Friese M, Borst J, Weller M. Immune stimulatory effects of CD70 override CD70-mediated immune cell apoptosis in rodent glioma models and confer long-lasting antiglioma immunity in vivo. *Int J Cancer* 2006; 118: 1728-35. (NKI)
40. Baas P, Belderbos JS, Senan S, Kwa HB, van Bochove A, van Tinteren H, Burgers JA, van Meerbeeck JP. Concurrent chemotherapy (carboplatin, paclitaxel, etoposide) and involved-field radiotherapy in limited stage small cell lung cancer: a Dutch multicenter phase II study. *Br J Cancer* 2006; 94(5): 625-630. (NKI/VUmc)
41. Baas P, Triesscheijn M, Burgers S, Van Pel R, Stewart F, Aalders M. Fluorescence detection of pleural malignancies using 5-aminolaevulinic acid. *Chest* 2006; 129: 718-24. (NKI)
42. Baas P, van 't Hullenaar N, Wagenaar J, Kaajan JPG, Koolen M, Schrijver M, Schlosser N, Burgers JA. Occupational asbestos exposure: How to deal with suspected mesothelioma cases - The Dutch approach. *Ann Oncol* 2006; 17: 848-52. (NKI)
43. Bahar M, Ballard C, Cohen SX, Cowtan KD, Dodson EJ, Emsley P, Esnouf RM, Keegan R, Lamzin V, Langer G, Levдикov V, Long F, Meier C, Muller A, Murshudov GN, Perrakis A, Siebold C, Stein N, Turkenburg MGW, Vagin AA, Winn M, Winter G, Wilson KS. SPINE workshop on automated X-ray analysis: a progress report. *Acta Crystallogr D Biol Crystallogr* 2006; 62: 1170-83. (NKI)
44. Bajanca F, Luz M, Raymond K, Martins GG, Sonnenberg A, Tajbakhsh S, Buckingham M, Thorsteinsdottir S. Integrin α 6 β 1-laminin interactions regulate early myotome formation in the mouse embryo. *Development* 2006; 133: 1635-44. (NKI)
45. Bakema JE, de Haij S, Hartog-Jager CF, Bakker J, Vidarsson G, van Egmond M, van de Winkel JG, Leusen JH. Signaling through mutants of the IgA receptor CD89 and consequences for Fc receptor gamma-chain interaction. *J Immunol* 2006; 176(6): 3603-3610. (VUmc)
46. Bakhshi S, Joenje H, Schindler D, Oostra A, Mohamed AN, Madgy D, Ravindranath Y, Abella E. A case report of a patient with microcephaly, facial dysmorphism, mitomycin-c-sensitive lymphocytes, and susceptibility to lymphoma. *Cancer Genet Cytogenet* 2006; 164(2): 168-171. (VUmc)
47. Bakker H, Rouwendal GJ, Karnoup AS, Florack DE, Stoop GM, Helsper JP, van Ree R, van Die IM, Bosch D. An antibody produced in tobacco expressing a hybrid beta-1,4-galactosyltransferase is essentially devoid of plant carbohydrate epitopes. *Proc Natl Acad Sci U S A* 2006; 103(20): 7577-7582. (VUmc)
48. Bakx R, Emous M, Legemate DA, Machado M, Zoetmulder FAN, van Tets WF, Bemelman WA, Slors JFM, van Lanschot JJB. Categorization of major and minor complications in the treatment of patients with resectable rectal cancer using short-term pre-operative radiotherapy and total mesorectal excision: a Delphi round. *Colorectal Dis* 2006; 8(4): 302-308. (AMC/NKI)
49. Bakx R, Emous M, Legemate DA, Zoetmulder FAN, van Tienhoven G, Bemelman WA, van Lanschot JJB. Harm and benefits of short-term pre-operative radiotherapy in patients with resectable rectal carcinomas. *Eur J Surg Oncol* 2006; 32(5): 520-526. (AMC/NKI)
50. Banci L, Bertini I, Cusack S, De Jong RN, Heinemann U, Jones EY, Maskos K, Kozielski F, Owens R, Perrakis A, Siebold C, Silman I, Messerschmidt A, Poterszman A, Schneider G, Sixma T, Sussman JL, Stewart-Jones G, Thierry JC, Moras D. First steps towards effective methods in exploiting high-throughput technologies for the determination of human protein structures of high biomedical value. *Acta Crystallogr D Biol Crystallogr* 2006; 62: 1208-17. (NKI)
51. Baricevic I, Jones DR, Malenkovic V, Nedic O. The effect of laparoscopy on the IGF system in patients diagnosed with acute cholecystitis. *Clin Endocrinol* 2006; 65: 373-9. (NKI)
52. Baricevic I, Jones DR, Nikolic JA, Nedic O. Gastrointestinal inflammation and the circulating IGF system in humans. *Horm Metab Res* 2006; 38: 22-7. (NKI)
53. Bartelds GM, Wolbink GJ, Stapel S, Aarden L, Lems WF, Dijkmans BAC, Nurmohamed MT. High levels of human anti-human antibodies to adalimumab in a patient not responding to adalimumab treatment. *Ann Rheum Dis* 2006; 65(9): 1249-1250. (VUmc)
54. Bartelink H. Partial breast irradiation: Is it a valid option? *Breast* 2006; 15: 297-9. (NKI)
55. Bartolomei F, Bosma I, Klein M, Baayen JC, Reijneveld JC, Postma TJ, Heimans JJ, van Dijk BW, de Munck JC, de Jongh A, Cover KS, Stam CJ. Disturbed functional connectivity in brain tumour patients: evaluation by graph analysis of synchronization matrices. *Clin Neurophysiol* 2006; 117(9): 2039-2049. (VUmc)
56. Bartolomei F, Bosma I, Klein M, Baayen JC, Reijneveld JC, Postma TJ, Heimans JJ, van Dijk BW, de Munck JC, de Jongh A, Cover KS, Stam CJ. How do brain tumors alter functional connectivity?

- A magnetoencephalography study. *Ann Neurol* 2006; 59(1): 128-138. (VUmc)
57. Bastiaannet E, Hoekstra OS, Oyen WJ, Jager PL, Wobbes T, Hoekstra HJ. Level of fluorodeoxyglucose uptake predicts risk for recurrence in melanoma patients presenting with lymph node metastases. *Ann Surg Oncol* 2006; 13(7): 919-926. (VUmc)
58. Bastiaannet E, Oyen WJ, Meijer S, Hoekstra OS, Wobbes T, Jager PL, Hoekstra HJ. Impact of [¹⁸F]fluorodeoxyglucose positron emission tomography on surgical management of melanoma patients. *Br J Surg* 2006; 93(2): 243-249. (VUmc)
59. Begg AC. Can the severity of normal tissue damage after radiation therapy be predicted? *PLoS Medicine* 2006; 3: 1713-4. (NKI)
60. Bekkers RL, Meijer CJLM, Massuger LF, Snijders PJF, Melchers WJ. Effects of HPV detection in population-based screening programmes for cervical cancer: a Dutch moment. *Gynecol Oncol* 2006; 100(3): 451-454. (VUmc)
61. Belderbos JSA, Heemsbergen WD, De Jaeger K, Baas P, Lebesque JV. Final results of a Phase I/II dose escalation trial in non-small-cell lung cancer using three-dimensional conformal radiotherapy. *Int J Radiat Oncol Biol Phys* 2006; 66: 126-34. (NKI)
62. Belt-Dusebout AW, Nuver J, de Wit R, Gietema JA, ten Bokkel Huinink WW, Rodrigus PT, Schimmel EC, Aleman BMP, van Leeuwen FE. Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. *J Clin Oncol* 2006; 24: 467-75. (NKI)
63. Benschop KS, Schinkel J, Luken ME, van den Broek PJ, Beersma MF, Menelik N, van Eijk HW, Zaaijer HL, Vandenbroucke-Grauls CMJE, Beld MG, Wolthers KC. Fourth human parechovirus serotype. *Emerg Infect Dis* 2006; 12(10): 1572-1575. (VUmc)
64. Bergink S, Salomons FA, Hoogstraten D, Groothuis TAM, De Waard H, Wu J, Yuan L, Citterio E, Houtsmuller AB, Neefjes J, Hoeijmakers JHJ, Vermeulen W, Dantuma NP. DNA damage triggers nucleotide excision repair-dependent monoubiquitylation of histone H2A. *Genes Dev* 2006; 20: 1343-52. (NKI)
65. Bergman JJGHM, Fockens P. Ablating Barrett's metaplastic epithelium: are the techniques ready for clinical use? *Gut* 2006; 55(9): 1222-1223. (AMC)
66. Bergman JJGHM. Latest developments in the endoscopic management of gastroesophageal reflux disease and Barrett's esophagus: An overview of the year's literature. *Endoscopy* 2006; 38(2): 122-132. (AMC)
67. Bergman JJGHM. New developments in the endoscopic detection and treatment of early neoplasia in Barrett's oesophagus. *Scand J Gastroentero* 2006; 41(Suppl. 243): 18-24. (AMC)
68. Bergman JJGHM. The endoscopic diagnosis and staging of oesophageal adenocarcinoma. *Best Pract Res Clin Oncol* 2006; 20(5): 843-866. (AMC)
69. Bergman M, Del Prete G, van Kooyk Y, Appelmek BJ. Helicobacter pylori phase variation, immune modulation and gastric autoimmunity. *Nat Rev Microbiol* 2006; 4(2): 151-159. (VUmc)
70. Berkhof J, Bulkman NW, Bleeker MC, Bulk S, Snijders PJF, Voorhorst FJ, Meijer CJLM. Human papillomavirus type-specific 18-month risk of high-grade cervical intraepithelial neoplasia in women with a normal or borderline/mildly dyskaryotic smear. *Cancer Epidemiol Biomarkers Prev* 2006; 15(7): 1268-1273. (VUmc)
71. Berkhof J, de Bruijne MC, Zielinski GD, Bulkman NW, Rozendaal L, Snijders PJF, Verheijen RHM, Meijer CJLM. Evaluation of cervical screening strategies with adjunct high-risk human papillomavirus testing for women with borderline or mild dyskaryosis. *Int J Cancer* 2006; 118(7): 1759-1768. (VUmc)
72. Berkhof J, van Kemenade FJ, Snijders PJF, Verheijen RHM, Meijer CJLM. When to test women for human papillomavirus: testing is possible without increasing colposcopy referral rate. *Br Med J* 2006; 332(7535): 23. (VUmc)
73. Bernad R, Engelsma D, Sanderson H, Pickersgill H, Fornerod M. Nup214-Nup88 nucleoporin subcomplex is required for CRM1-mediated 60 S preribosomal nuclear export. *J Biol Chem* 2006; 281: 19378-86. (NKI)
74. Bernards R, Brummelkamp TR, Beijersbergen RL. shRNA libraries and their use in cancer genetics. *Nat Meth* 2006; 3: 701-6. (NKI)
75. Bernards R. Exploring the uses of RNAi - Gene knockdown and the nobel prize. *N Engl J Med* 2006; 355: 2391-3. (NKI)
76. Berns A. Cancer biology: Can less be more for p53? *Nature* 2006; 443: 153-4. (NKI)
77. Berry I, Dym O, Esnouf RM, Harlos K, Meged R, Perrakis A, Sussman JL, Walter TS, Wilson J, Messerschmidt A. SPINE high-throughput crystallization, crystal imaging and recognition techniques: current state, performance analysis, new technologies and future aspects. *Acta Crystallogr D Biol Crystallogr* 2006; 62: 1137-49. (NKI)
78. Beumer JH, Beijnen JH, Schellens JHM. Mass balance studies, with a focus on anticancer drugs. *Clin Pharmacokinet* 2006; 45: 33-58. (NKI)
79. Bex A, Kerst M, Mallo H, Meinhardt W, Horenblas S, De Gast GC. Interferon alpha 2b as medical selection for nephrectomy in patients with synchronous metastatic renal cell carcinoma: A consecutive study. *Eur Urol* 2006; 49: 76-81. (NKI)
80. Bianco C, Giovannetti E, Ciardiello F, Mey V, Nannizzi S, Tortora G, Troiani T, Pasqualetti F, Eckhardt G, de Liguoro M, Ricciardi S, Del Tacca M, Raben D, Cionini L, Danesi R. Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine

- and ionizing radiation against pancreatic cancer. *Clin Cancer Res* 2006; 12(23): 7099-7107. (VUmc)
81. Bierau J, van Gennip AH, Leen R, Meisma R, Caron HN, van Kuilenburg ABP. Cyclopentenyl cytosine-induced activation of deoxycytidine kinase increases gemcitabine anabolism and cytotoxicity in neuroblastoma. *Cancer Chemoth Pharm* 2006; 57(1): 105-113. (AMC)
82. Biesheuvel CJ, Koomen I, Vergouwe Y, van Furth AM, Oostenbrink R, Moll HA, Grobbee DE, Moons KG. Validating and updating a prediction rule for neurological sequelae after childhood bacterial meningitis. *Scand J Infect Dis* 2006; 38(1): 19-26. (VUmc)
83. Bijker N, Meijnen P, Peterse JL, Bogaerts J, Van Hoorebeek I, Julien JP, Gennaro M, Rouanet P, Avril A, Fentiman IS, Bartelink H, Rutgers EJ. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853--a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. *J Clin Oncol* 2006; 24: 3381-7. (NKI)
84. Bleeker MC, Snijders PJF, Voorhorst FJ, Meijer CJLM. Flat penile lesions: the infectious "invisible" link in the transmission of human papillomavirus. *Int J Cancer* 2006; 119(11): 2505-2512. (VUmc)
85. Bloemen-van Gorp E, Minken A, Mijnheer B, Dehing-Oberye C, Lambin P. Clinical implementation of MOSFET detectors for dosimetry in electron beams. *Radiother Oncol* 2006; 80: 288-95. (NKI)
86. Boekhout AH, Beijnen JH, Schellens JHM. Symptoms and treatment in cancer therapy-induced early menopause. *Oncologist* 2006; 11: 641-54. (NKI)
87. Boesten L, Zadelaar AS, van Nieuwkoop A, Hu L, Jonkers J, van de Water B, Gijbels M, van der Made I, de Winther M, Havekes L, van Vlijmen B. Macrophage retinoblastoma deficiency leads to enhanced atherosclerosis development in ApoE-deficient mice. *FASEB J* 2006; 20: 953-5. (NKI)
88. Bogaerts J, Cardoso F, Buyse M, Braga S, Loi S, Harrison JA, Bines J, Mook S, Decker N, Ravdin P, Therasse P, Rutgers E, van 't Veer LJ, Piccart M. Gene signature evaluation as a prognostic tool: Challenges in the design of the MINDACT trial. *Nat Clin Pract Oncol* 2006; 3: 540-51. (NKI)
89. Bolliger CT, Sutedja TG, Strausz J, Freitag L. Therapeutic bronchoscopy with immediate effect: laser, electrocautery, argon plasma coagulation and stents. *Eur Respir J* 2006; 27(6): 1258-1271. (VUmc)
90. Bolscher JG, van der Kraan MI, Nazmi K, Kalay H, Grun CH, Van't Hof W, Veerman EC, Nieuw Amerongen AV. A one-enzyme strategy to release an antimicrobial peptide from the LFampin-domain of bovine lactoferrin. *Peptides* 2006; 27(1): 1-9. (VUmc)
91. Bontkes HJ, Ruizendaal JJ, Kramer D, Santegoets SJ, Scheper RJ, De Gruijl TD, Meijer CJ, Hooijberg E. Constitutively active STAT5b induces cytokine-independent growth of the acute myeloid leukemia-derived MUTZ-3 cell line and accelerates its differentiation into mature dendritic cells. *J Immunother* 2006; 29: 188-200. (VUmc)
92. Boogaerts M, Oberhoff C, ten Bokkel Huinink W, Nowroosian MR, Hayward CRW, Burger HU. Epoetin beta (NeoRecormon(r)) therapy in patients with solid tumours receiving platinum and non-platinum chemotherapy: A meta-analysis. *Anticancer Res* 2006; 26: 479-84. (NKI)
93. Booman M, Douwes J, Glas AM, de Jong D, Schuurung E, Kluin PM. Primary testicular diffuse large B-cell lymphomas have activated B-cell-like subtype characteristics. *J Pathol* 2006; 210: 163-71. (NKI)
94. Booman M, Douwes J, Glas AM, Riemersma SA, Jordanova ES, Kok K, Rosenwald A, de Jong D, Schuurung E, Kluin PM. Mechanisms and effects of loss of human leukocyte antigen class II expression in immune-privileged site-associated B-cell lymphoma. *Clin Cancer Res* 2006; 12: 2698-705. (NKI)
95. Boon EMJ, Pouwels W, Redeker S, Joosten SPJ, Hamann J, van der Neut R, Pals ST. Activation of Wnt signaling in the intestinal mucosa of Apc(+/-min) mice does not cause overexpression of the receptor tyrosine kinase Met. *Cancer Sci* 2006; 97(8): 710-715. (AMC)
96. Boonman ZF, Schurmans LR, van Rooijen N, Melief CJ, Toes RE, Jager MJ. Macrophages are vital in spontaneous intraocular tumor eradication. *Invest Ophthalmol Vis Sci* 2006; 47(7): 2959-2965. (VUmc)
97. Boorn, J.G. van den, Poole, I.C. Le & Luiten, R.M. (2006). T-cell avidity and tuning: The flexible connection between tolerance and autoimmunity. *Int Rev Immunol*, 25(3-4), 235-258. (AMC)
98. Borchert A, Chi CW, Ufer C, Schiebel H, Savaskan NE, Kuhn H. The role of phospholipid hydroperoxide glutathione peroxidase isoforms in murine embryogenesis. *J Biol Chem* 2006; 281: 19655-64. (NKI)
99. Borjesson PKE, Jauw YW, Boellaard R, de Bree R, Comans EFI, Roos JC, Castelijns JA, Vosjan MJ, Kummer JA, Leemans CR, Lammertsma AA, van Dongen GAMS. Performance of immuno-positron emission tomography with zirconium-89-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients. *Clin Cancer Res* 2006; 12(7 Pt 1): 2133-2140. (VUmc)
100. Borst P, Genest PA. Parasitology - Switching like for like. *Nature* 2006; 439(7079): 926-927. (AMC/NKI)
101. Borst P, Zelcer N, Van De Wetering K, Poolman B. On the putative co-transport of drugs by multidrug resistance proteins. *FEBS Lett* 2006; 580: 1085-93. (NKI)

102. Borst P, Zelcer N, Van De Wetering K. MRP2 and 3 in health and disease. *Cancer Lett* 2006; 234: 51-61. (NKI)
103. Borst P. From cancer cells to trypanosomes and back again. *Cell Mol Life Sci* 2006; 63: 745-54. (NKI)
104. Borst P. How I became a biochemist. *IUBMB Life* 2006; 58: 177-82. (NKI)
105. Bos CL, Diks SH, Hardwick JCH, Walburg KV, Peppelenbosch MP, Richel DJ. Protein phosphatase 2A is required for mesalazine-dependent inhibition of Wnt/beta-catenin pathway activity. *Carcinogenesis* 2006; 27(12): 2371-2382. (AMC)
106. Bos CL, Kodach LL, van den Brink GR, Diks SH, van Santen MM, Richel DJ, Peppelenbosch MP, Hardwick JCH. Effect of aspirin on the Wnt/beta-catenin pathway is mediated via protein phosphatase 2A. *Oncogene* 2006; 25(49): 6447-6456. (AMC)
107. Bos E, Bomans P, De Haas F, Voorhout W, Gnaegi H, Frederik P, Hubert D, Peters PJ. Understanding the three-dimensional architecture in terms of spatial arrangements of organelle-bound protein complexes - Our next great challenge. *Microsc Microanal* 2006; 12: 1588. (NKI)
108. Bosch TM, Deenen M, Pruntel R, Smits PHM, Schellens JHM, Beijnen JH, Meijerman I. Screening for polymorphisms in the PXR gene in a Dutch population. *Eur J Clin Pharmacol* 2006; 62: 395-9. (NKI)
109. Bosch TM, Doodeman VD, Smits PHM, Meijerman I, Schellens JHM, Beijnen JH. Pharmacogenetic screening for polymorphisms in drug-metabolizing enzymes and drug transporters in a Dutch population. *Mol Diagn Ther* 2006; 10: 175-85. (NKI)
110. Bosch TM, Huitema ADR, Doodeman VD, Jansen R, Witteveen E, Smit WM, Jansen RL, Van Herpen CM, Soesan M, Beijnen JH, Schellens JHM. Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel. *Clin Cancer Res* 2006; 12: 5786-93. (NKI)
111. Bosch TM, Meijerman I, Beijnen JH, Schellens JHM. Genetic polymorphisms of drug metabolising enzymes and drug transporters in relation to cancer risk. *Curr Cancer Ther Rev* 2006; 2: 137-55. (NKI)
112. Bosch TM, Meijerman I, Beijnen JH, Schellens JHM. Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer. *Clin Pharmacokinet* 2006; 45: 253-85. (NKI)
113. Bosga-Bouwer A, van den Berg A, Haralambieva E, de Jong D, Boonstra R, Kluin P, van den Berg E, Poppema S. Molecular, cytogenetic, and immunophenotypic characterization of follicular lymphoma grade 3B; a separate entity or part of the spectrum of diffuse large B-cell lymphoma or follicular lymphoma? *Hum Pathol* 2006; 37: 528-33. (NKI)
114. Bots M, Medema JP. Granzymes at a glance. *J Cell Sci* 2006; 119(24): 5011-5014. (AMC)
115. Bots M, Offringa R, Medema JP. Does the serpin PI-9 protect tumor cells? *Blood* 2006; 107(12): 4974-4975. (AMC)
116. Bots M, van Bostelen, Rademaker MTGA, Offringa R, Medema JP. Serpins prevent granzyme-induced death in a species-specific manner. *Immunol Cell Biol* 2006; 84(1): 79-86. (AMC)
117. Bottomley A, Gaafa R, Manegold C, Burgers S, Coens C, Legrand C, Vincent M, Giaccone G, Van Meerbeeck J. Short-Term Treatment-Related Symptoms and Quality of Life: Results From an International Randomized Phase III Study of Cisplatin With or Without Raltitrexid in Patients With Malignant Pleural Mesothelioma: An EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup Study. *J Clin Oncol* 2006; 24: 1435-42. (NKI)
118. Bourquin JP, Subramanian A, Langebrake C, Reinhardt D, Bernard O, Ballerini P, Baruchel A, Cave H, Dastugue N, Hasle H, Kaspers GJL, Lessard M, Michaux L, Vyas P, van Wering E, Zwaan CM, Golub TR, Orkin SH. Identification of distinct molecular phenotypes in acute megakaryoblastic leukemia by gene expression profiling. *Proc Natl Acad Sci U S A* 2006; 103(9): 3339-3344. (VUmc)
119. Boutaga K, van Winkelhoff AJ, Vandenbroucke-Grauls CMJE, Savelkoul PHM. The additional value of real-time PCR in the quantitative detection of periodontal pathogens. *J Clin Periodontol* 2006; 33(6): 427-433. (VUmc)
120. Bovenschen HJ, Tjioe M, Vermaat H, de Hoop D, Witteman BM, Janssens RW, Stoof TJ, van de Kerkhof PC. Induction of eruptive benign melanocytic naevi by immune suppressive agents, including biologicals. *Br J Dermatol* 2006; 154(5): 880-884. (VUmc)
121. Boyle P, Ariyaratne MAY, Barrington R, Bartelink H, Bartsch G, Berns A, de Valeriola D, Dinshaw KA, Eggermont AMM, Gray N, Kakizoe T, Singh Karki B, Kaslar M, Kerr DJ, Khayat D, Khuhaprema T, Kim IH, Martin-Moreno J, McVie G, Park JG, Philip T, Ringborg U, Rodger A, Seffrin JR, Semiglazov V, Soo KC, Sun Y, Thomas R, Tursz T, Veronesi U, Wiestler O, Yoo KY, Zatonski W, Zhao P. Tobacco: deadly in any form or disguise. *Lancet* 2006; 367: 1710-2. (NKI)
122. Braakhuis BJM, Senft A, de Bree R, de Vries J, Ylstra B, Cloos J, Kuik DJ, Leemans CR, Brakenhoff RH. Expression profiling and prediction of distant metastases in head and neck squamous cell carcinoma. *J Clin Pathol* 2006; 59(12): 1254-1260. (VUmc)
123. Bradley PJ, Ferlito A, Suarez C, Werner JA, Genden EM, Saha AR, Leemans CR, Langendijk JA, Rinaldo A. Options for salvage after failed initial treatment of anterior vocal commissure squamous carcinoma. *Eur Arch Otorhinolaryngol* 2006; 263(10): 889-894. (VUmc)

124. Bradley PJ, Rinaldo A, Suarez C, Shaha AR, Rene LC, Langendijk JA, Patel SG, Ferlito A. Primary treatment of the anterior vocal commissure squamous carcinoma. *Eur Arch Otorhinolaryngol* 2006; 263(10): 879-888. (VUmc)
125. Bram E, Ifergan I, Shafran A, Berman B, Jansen G, Assaraf YG. Mutant Gly482 and Thr482 ABCG2 mediate high-level resistance to lipophilic antifolates. *Cancer Chemother Pharmacol* 2006; 58(6): 826-834. (VUmc)
126. Brandon EFA, Bosch TM, Deenen MJ, Levink R, Van Der Wal E, Van Meerveld JBM, Bijl M, Beijnen JH, Schellens JHM, Meijerman I. Validation of in vitro cell models used in drug metabolism and transport studies; Genotyping of cytochrome P450, phase II enzymes and drug transporter polymorphisms in the human hepatoma (HepG2), ovarian carcinoma (IGROV-1) and colon carcinoma (CaCo-2, LS180) cell lines. *Toxicol Appl Pharmacol* 2006; 211: 1-10. (NKI)
127. Brandon EFA, Sparidans RW, Guijt KJ, Lowenthal S, Meijerman I, Beijnen JH, Schellens JHM. In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis(r), Trabectedin(r)), a novel marine anti-cancer drug. *Invest New Drugs* 2006; 24: 3-14. (NKI)
128. Brandsma D, Taphoorn MJB, De Jager W, Bonfrer H, Algra A, Reijneveld JC, Boogerd W, Korse T, Verbeek MM, Rijkers GT, Voest EE. Interleukin-8 CSF levels predict survival in patients with leptomeningeal metastases. *Neurology* 2006; 66: 243-6. (NKI)
129. Brandsma D, Voest EE, De Jager W, Bonfrer H, Algra A, Boogerd W, Korse T, Reijneveld JC, Verbeek MM, Rijkers G, Taphoorn MJB. CSF protein profiling using Multiplex Immuno-assay: A potential new diagnostic tool for leptomeningeal metastases. *J Neurol* 2006; 253: 1177-84. (NKI)
130. Breedveld P, Beijnen JH, Schellens JHM. Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs. *Trends Pharmacol Sci* 2006; 27: 17-24. (NKI)
131. Breetveld M, Richters CD, Rustemeyer T, Scheper RJ, Gibbs S. Comparison of wound closure after burn and cold injury in human skin equivalents. *J Invest Dermatol* 2006; 126(8): 1918-1921. (VUmc)
132. Breij EC, Heijnen P, van der Goes A, Teunissen CE, Polman CH, Dijkstra CD. Myelin flow cytometry assay detects enhanced levels of antibodies to human whole myelin in a subpopulation of multiple sclerosis patients. *J Neuroimmunol* 2006; 176(1-2): 106-114. (VUmc)
133. Breitbach K, Klocke S, Tschernig T, van Rooijen N, Baumann U, Steinmetz I. Role of inducible nitric oxide synthase and NADPH oxidase in early control of *Burkholderia pseudomallei* infection in mice. *Infect Immun* 2006; 74(11): 6300-6309. (VUmc)
134. Brink AA, Meijer CJLM, Wiegerinck MA, Nieboer TE, Kruitwagen RF, van Kemenade FJ, Fransen DN, Hesselink AT, Berkhof J, Snijders PJF. High concordance of results of testing for human papillomavirus in cervicovaginal samples collected by two methods, with comparison of a novel self-sampling device to a conventional endocervical brush. *J Clin Microbiol* 2006; 44(7): 2518-2523. (VUmc)
135. Brink AA, Snijders PJF, Meijer CJLM, Berkhof J, Verheijen RHM. HPV testing in cervical screening. *Best Pract Res Clin Obstet Gynaecol* 2006; 20(2): 253-266. (VUmc)
136. Broberger E, Sprangers M, Tishelman C. Do internal standards of quality of life change in lung cancer patients? *Nurs Res* 2006; 55(4): 274-282. (AMC)
137. Broekhuizen LN, Wijsman JH, Peterse JL, Rutgers EJT. The incidence and significance of micrometastases in lymph nodes of patients with ductal carcinoma in situ and T1a carcinoma of the breast. *Eur J Surg Oncol* 2006; 32: 502-6. (NKI)
138. Broker LE, de Vos FY, van Groeningen CJ, Kuenen BC, Gall HE, Woo MH, Voi M, Gietema JA, de Vries EG, Giaccone G. Phase I trial with BMS-275183, a novel oral taxane with promising antitumor activity. *Clin Cancer Res* 2006; 12(6): 1760-1767. (VUmc)
139. Brosens RP, Oomen JL, Glas AS, van Bochove A, Cuesta MA, Engel AF. POSSUM predicts decreased overall survival in curative resection for colorectal cancer. *Dis Colon Rectum* 2006; 49(6): 825-832. (VUmc)
140. Brouwer J, Senft A, de Bree R, Comans EFI, Golding RP, Castelijn JA, Hoekstra OS, Leemans CR. Screening for distant metastases in patients with head and neck cancer: is there a role for (18)FDG-PET?. *Oral Oncol* 2006; 42(3): 275-280. (VUmc)
141. Brouwers EEM, Tibben MM, Rosing H, Hillebrand MJX, Joerger M, Schellens JHM, Beijnen JH. Sensitive inductively coupled plasma mass spectrometry assay for the determination of platinum originating from cisplatin, carboplatin, and oxaliplatin in human plasma ultrafiltrate. *J Mass Spectrom* 2006; 41: 1186-94. (NKI)
142. Bruggeman SWM, Van Lohuizen M. Controlling stem cell proliferation: CKIs at work. *Cell Cycle* 2006; 5: 1281-5. (NKI)
143. Brummelkamp TR, Fabius AWM, Mullenders J, Madiredjo M, Velds A, Kerkhoven RM, Bernards R, Beijersbergen RL. An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors. *Nat Chem Biol* 2006; 2: 202-6. (NKI)
144. Bruynzeel AME, Mul PP, Berkhof J, Bast A, Niessen HW, Van der Vijgh WJ. The influence of the time interval between monoHER and doxorubicin administration on the protection against doxorubicin-induced cardiotoxicity in mice.

- Cancer Chemother Pharmacol 2006; 58(5): 699-702. (VUmc)
145. Buchwald G, Van Der Stoop P, Weichenrieder O, Perrakis A, Van Lohuizen M, Sixma TK. Structure and E3-ligase activity of the Ring-Ring complex of Polycomb proteins Bmi1 and Ring1b. *EMBO J* 2006; 25: 2465-74. (NKI)
146. Buitelaar DR, Balm AJM, Antonini N, Van Tinteren H, Huitink JM. Cardiovascular and respiratory complications after major head and neck surgery. *Head Neck* 2006; 28: 595-602. (NKI)
147. Buizer AI, de Sonnevill LM, van den Heuvel-Eibrink MM, Veerman AJP. Behavioral and educational limitations after chemotherapy for childhood acute lymphoblastic leukemia or Wilms tumor. *Cancer* 2006; 106(9): 2067-2075. (VUmc)
148. Bulk S, Berkhof J, Bulkman NW, Zielinski GD, Rozendaal L, van Kemenade FJ, Snijders PJF, Meijer CJLM. Preferential risk of HPV16 for squamous cell carcinoma and of HPV18 for adenocarcinoma of the cervix compared to women with normal cytology in The Netherlands. *Br J Cancer* 2006; 94(1): 171-175. (VUmc)
149. Bulkman NW, Bulk S, Ottevanger MS, Rozendaal L, Hellenberg SM, van Kemenade FJ, Snijders PJF, Boeke AJ, Meijer CJLM. Implementation of human papillomavirus testing in cervical screening without a concomitant decrease in participation rate. *J Clin Pathol* 2006; 59(11): 1218-1220. (VUmc)
150. Bultink IEM, Hamann D, Seelen MA, Hart MH, Dijkman BAC, Daha MR, Voskuyl AE. Deficiency of functional mannose-binding lectin is not associated with infections in patients with systemic lupus erythematosus. *Arthritis Res Ther* 2006; 8(6): R183. (VUmc)
151. Buskens CJ, Huscher JBF, van Gulik TM, ten Kate FJ, van Lanschot JJB. Histopathologic evaluation of an animal model for Barrett's esophagus and adenocarcinoma of the distal esophagus. *J Surg Res* 2006; 135(2): 337-344. (AMC)
152. Buyse M, Loi S, van 't Veer L, Viale G, Delorenzi M, Glas AM, d'Assignies MS, Bergh J, Lidereau R, Ellis P, Harris A, Bogaerts J, Therasse P, Floore A, Amakrane M, Piette F, Rutgers E, Sotiriou C, Cardoso F, Piccart MJ, Decker N, Straehle C. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. *J Natl Cancer Inst* 2006; 98: 1183-92. (NKI)
153. Calbo J, Meuwissen R, van Montfort E, van Tellinghen O, Berns A. Genotype-phenotype relationships in a mouse model for human small-cell lung cancer. *Cold Spring Harb Symp Quant Biol* 2005; 70: 225-32. (NKI)
154. Campo E, Chott A, Kinney MC, Leoncini L, Meijer CJLM, Papadimitriou CS, Piris MA, Stein H, Swerdlow SH. Update on extranodal lymphomas. Conclusions of the Workshop held by the EAHP and the SH in Thessaloniki, Greece. *Histopathology* 2006; 48(5): 481-504. (VUmc)
155. Castellsague X, Diaz M, de Sanjose S, Munoz N, Herrero R, Franceschi S, Peeling RW, Ashley R, Smith JS, Snijders PJF, Meijer CJLM, Bosch FX. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. *J Natl Cancer Inst* 2006; 98(5): 303-315. (VUmc)
156. Cense HA, Busch ORC, Bemelman WA, Obertop H, van Lanschot JJB. Results of the combination of open transthoracic esophagectomy with laparoscopic gastric tube formation for esophageal cancer. *Digest Surg* 2006; 23(3): 164-168. (AMC)
157. Cense HA, Hulscher JBF, de Boer AGEM, Dongelmans DA, Tilanus HW, Obertop H, Sprangers MAG, van Lanschot JJB. Effects of prolonged intensive care unit stay on quality of life and long-term survival after transthoracic esophageal resection. *Crit Care Med* 2006; 34(2): 354-362. (AMC)
158. Cense HA, Lagarde SM, de Jong K, Omlou JMT, Busch ORC, Henny CP, van Lanschot JJB. Association of no epidural analgesia with postoperative morbidity and mortality after transthoracic esophageal cancer resection. *J Am Coll Surgeons* 2006; 202(3): 395-400. (AMC)
159. Chamuleau MED, Ossenkuppele GJ, van de Loosdrecht AA. MHC class II molecules in tumour immunology: prognostic marker and target for immune modulation. *Immunobiology* 2006; 211(6-8): 619-625. (VUmc)
160. Chanudet E, Zhou Y, Bacon CM, Wotherspoon AC, Müller-Hermelink HK, Adam P, Dong HY, de Jong D, Li Y, Wei R, Gong X, Wu Q, Ranaldi R, Goteri G, Pileri SA, Ye H, Hamoudi RA, Liu H, Radford J, Du MQ. Chlamydia psittaci is variably associated with ocular adnexal MALT lymphoma in different geographical regions. *J Pathol* 2006; 209: 344-51. (NKI)
161. Checinska A, Giaccone G, Hoogeland BS, Ferreira CG, Rodriguez JA, Kruyt FAE. TUCAN/CARDINAL/CARD8 and apoptosis resistance in non-small cell lung cancer cells. *BMC Cancer* 2006; 6: 166. (VUmc)
162. Checinska A, Oudejans JJ, Span SW, Rodriguez JA, Kruyt FAE, Giaccone G. The expression of TUCAN, an inhibitor of apoptosis protein, in patients with advanced non-small cell lung cancer treated with chemotherapy. *Anticancer Res* 2006; 26(5B): 3819-3824. (VUmc)
163. Chi JT, Wang Z, Nuyten DSA, Rodriguez EH, Schaner ME, Salim A, Wang Y, Kristensen GB, Helland A, Borresen-Dale AL, Giaccia A, Longaker MT, Hastie T, Yang GP, Van De Vijver MJ, Brown PO. Gene expression programs in response to hypoxia: Cell type specificity and prognostic significance in human cancers. *PLoS Medicine* 2006; 3: 395-409. (NKI)
164. Choksi SP, Southall TD, Bossing T, Edoff K, de Wit E, Fischer B, van Steensel B, Micklem G,

- Brand AH. Prospero Acts as a Binary Switch between Self-Renewal and Differentiation in *Drosophila* Neural Stem Cells. *Dev Cell* 2006; 11: 775-89. (NKI)
165. Cillessen SAGM, Meijer CJLM, Ossenkoppele GJ, Castricum KC, Westra AH, Niesten P, Muris JJF, Nijdam HF, van der Hem KG, Flens M, Hooijberg E, Oudejans JJ. Human soluble TRAIL/Apo2L induces apoptosis in a subpopulation of chemotherapy refractory nodal diffuse large B-cell lymphomas, determined by a highly sensitive in vitro apoptosis assay. *Br J Haematol* 2006; 134(3): 283-293. (VUmc)
166. Clark K, Langeslag M, Van Leeuwen B, Ran L, Ryazanov AG, Figdor CG, Moolenaar WH, Jalink K, Van Leeuwen FN. TRPM7, a novel regulator of actomyosin contractility and cell adhesion. *EMBO J* 2006; 25: 290-301. (NKI)
167. Cloos J, de Boer WP, Snel MH, van Die IM, Ylstra B, Leemans CR, Brakenhoff RH, Braakhuis BJM. Microarray analysis of bleomycin-exposed lymphoblastoid cells for identifying cancer susceptibility genes. *Mol Cancer Res* 2006; 4(2): 71-77. (VUmc)
168. Cloos J, Goemans BF, Hess CJ, van Oostveen JW, Waisfisz Q, Corthals S, de Lange D, Boeckx N, Hahlen K, Reinhardt D, Creutzig U, Schuurhuis GJ, Zwaan CM, Kaspers GJL. Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples. *Leukemia* 2006; 20(7): 1217-1220. (VUmc)
169. Cloosen S, Gratama J, van Leeuwen EB, Senden-Gijsbers BL, Oving EB, Mensdorff-Pouilly S, Tarp MA, Mandel U, Clausen H, Germeraad WT, Bos GM. Cancer specific Mucin-1 glycoforms are expressed on multiple myeloma. *Br J Haematol* 2006; 135(4): 513-516. (VUmc)
170. Corporaal S, Smit WM, Russel MGVM, van der Palen J, Boot H, Legdeur MCJC. Capecitabine, epirubicin and cisplatin in the treatment of oesophagogastric adenocarcinoma. *Neth J Med* 2006; 64: 141-6. (NKI)
171. Corten EML, Schellekens PPA, Bleys RLAW, Hage JJ, Kon M. The segmental pectoralis major free flap: Anatomical features of its vascular pedicle. *Ann Plast Surg* 2006; 56: 82-6. (NKI)
172. Cote CK, van Rooijen N, Welkos SL. Roles of macrophages and neutrophils in the early host response to *Bacillus anthracis* spores in a mouse model of infection. *Infect Immun* 2006; 74(1): 469-480. (VUmc)
173. Cover KS, Lagerwaard FJ, Senan S. Color intensity projections: a rapid approach for evaluating four-dimensional CT scans in treatment planning. *Int J Radiat Oncol Biol Phys* 2006; 64(3): 954-961. (VUmc)
174. Craanen ME, van Triest B, Verheijen RHM, Mulder CJ. Thalidomide in refractory haemorrhagic radiation induced proctitis. *Gut* 2006; 55(9): 1371-1372. (VUmc)
175. Craanen ME, van Waesberghe JH, van der Peet DL, Loffeld RJ, Cuesta MA, Mulder CJ. Endoscopic ultrasound in patients with obstructive jaundice and inconclusive ultrasound and computer tomography findings. *Eur J Gastroenterol Hepatol* 2006; 18(12): 1289-1292. (VUmc)
176. Crawford A, MacLeod M, Schumacher T, Corlett L, Gray D. Primary T cell expansion and differentiation in vivo requires antigen presentation by B cells. *J Immunol* 2006; 176: 3498-506. (NKI)
177. Crawford L, Walker B, Ovaia H, Chauhan D, Anderson K, Morris T, Irvine A. Comparative selectivity and specificity of the proteasome inhibitors BzLLLCOCHO, PS-341, and MG-132. *Cancer Res* 2006; 66: 6379-86. (NKI)
178. Crettaz J, Berraondo P, Mauleon I, Ochoa L, Shankar V, Barajas M, van Rooijen N, Kochanek S, Qian C, Prieto J, Hernandez-Alcoceba R, Gonzalez-Aseguinolaza G. Intrahepatic injection of adenovirus reduces inflammation and increases gene transfer and therapeutic effect in mice. *Hepatology* 2006; 44(3): 623-632. (VUmc)
179. Creighton MP, Roël G, Eichhorn PJA, Vredevelde LC, Destrée O, Bernards R. PR130 is a modulator of the Wnt-signaling cascade that counters repression of the antagonist Naked cuticle. *Proc Natl Acad Sci U S A* 2006; 103: 5397-402. (NKI)
180. Cserni G, Bianchi S, Vezzosi V, Peterse H, Sapino A, Arisio R, Reiner-Concin A, Regitnig P, Bellocco JP, Marin C, Bori R, Penuela JM, Iturriagagoitia AC. The value of cytokeratin immunohistochemistry in the evaluation of axillary sentinel lymph nodes in patients with lobular breast carcinoma. *J Clin Pathol* 2006; 59: 518-22. (NKI)
181. Cuzick J, Clavel C, Petry KU, Meijer CJLM, Hoyer H, Ratnam S, Szarewski A, Birembaut P, Kulasingam S, Sasieni P, Iftner T. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. *Int J Cancer* 2006; 119(5): 1095-1101. (VUmc)
182. Dai M, Bao YP, Li N, Clifford GM, Vaccarella S, Snijders PJF, Huang RD, Sun LX, Meijer CJLM, Qiao YL, Franceschi S. Human papillomavirus infection in Shanxi Province, People's Republic of China: a population-based study. *Br J Cancer* 2006; 95(1): 96-101. (VUmc)
183. Dantuma NP, Groothuis TAM, Salomons FA, Neefjes J. A dynamic ubiquitin equilibrium couples proteasomal activity to chromatin remodeling. *J Cell Biol* 2006; 173: 19-26. (NKI)
184. Davies AHG, Larsson G, Ardill J, Friend E, Jones L, Falconi M, Bettini R, Koller M, Sezer O, Fleissner C, Taal B, Blazeby JM, Ramage JK. Development of a disease-specific quality of life questionnaire module for patients with gastrointestinal neuroendocrine tumours. *Eur J Cancer* 2006; 42: 477-84. (NKI)

185. Davies P, Arbyn M, Dillner J, Kitchener HC, Meijer CJLM, Ronco G, Hakama M. A report on the current status of European research on the use of human papillomavirus testing for primary cervical cancer screening. *Int J Cancer* 2006; 118(4): 791-796. (VUmc)
186. de Bock GH, van der Hage JA, Putter H, Bonnema J, Bartelink H, Van De Velde CJ. Isolated loco-regional recurrence of breast cancer is more common in young patients and following breast conserving therapy: Long-term results of European Organisation for Research and Treatment of Cancer studies. *Eur J Cancer* 2006; 42: 351-6. (NKI)
187. de Boer P, Vos HR, Faber AW, Vos JC, Rau, HA. Rrp5p, a trans-acting factor in yeast ribosome biogenesis, is an RNA-binding protein with a pronounced preference for U-rich sequences. *RNA* 2006; 12: 263-71. (NKI)
188. de Bondt BJ, Stokroos R, Balm F, Casselman J. The "silent" progression of a secondary paranasal malignancy in a laryngectomized patient. *Eur J Radiol Extra* 2006; 58: 77-80. (NKI)
189. de Bree E, Koops W, Kroger R, van Ruth S, Verwaal VJ, Zoetmulder FAN. Preoperative computed tomography and selection of patients with colorectal peritoneal carcinomatosis for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. *Eur J Surg Oncol* 2006; 32: 65-71. (NKI)
190. de Bree E, Manios A, de Bree R, Tsiftis DD. Malignant cutaneous melanoma. *Hellenic Surg Oncol* 2006; : 70-80. (VUmc)
191. de Bree E, Rosing H, Michalakis J, Romanos J, Relakis K, Theodoropoulos PA, Beijnen JH, Georgoulas V, Tsiftis DD. Intraperitoneal chemotherapy with taxanes for ovarian cancer with peritoneal dissemination. *Eur J Surg Oncol* 2006; 32: 666-70. (NKI)
192. de Bree E, Theodoropoulos PA, Rosing H, Michalakis J, Romanos J, Beijnen JH, Tsiftis DD. Treatment of ovarian cancer using intraperitoneal chemotherapy with taxanes: From laboratory bench to bedside. *Cancer Treat Rev* 2006; 32: 471-82. (NKI)
193. de Bree R, Tijink BM, van Groeningen CJ, Leemans CR. Electroporation Therapy in Soft Tissue Sarcoma: A Potentially Effective Novel Treatment. *Sarcoma* 2006; : 85234. (VUmc)
194. de Bree R, van der Valk P, Kuik DJ, van Diest PJ, Doornaert PA, Buter J, Eerenstein SE, Langendijk JA, van der Waal I, Leemans CR. Prognostic factors in adult soft tissue sarcomas of the head and neck: a single-centre experience. *Oral Oncol* 2006; 42(7): 703-709. (VUmc)
195. de Bruin EC, Van De Velde CJH, Van De Pas S, Nagtegaal ID, Van Krieken JHJM, Gosens MJEM, Peltenburg LTC, Medema JP, Marijnen CAM. Prognostic value of apoptosis in rectal cancer patients of the Dutch Total Mesorectal Excision trial: Radiotherapy is redundant in intrinsically high-apoptotic tumors. *Clin Cancer Res* 2006; 12: 6432-6 (AMC/NKI)
196. de Bruin M, Temmink OH, Hoekman K, Pinedo HM, Peters GJ. Role of platelet derived endothelial cell growth factor / thymidine phosphorylase in health and disease. *Cancer Therapy* 2006; : 99-124. (VUmc)
197. de Castro S, Busch O, van Delden O, Lameris J, Gouma D. Delayed massive hemorrhage after pancreatic and biliary surgery: Embolization or surgery? Reply. *Ann Surg* 2006; 243(1):139. (AMC)
198. de Donk NWCJV, Kroger N, Hegenbart U, Corradini P, Miguel JFS, Goldschmidt H, Perez-Simon JA, Zijlmans M, Raymakers RA, Montefusco V, Ayuk FA, van Oers MHJ, Nagler A, Verdonck LF, Lokhorst HM. Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma. *Bone Marrow Transpl* 2006; 37(12): 1135-1141. (AMC)
199. de Gruijl TD, Ophorst OJ, Goudsmit J, Verhaagh S, Loughheed SM, Radosevic K, Havenga MJ, Scheper RJ. Intradermal delivery of adenoviral type-35 vectors leads to high efficiency transduction of mature, CD8+ T cell-stimulating skin-emigrated dendritic cells. *J Immunol* 2006; 177(4): 2208-2215. (VUmc)
200. de Gruijl TD, Sombroek CC, Loughheed SM, Oosterhoff D, Buter J, van den Eertwegh AJM, Scheper RJ, Pinedo HM. A postmigrational switch among skin-derived dendritic cells to a macrophage-like phenotype is predetermined by the intracutaneous cytokine balance. *J Immunol* 2006; 176(12): 7232-7242. (VUmc)
201. de Haas T, Oussoren E, Grajkowska W, Perek-Polnik M, Popovic M, Zadavec-Zaletel L, Perera M, Corte G, Wirths O, van Sluis P, Pietsch T, Troost D, Baas F, Versteeg R, Kool M. OTX1 and OTX2 expression correlates with the clinicopathologic classification of medulloblastomas. *J Neuropath Exp Neur* 2006; 65(2): 176-186. (AMC)
202. de Jong AE, Hendriks YMC, Kleibeuker JH, De Boer SY, Cats A, Griffioen G, Nagengast FM, Nelis FG, Rookus MA, Vasen HFA. Decrease in mortality in Lynch syndrome families because of surveillance. *Gastroenterology* 2006; 130: 665-71. (NKI)
203. de Jong AE, Nagengast FM, Kleibeuker JH, van de Meeberg PC, van Wijk HJ, Cats A, Griffioen G, Vasen FA. What is the appropriate screening protocol in Lynch syndrome? *Fam Cancer* 2006; 5: 373-8. (NKI)
204. de Jong D, Bosq J, MacLennan KA, Diebold J, Audouin J, Chasle J, Mandard AM, Marnay J, Henry-Amar M. Lymphocyte-rich classical Hodgkin lymphoma (LRCHL): Clinico-pathological characteristics and outcome of a rare entity. *Ann Oncol* 2006; 17: 141-5. (NKI)
205. de Jonge ME, Huitema ADR, Beijnen JH, Rodenhuis S. High exposures to bioactivated

- cyclophosphamide are related to the occurrence of veno-occlusive disease of the liver following high-dose chemotherapy. *Br J Cancer* 2006; 94: 1226-30. (NKI)
206. de Jongh CM, Verberk MM, Withagen CE, Jacobs JJ, Rustemeyer T, Kezic S. Stratum corneum cytokines and skin irritation response to sodium lauryl sulfate. *Contact Dermatitis* 2006; 54(6): 325-333. (VUmc)
207. de Kort SJ de, Willemse PHB, Habraken JM, de Haes HCJM, Willems DL, Richel DJ. Quality of life versus prolongation of life in patients treated with chemotherapy in advanced colorectal cancer: A review of randomized controlled clinical trials. *Eur J Cancer* 2006; 42(7): 835-845.
208. de la Rosette J, Alivizatos G. Lasers for the treatment of bladder outlet obstruction: Are they challenging conventional treatment modalities? *Eur Urol* 2006; 50(3): 418-420. (AMC)
209. de la Rosette J. Optimising assessment and treatment decisions for men with BPH. *Euro Urol Suppl* 2006; 5(12): 710-715. (AMC)
210. de Lange J, van den Akker HP, van den Berg H, Richel DJ, Gortzak RAT. Limited regression of central giant cell granuloma by interferon alpha after failed calcitonin therapy: a report of 2 cases. *Int J Oral Max Surg* 2006; 35(9): 865-869. (AMC)
211. de Langen AJ, Raijmakers P, Riphagen I, Paul MA, Hoekstra OS. The size of mediastinal lymph nodes and its relation with metastatic involvement: a meta-analysis. *Eur J Cardiothorac Surg* 2006; 29(1): 26-29. (VUmc)
212. de Nijs RN, Jacobs JW, Lems WF, Laan RF, Algra A, Huisman AM, Buskens E, de Laet CE, Oostveen AC, Geusens PPMM, Bruyn GA, Dijkmans BAC, Bijlsma JW. Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. *New Engl J Med* 2006; 355(7): 675-684. (VUmc)
213. de Ridder J, Uren A, Kool J, Reinders M, Wessels L. Detecting Statistically Significant Common Insertion Sites in Retroviral Insertional Mutagenesis Screens. *PLoS Comput Biol* 2006; 2: e166. (NKI)
214. de Rooij J, Bruynzeel DP, Rustemeyer T. Occupational allergic contact dermatitis from hydrangea. *Contact Dermatitis* 2006; 54(1): 65-66. (VUmc)
215. de Ruijter AJM, Leen R, Hoebink J, Caron HN, van Kuilenburg ABP van. Antagonistic effects of sequential administration of BL1521, a histone deacetylase inhibitor, and gemcitabine to neuroblastoma cells. *Cancer Lett* 2006; 233(2): 240-246. (AMC)
216. de Schutter H, Barb, B, Spaepen M, Begg AC, Balm A, Gregoire V, Haustermans K, Mahy P, Vander Poorten V, Nuyts S. Microsatellite alterations in head and neck squamous cell carcinoma and relation to expression of pimonidazole, CA IX and GLUT-1. *Radiother Oncol* 2006; 80: 143-50. (NKI)
217. de Visser KE, Coussens LM. The inflammatory tumor microenvironment and its impact on cancer development. *Contrib Microbiol* 2006; 13: 118-37. (NKI)
218. de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. *Nat Rev Cancer* 2006; 6: 24-37. (NKI)
219. de Vries HJ, Fennema JS, Morre SA. Lymphogranuloma venereum among men having sex with men: what have we learned so far?. *Sex Transm Infect* 2006; 82(4): 344. (VUmc)
220. de Vries NA, Beijnen JH, Boogerd W, van Tellingen O. Blood-brain barrier and chemotherapeutic treatment of brain tumors. *Expert Rev Neurother* 2006; 6: 1199-209. (NKI)
221. de Weert S, Dekkers LC, Bitter W, Tuinman S, Wijfjes AH, van Boxtel R, Lugtenberg BJ. The two-component colR/S system of *Pseudomonas fluorescens* WCS365 plays a role in rhizosphere competence through maintaining the structure and function of the outer membrane. *FEMS Microbiol Ecol* 2006; 58(2): 205-213. (VUmc)
222. de Witte L, Abt M, Schneider-Schaulies S, van Kooyk Y, Geijtenbeek TBH. Measles virus targets DC-SIGN to enhance dendritic cell infection. *J Virol* 2006; 80(7): 3477-3486. (VUmc)
223. de Witte L, van Kooyk Y, Geijtenbeek TBH. Dendritic Cell-mediated transmission: a potential drug target?. *Future Virology* 2006; 1: 615-622. (VUmc)
224. de Witte MA, Coccoris M, Wolkers MC, Van Den Boom MD, Mesman EM, Song JY, Van Der Valk M, Haanen JBAG, Schumacher TNM. Targeting self-antigens through allogeneic TCR gene transfer. *Blood* 2006; 108: 870-7. (NKI)
225. Debicki K, Van Uitert M. Large buffer asymptotics for generalized processor sharing queues with Gaussian inputs. *Queueing Syst* 2006; 54: 111-20. (NKI)
226. Dekker M, Brouwers C, Aarts M, van der Torre J, de Vries S, van de Vrugt H, te Riele H. Effective oligonucleotide-mediated gene disruption in ES cells lacking the mismatch repair protein MSH3. *Gene Ther* 2006; 13: 686-94. (NKI)
227. Den Brok MWJ, Nuijen B, García JL, Miranda E, Calvo P, Manada C, Beijnen JH. Compatibility and stability of the novel anticancer agent ES-285 + HCl formulated with 2-hydroxypropyl- β -cyclodextrin in infusion devices. *Pharmazie* 2006; 61: 21-4. (NKI)
228. den Hartog JE, Morre SA, Land JA. Chlamydia trachomatis-associated tubal factor subfertility: Immunogenetic aspects and serological screening. *Hum Reprod Update* 2006; 12(6): 719-730. (VUmc)
229. den Hartog JE, Ouburg S, Land JA, Lyons JM, Ito JI, Pena AS, Morre SA. Do host genetic traits in the bacterial sensing system play a role in the development of Chlamydia trachomatis-associated

- tubal pathology in subfertile women?. *BMC Infect Dis* 2006; 6: 122. (VUmc)
230. den Hertog AL, van Marle J, Veerman EC, Valentijn-Benz M, Nazmi K, Kalay H, Grun CH, Van't Hof W, Bolscher JG, Nieuw Amerongen AV. The human cathelicidin peptide LL-37 and truncated variants induce segregation of lipids and proteins in the plasma membrane of *Candida albicans*. *Biol Chem* 2006; 387(10-11): 1495-1502. (VUmc)
231. Derksen PWB, Liu X, Saridin F, van der Gulden H, Zevenhoven J, Evers B, van Beijnum JR, Griffioen AW, Vink J, Krimpenfort P, Peterse JL, Cardiff RD, Berns A, Jonkers J. Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis. *Cancer Cell* 2006; 10: 437-49. (NKI)
232. Desmet CJ, Peeper DS. The neurotrophic receptor TrkB: A drug target in anti-cancer therapy? *Cell Mol Life Sci* 2006; 63: 755-9. (NKI)
233. Deurloo EE, Klein Zeggelink WFA, Teertstra HJ, Peterse JL, Rutgers EJT, Muller SH, Bartelink H, Gilhuijs KGA. Contrast-enhanced MRI in breast cancer patients eligible for breast-conserving therapy: Complementary value for subgroups of patients. *Eur Radiol* 2006; 16: 692-701. (NKI)
234. Diederens BM, de Jong CM, Kluytmans JAJW, van der Zee A, Peeters MF. Detection and quantification of *Legionella pneumophila* DNA in serum: case reports and review of the literature. *J Med Microbiol* 2006; 55(Pt 5): 639-642. (VUmc)
235. Diederens BM, Kluytmans JAJW, Peeters MF. Evaluation of Vircell enzyme-linked immunosorbent assay and indirect immunofluorescence assay for detection of antibodies against *Legionella pneumophila*. *Clin Vaccine Immunol* 2006; 13(3): 361-364. (VUmc)
236. Diederens BM, Kluytmans JAJW. The emergence of infections with community-associated methicillin resistant *Staphylococcus aureus*. *J Infect* 2006; 52(3): 157-168. (VUmc)
237. Diederens BM, van Duijn I, Willemse P, Kluytmans JAJW. In vitro activity of daptomycin against methicillin-resistant *Staphylococcus aureus*, including heterogeneously glycopeptide-resistant strains. *Antimicrob Agents Chemother* 2006; 50(9): 3189-3191. (VUmc)
238. Diederens BM, van Leest CM, van Duijn I, Willemse P, van Keulen PH, Kluytmans JAJW. Evaluation of Saureus ID, a Chromogenic Agar Medium for the Detection of *Staphylococcus aureus*. *Infection* 2006; 34(2): 95-97. (VUmc)
239. Diederens BM, van Leest ML, van Duijn I, Willemse P, van Keulen PH, Kluytmans JAJW. Performance of MRSA ID, a new chromogenic medium for detection of methicillin-resistant *Staphylococcus aureus*. *J Clin Microbiol* 2006; 44(2): 586-588. (VUmc)
240. Diederens BM, Verhulst C, van't Veen A, van Keulen PH, Kluytmans JAJW. Pseudo-outbreak of hepatitis B virus infection associated with contamination of a semiautomatic cap remover. *Infect Control Hosp Epidemiol* 2006; 27(11): 1258-1260. (VUmc)
241. Diepgen TL, Bruynzeel DP, Andersen KE, Brandao FM, Bruze M, Goncalo M, Goossens A, Lahti A, Mahler V, Menne T, White IR, Wilkinson JD. Mercaptobenzothiazole or the mercapto-mix: which should be in the standard series?. *Contact Dermatitis* 2006; 55(1): 36-38. (VUmc)
242. Dinant S, Gerhards MF, Rauws EAJ, Busch ORC, Gouma DJ, van Gulik TM. Improved outcome of resection of hilar cholangiocarcinoma (Klatskin tumor). *Ann Surg Oncol* 2006; 13(6): 872-880. (AMC)
243. Dirksen EH, Cloos J, Braakhuis BJM, Brakenhoff RH, Heck AJ, Slijper M. Human lymphoblastoid proteome analysis reveals a role for the inhibitor of acetyltransferases complex in DNA double-strand break response. *Cancer Res* 2006; 66(3): 1473-1480. (VUmc)
244. Dirksen EH, Pinkse MW, Rijkers DT, Cloos J, Liskamp RM, Slijper M, Heck AJ. Investigating the dynamic nature of the interactions between nuclear proteins and histones upon DNA damage using an immobilized peptide chemical proteomics approach. *J Proteome Res* 2006; 5(9): 2380-2388. (VUmc)
245. Domchek SM, Friebel TM, Neuhausen SL, Wagner T, Evans G, Isaacs C, Garber JE, Daly MB, Eeles R, Matloff E, Tomlinson GE, van't Veer L, Lynch HT, Olopade OI, Weber BL, Rebbeck TR. Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: A prospective cohort study. *Lancet Oncol* 2006; 7: 223-9. (NKI)
246. Doorn HC, Ansink AC, Verhaar-Langereis M, Stalpers LJA. Neoadjuvant chemoradiation for advanced primary vulvar cancer. *Cochrane Database Syst Rev* 2006; 3(CD003752), online. (AMC)
247. Dorresteijn L, Stewart F, Boogerd W. Stroke As a Late Treatment Effect of Hodgkin's Disease. *J Clin Oncol* 2006; 24: 1480. (NKI)
248. Echeverri CJ, Beachy PA, Baum B, Boutros M, Buchholz F, Chanda SK, Downward J, Ellenberg J, Fraser AG, Hacohen N, Hahn WC, Jackson AL, Kiger A, Linsley PS, Lum L, Ma Y, Mathey P, Root DE, Sabatini DM, Taipale J, Perrimon N, Bernards R. Minimizing the risk of reporting false positives in large-scale RNAi screens. *Nat Meth* 2006; 3: 777-9. (NKI)
249. Efficace F, Bottomley A, Smit EF, Lianes P, Legrand C, Debruyne C, Schramel FM, Smit HJ, Gaafar R, Biesma B, Manegold C, Coens C, Giaccone G, Van Meerbeek J. Is a patient's self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients? A multivariate analysis of prognostic factors of EORTC study 08975. *Ann Oncol* 2006; 17(11): 1698-1704. (VUmc)

250. Efficace F, Horneber M, Lejeune S, Van Dam F, Leering S, Rottmann M, Aaronson NK. Methodological quality of patient-reported outcome research was low in complementary and alternative medicine in oncology. *J Clin Epidemiol* 2006; 59: 1257-65. (NKI)
251. Ekhart C, De Jonge ME, Huitema ADR, Schellens JHM, Rodenhuis S, Beijnen JH. Flat dosing of carboplatin is justified in adult patients with normal renal function. *Clin Cancer Res* 2006; 12: 6502-8. (NKI)
252. Elliott T, Neefjes J. The Complex Route to MHC Class I-Peptide Complexes. *Cell* 2006; 127: 249-51. (NKI)
253. Engers R, Mueller M, Walter A, Collard JG, Willers R, Gabbert HE. Prognostic relevance of Tiam1 protein expression in prostate carcinomas. *Br J Cancer* 2006; 95: 1081-6. (NKI)
254. Engwegen JYMN, Gast MCW, Schellens JHM, Beijnen JH. Clinical proteomics: searching for better tumour markers with SELDI-TOF mass spectrometry. *Trends Pharmacol Sci* 2006; 27: 251-9. (NKI)
255. Engwegen JYMN, Helgason HH, Cats A, Harris N, Bonfrer JMG, Schellens JHM, Beijnen JH. Identification of serum proteins discriminating colorectal cancer patients and healthy controls using surface-enhanced laser desorption ionisation-time of flight mass spectrometry. *World J Gastroenterol* 2006; 12: 1536-44. (NKI)
256. Epping MT, Bernards R. A causal role for the human tumor antigen preferentially expressed antigen of melanoma in cancer. *Cancer Res* 2006; 66: 10639-42. (NKI)
257. Erdogan D, Busch ORC, Rauws EAJ, van Delden OM, Gouma DJ, van Gulik TM. Obstructive jaundice due to hepatobiliary cystadenoma or cystadenocarcinoma. *World J Gastroenterol* 2006; 12(35): 5735-5738. (AMC)
258. Erdogan D, Busch ORC, van Delden OM, ten Kate FJW, Gouma DJ, van Gulik TM. Management of spontaneous haemorrhage and rupture of hepatocellular adenomas. A single centre experience. *Liver Int* 2006; 26(4): 433-438. (AMC)
259. Erdogan D, Lamers WH, Offerhaus GJA, Busch ORC, Gouma DJ, van Gulik TM. Cystadenomas with ovarian stroma in liver and pancreas: An evolving concept. *Digest Surg* 2006; 23(3): 186-191. (AMC)
260. Evans KJ, Hansen DS, van Rooijen N, Buckingham LA, Schofield L. Severe malarial anemia of low parasite burden in rodent models results from accelerated clearance of uninfected erythrocytes. *Blood* 2006; 107(3): 1192-1199. (VUmc)
261. Evers B, Jonkers J. Mouse models of BRCA1 and BRCA2 deficiency: Past lessons, current understanding and future prospects. *Oncogene* 2006; 25: 5885-97. (NKI)
262. Eyüpoglu IY, Hahnen E, Tränkle C, Savaskan NE, Siebzehnrübl FA, Buslei R, Lemke D, Wick W, Fahlbusch R, Blümcke I. Experimental therapy of malignant gliomas using the inhibitor of histone deacetylase MS-275. *Mol Cancer Ther* 2006; 5: 1248-55. (NKI)
263. Fabbrini P, Zareie M, Ter Wee PM, Keuning ED, Beelen RHJ, van den Born J. Peritoneal exposure model in the rat as a tool to unravel bio(in)compatibility of PDF. *Nephrol Dial Transplant* 2006; 21 Suppl 2: ii8-11. (VUmc)
264. Fachiroh J, Paramita DK, Hariwiyanto B, Harijadi A, Dahlia HL, Indrasari SR, Kusumo H, Zeng YS, Schouten T, Mubarika S, Middeldorp JM. Single-assay combination of Epstein-Barr Virus (EBV) E. *J Clin Microbiol* 2006; 44(4): 1459-1467. (VUmc)
265. Fan C, Oh DS, Wessels L, Weigelt B, Nuyten DSA, Nobel AB, van 't Veer LJ, Perou CM. Concordance among gene-expression-based predictors for breast cancer. *N Engl J Med* 2006; 355: 560-9. (NKI)
266. Fehlaue F, Muench M, Smid EJ, Slotman BJ, Richter E, Sminia P. Combined modality therapy of gemcitabine and irradiation on human glioma spheroids derived from cell lines and biopsy tissue. *Oncol Rep* 2006; 15(1): 97-105. (VUmc)
267. Ferguson CG, Bigman CS, Richardson RD, Van Meeteren LA, Moolenaar WH, Prestwich GD. Fluorogenic Phospholipid Substrate to Detect Lysophospholipase D/Autotaxin Activity. *Org Lett* 2006; 8: 2023-6. (NKI)
268. Ferlito A, Rinaldo A, Silver CE, Gourin CG, Shah JP, Clayman GL, Kowalski LP, Shaha AR, Robbins KT, Suarez C, Leemans CR, Ambrosch P, Medina JE, Weber RS, Genden EM, Pellitteri PK, Werner JA, Myers EN. Elective and therapeutic selective neck dissection. *Oral Oncol* 2006; 42: 14-25. (VUmc)
269. Ferlito A, Rinaldo A, Silver CE, Shah JP, Suarez C, Medina JE, Kowalski LP, Johnson JT, Strome M, Rodrigo JP, Werner JA, Takes RP, Towpik E, Robbins KT, Leemans CR, Herranz J, Gavilan J, Shaha AR, Wei WI. Neck dissection: then and now. *Auris Nasus Larynx* 2006; 33(4): 365-374. (VUmc)
270. Fidler IJ, Heijmans R, Chowder Y, Bar-Meir S, Avidan B, Pena AS, Crusius JBA. TNF-857 polymorphism in Israeli Jewish patients with inflammatory bowel disease. *Int J Immunogenet* 2006; 33(2): 81-85. (VUmc)
271. Field JK, Smith RA, Duffy SW, Berg CD, van Klaveren RJ, Henschke CI, Carbone D, Postmus PE, Paci E, Hirsch FR, Mulshine JL. Priorities for the European Union/United States spiral computed tomography collaborative group. *J Thor Oncol* 2006; 1: 497-498. (VUmc)
272. Fijneman RJA. Paving the road towards non-invasive molecular imaging. *Cell Oncol* 2006; 28(4): 125-126. (VUmc)

273. Foijer F, te Riele H. Check, double check: the G2 barrier to cancer. *Cell Cycle* 2006; 5: 831-6. (NKI)
274. Foijer F, te Riele H. Restriction beyond the restriction point: mitogen requirement for G2 passage. *Cell Division* 2006; 1: 8. (NKI)
275. Foiry L, Dong L, Savouret C, Hubert L, te Riele H, Junien C, Gourdon G. Msh3 is a limiting factor in the formation of intergenerational CTG expansions in DM1 transgenic mice. *Hum Genet* 2006; 119: 520-6. (NKI)
276. Fontijn D, Duijndam MCA, van Berkel MPA, Yuana Y, Shapiro LH, Pinedo HM, Broxterman HJ, Boven E. CD13/Aminopeptidase N overexpression by basic fibroblast growth factor mediates enhanced invasiveness of 1F6 human melanoma cells. *Br J Cancer* 2006; 94: 1627-1636. (VUmc)
277. Frakking FNJ, van de Wetering MD, Brouwer N, Dolman KM, Geissler J, Lemkes B, Caron HN, Kuijpers TW. The role of mannose-binding lectin (MBL) in paediatric oncology patients with febrile neutropenia. *Eur J Cancer* 2006; 42(7): 909-916. (AMC)
278. Franceschi S, Herrero R, Clifford GM, Snijders PJF, Arslan A, Anh PT, Bosch FX, Ferreccio C, Hieu NT, Lazcano-Ponce E, Matos E, Molano M, Qiao YL, Rajkumar R, Ronco G, de Sanjose S, Shin HR, Sukvirach S, Thomas JO, Meijer CJLM, Munoz N. Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. *Int J Cancer* 2006; 119(11): 2677-2684. (VUmc)
279. Franken NAP, Bergs JWJ, Kok TT, Kuperus RRN, Stecher-Rasmussen F, Haveman J, Bree C van, Stalpers LJA. Gadolinium enhances the sensitivity of SW-1573 cells for thermal neutron irradiation. *Oncol Rep* 2006; 15(3): 715-720. (AMC)
280. Frid MG, Brunetti JA, Burke DL, Carpenter TC, Davie NJ, Reeves JT, Roedersheimer MT, van Rooijen N, Stenmark KR. Hypoxia-induced pulmonary vascular remodeling requires recruitment of circulating mesenchymal precursors of a monocyte/macrophage lineage. *Am J Pathol* 2006; 168(2): 659-669. (VUmc)
281. Fujimura YI, Isono KI, Vidal M, Endoh M, Kajita H, Mizutani-Koseki Y, Takihara Y, Van Lohuizen M, Otte A, Jenuwein T, Deschamps J, Koseki H. Distinct roles of Polycomb group gene products in transcriptionally repressed and active domains of Hoxb8. *Development* 2006; 133: 2371-81. (NKI)
282. Furtado GC, Pina B, Tacke F, Gaupp S, van Rooijen N, Moran TM, Randolph GJ, Ransohoff RM, Chensue SW, Raine CS, Lira SA. A novel model of demyelinating encephalomyelitis induced by monocytes and dendritic cells. *J Immunol* 2006; 177(10): 6871-6879. (VUmc)
283. Garcia-Vallejo JJ, Gringhuis SI, van Dijk W, van Die IM. Gene expression analysis of glycosylation-related genes by real-time polymerase chain reaction. *Methods Mol Biol* 2006; 347: 187-209. (VUmc)
284. Garcia-Vallejo JJ, van Dijk W, van het Hof B, van Die IM, Engelse MA, Van Hinsbergh VW, Gringhuis SI. Activation of human endothelial cells by tumor necrosis factor-alpha results in profound changes in the expression of glycosylation-related genes. *J Cell Physiol* 2006; 206(1): 203-210. (VUmc)
285. Gawlik KI, Mayer U, Blomberg K, Sonnenberg A, Ekblom P, Durbeej M. Laminin alpha1 chain mediated reduction of laminin alpha2 chain deficient muscular dystrophy involves integrin alpha7beta1 and dystroglycan. *FEBS Lett* 2006; 580: 1759-65. (NKI)
286. Gehring S, Dickson EM, San Martin ME, van Rooijen N, Papa EF, Harty MW, Tracy TF, Gregory SH. Kupffer cells abrogate cholestatic liver injury in mice. *Gastroenterology* 2006; 130(3): 810-822. (VUmc)
287. Geubbels EL, Grobbee DE, Vandenbroucke-Grauls CMJE, Wille JC, de Boer AS. Improved risk adjustment for comparison of surgical site infection rates. *Infect Control Hosp Epidemiol* 2006; 27(12): 1330-1339. (VUmc)
288. Geubbels EL, Nagelkerke NJ, Mintjes-De Groot AJ, Vandenbroucke-Grauls CMJE, Grobbee DE, de Boer AS. Reduced risk of surgical site infections through surveillance in a network. *Int J Qual Health Care* 2006; 18(2): 127-133. (VUmc)
289. Geurts TW, Ackerstaff AH, Van Zandwijk N, Hart AAM, Hilgers FJM, Balm AJM. The psychological impact of annual chest X-ray follow-up in head and neck cancer. *Acta Otolaryngol* 2006; 126: 1315-20. (NKI)
290. Geusens PPM, Landewe RB, Garnero P, Chen D, Dunstan CR, Lems WF, Stinissen P, van der Heijde DM, van der Linden S, Boers M. The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction. *Arthritis Rheum* 2006; 54(6): 1772-1777. (VUmc)
291. Gheit T, Landi S, Gemignani F, Snijders PJF, Vaccarella S, Franceschi S, Canzian F, Tommasino M. Development of a sensitive and specific assay combining multiplex PCR and DNA microarray primer extension to detect high-risk mucosal human papillomavirus types. *J Clin Microbiol* 2006; 44(6): 2025-2031. (VUmc)
292. Giaccone G, Gallegos-Ruiz M, Le Chevalier T, Thatcher N, Smit EF, Rodriguez JA, Janne P, Oulid-Aissa D, Soria JC. Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study. *Clin Cancer Res* 2006; 12(20 Pt 1): 6049-6055. (VUmc)
293. Giaccone G, Wilmink H, Paul MA. Systemic treatment of malignant thymoma: a decade experience at a single institution. *Am J Clin Oncol* 2006; 29(4): 336-344. (VUmc)
294. Gibbs S, van den Hoogenband HM, Kirtschig G, Richters CD, Spiekstra SW, Breetveld M, Scheper RJ, de Boer EM. Autologous full-thickness skin substitute for healing chronic wounds. *Br J Dermatol* 2006; 155(2): 267-274. (VUmc)

295. Gilfillan GD, Straub T, de Wit E, Greil F, Lamm R, van Steensel B, Becker PB. Chromosome-wide gene-specific targeting of the *Drosophila* dosage compensation complex. *Genes Dev* 2006; 20: 858-70. (NKI)
296. Gillio-Tos A, De Marco L, Ghisetti V, Snijders PJF, Segnan N, Ronco G, Merletti F. Human papillomavirus typing with GP5+/6+ polymerase chain reaction reverse line blotting and with commercial type-specific PCR kits. *J Clin Virol* 2006; 36(2): 126-132. (VUmc)
297. Giovannetti E, Danesi R, Mey V, Nannizzi S, Pasqualetti G, Del Tacca M. In vitro studies on gemcitabine combinations with other antineoplastic agents. *Ann Oncol* 2006; 17 Suppl 5: v17-v19. (VUmc)
298. Giovannetti E, Del Tacca M, Mey V, Funel N, Nannizzi S, Ricci S, Orlandini C, Boggi U, Campani D, Del Chiaro M, Iannopollo M, Bevilacqua G, Mosca F, Danesi R. Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. *Cancer Res* 2006; 66(7): 3928-3935. (VUmc)
299. Giovannetti E, Mey V, Nannizzi S, Pasqualetti G, Del Tacca M, Danesi R. Pharmacogenetics of anticancer drug sensitivity in pancreatic cancer. *Mol Cancer Ther* 2006; 5(6): 1387-1395. (VUmc)
300. Girinsky T, van der Maazen R, Specht L, Aleman B, Poortmans P, Lievens Y, Meijnders P, Ghalibafian M, Meerwaldt J, Noordijk E. Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: Concepts and guidelines. *Radiother Oncol* 2006; 79: 270-7. (NKI)
301. Glas AM, Floore A, Delahaye LJM, Witteveen AT, Pover RCF, Bakx N, Lahti-Domenici JST, Bruinsma TJ, Warmoes MO, Bernardis R, Wessels LFA, van 't Veer LJ. Converting a breast cancer microarray signature into a high-throughput diagnostic test. *BMC Genomics* 2006; 7: 278. (NKI)
302. Glaviano A, Nayak V, Cabuy E, Baird DM, Yin Z, Newson R, Ladon D, Rubio MA, Slijepcevic P, Lyng F, Mothersill C, Case CP. Effects of hTERT on metal ion-induced genomic instability. *Oncogene* 2006; 25: 3424-35. (NKI)
303. Godthelp BC, van Buul PP, Jaspers NG, Elghalbzouri-Maghrani E, Duijn-Goedhart A, Arwert F, Joenje H, Zdzienicka MZ. Cellular characterization of cells from the Fanconi anemia complementation group, FA-D1/BRCA2. *Mutat Res* 2006; 601(1-2): 191-201. (VUmc)
304. Godthelp BC, Wiegant WW, Waisfisz Q, Medhurst AL, Arwert F, Joenje H, Zdzienicka MZ. Inducibility of nuclear Rad51 foci after DNA damage distinguishes all Fanconi anemia complementation groups from D1/BRCA2. *Mutat Res* 2006; 594(1-2): 39-48. (VUmc)
305. Goemans BF, Zwaan CM, Reinhardt D, Gibson BE, Hahlen K, Kaspers GJL. A comparison of the in vitro cytotoxicity of daunorubicin and liposomal daunorubicin in pediatric acute leukemia. *Haematologica* 2006; 91(11): 1573-1574. (VUmc)
306. Goethals L, Debucquoy A, Perneel C, Geboes K, Ectors N, De Schutter H, Penninckx F, McBride WH, Begg AC, Haustermans KM. Hypoxia in human colorectal adenocarcinoma: Comparison between extrinsic and potential intrinsic hypoxia markers. *Int J Radiat Oncol Biol Phys* 2006; 65: 246-54. (NKI)
307. Golay J, Cittera E, Di Gaetano N, Manganini M, Mosca M, Nebuloni M, van Rooijen N, Vago L, Introna M. The role of complement in the therapeutic activity of rituximab in a murine B lymphoma model homing in lymph nodes. *Haematologica* 2006; 91(2): 176-183. (VUmc)
308. Goldstraw P, Crowley JJ, on behalf of the IASLC international staging project. The International Association for the study of lung cancer. The International staging project on lung cancer. *JTO* 2006; 1: 281-286. (VUmc)
309. Gorter AC, Segura ZE, Savelkoul PHM, Morre SA. Chlamydia trachomatis infections in Nicaragua: preliminary results from a competitive voucher scheme to prevent and treat sexually transmitted infections and HIV/AIDS among sex workers. *Drugs Today (Barc)* 2006; 42 Suppl A: 47-54. (VUmc)
310. Gouma DJ. Conversion from laparoscopic to open cholecystectomy. *Brit J Surg* 2006; 93(8): 905-906. (AMC)
311. Graat HCA, Witlox MA, Schagen FHE, Kaspers GJL, Helder MN, Bras J, Schaap GR, Gerritsen WR, Wuisman PIJM, Van Beusechem VW. Different susceptibility of osteosarcoma cell lines and primary cells to treatment with oncolytic adenovirus and doxorubicin or cisplatin. *Br J Cancer* 2006; 94: 1837-1844. (VUmc)
312. Green JA, Berns EMJJ, Coens C, van Luijk I, Thompson-Hehir J, van Diest P, Verheijen RHM, van de Vijver M, van Dam P, Kenter GG, Tjalma W, Ewing PC, Teodorovic I, Vergote I, van der Burg MEL. Alterations in the p53 pathway and prognosis in advanced ovarian cancer: A multi-factorial analysis of the EORTC Gynaecological Cancer group (study 55865). *Eur J Cancer* 2006; 42: 2539-48 (NKI/VUmc)
313. Greil F, Moorman C, van Steensel B. DamID: Mapping of in vivo protein-genome interactions using tethered DNA adenine methyltransferase. *Meth Enzymol* 2006; 410: 342-59. (NKI)
314. Griekspoor A, Margarido TC, Zwart W, Michalides R. Review of: BRCA1 and cyclin D1: Gate keepers in hormone responsive tissues? *Breast Cancer Online* 2006; 9: . (NKI)
315. Griffiths CE, Katsambas A, Dijkmans BAC, Finlay AY, Ho VC, Johnston A, Luger TA, Mrowietz U, Thestrup-Pedersen K. Update on the use of ciclosporin in immune-mediated dermatoses. *Br J Dermatol* 2006; 155 Suppl 2: 1-16. (VUmc)
316. Grinstein E, Shan Y, Karawajew L, Snijders PJF, Meijer CJLM, Royer HD, Wernet P. Cell cycle-controlled interaction of nucleolin with the

- retinoblastoma protein and cancerous cell transformation. *J Biol Chem* 2006; 281(31): 22223-22235. (VUmc)
317. Groeneweg M, Kanters E, Vergouwe MN, Duerink H, Kraal G, Hofker MH, de Winther MP. Lipopolysaccharide-induced gene expression in murine macrophages is enhanced by prior exposure to oxLDL. *J Lipid Res* 2006; 47(10): 2259-2267. (VUmc)
318. Groenvold M, Petersen MA, Aaronson NK, Arraras JI, Blazeby JM, Bottomley A, Fayers PM, de Graeff A, Hammerlid E, Kaasa S, Sprangers MAG, Bjorner JB. EORTC QLQ-C15-PAL: the new standard in the assessment of health-related quality of life in advanced cancer? *Palliative Med* 2006; 20(2): 59-61. (AMC)
319. Groenvold M, Petersen MA, Aaronson NK, Arraras JI, Blazeby JM, Bottomley A, Fayers PM, de Graeff A, Hammerlid E, Kaasa S, Sprangers MAG, Bjorner JB. The development of the EORTC QLQ-C15-PAL: A shortened questionnaire for cancer patients in palliative care. *Eur J Cancer* 2006; 42(1): 55-64. (AMC/NKI)
320. Groll M, Berkers C, Ploegh H, Ovaa H. Crystal Structure of the Boronic Acid-Based Proteasome Inhibitor Bortezomib in Complex with the Yeast 20S Proteasome. *Structure* 2006; 14: 451-6. (NKI)
321. Groothuis T, Dantuma N, Neefjes J, Salomons F. Ubiquitin crosstalk connecting cellular processes. *Cell Division* 2006; 1: 21. (NKI)
322. Groothuis T, Neefjes J. The ins and outs of intracellular peptides and antigen presentation by MHC class I molecules. *Curr Top Microbiol Immunol* 2006; 300: 127-48. (NKI)
323. Grun CH, van Vliet SJ, Schiphorst WE, Bank CM, Meyer S, van Die IM, van Kooyk Y. One-step biotinylation procedure for carbohydrates to study carbohydrate-protein interactions. *Anal Biochem* 2006; 354(1): 54-63. (VUmc)
324. Guikema JEJ, de Boer C, Haralambieva E, Smit LA, van Noesel CJM, Schuurin E, Kluin PM. IGH switch breakpoints in Burkitt lymphoma: Exclusive involvement of noncanonical class switch recombination. *Gene Chromosome Canc* 2006; 45(9): 808-819. (AMC)
325. Haanen JB, Baars A, Gomez R, Weder P, Smits M, de Gruij TD, von Blomberg BM, Bloemena E, Scheper RJ, van Ham SM, Pinedo HM, van den Eertwegh AJ. Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients. *Cancer Immunol Immunother* 2006; 55: 451-458. (NKI/ VUmc)
326. Hadithi M, Mallant M, Oudejans JJ, van Waesberghe JH, Mulder CJ, Comans EFI. 18F-FDG PET versus CT for the detection of enteropathy-associated T-cell lymphoma in refractory celiac disease. *J Nucl Med* 2006; 47(10): 1622-1627. (VUmc)
327. Hage JJ, Karim RB. Risk of breast cancer among reduction mammoplasty patients and the strategies used by plastic surgeons to detect such cancer. *Plast Reconstr Surg* 2006; 117: 727-35. (NKI)
328. Hage JJ, Van Turnhout AAWM, Dekker JJML, Karim RB. Saving labium minus skin to treat possible urethral stenosis in female-to-male transsexuals. *Ann Plast Surg* 2006; 56: 456-9. (NKI)
329. Hage JJ, Van Turnhout AAWM. Long-term outcome of metoidioplasty in 70 female-to-male transsexuals. *Ann Plast Surg* 2006; 57: 312-6. (NKI)
330. Halstead JR, van Rheenen J, Snel M, Meeuwis S, Mohammed S, D'Santos CS, Heck A, Jalink K, Divecha N. A Role for PtdIns(4,5)P2 and PIP5K? in Regulating Stress-Induced Apoptosis. *Curr Biol* 2006; 16: 1850-6. (NKI)
331. Hannemann J, Kristel P, Van Tinteren H, Bontenbal M, Van Hoesel OGCM, Smit WM, Nooij MA, Voest EE, Van Der Wall E, Hupperets P, De Vries EGE, Rodenhuis S, Van De Vijver MJ. Molecular subtypes of breast cancer and amplification of topoisomerase II...: Predictive role in dose intensive adjuvant chemotherapy. *Br J Cancer* 2006; 95: 1334-41. (NKI)
332. Hannemann J, Velds A, Halfwerk JBG, Kreike B, Peterse JL, Van De Vijver MJ. Classification of ductal carcinoma in situ by gene expression profiling. *Breast Cancer Res* 2006; 8: . (NKI)
333. Haque A, Easton A, Smith D, O'Garra A, van Rooijen N, Lertmemongkolkhai G, Titball RW, Bancroft GJ. Role of T cells in innate and adaptive immunity against murine *Burkholderia pseudomallei* infection. *J Infect Dis* 2006; 193(3): 370-379. (VUmc)
334. Haramis AP, Hurlstone A, van der Velden Y, Begthel H, van den Born M, Offerhaus GJA, Clevers HC. Adenomatous polyposis coli-deficient zebrafish are susceptible to digestive tract neoplasia. *EMBO Rep* 2006; 7: 444-9. (NKI)
335. Haramis APG, Perrakis A. Selectivity and promiscuity in Eph receptors. *Structure* 2006; 14: 169-71. (NKI)
336. Haveman J, Sigmond J, van Bree C, Franken NA, Koedooder C, Peters GJ. Time course of enhanced activity of deoxycytidine kinase and thymidine kinase 1 and 2 in cultured human squamous lung carcinoma cells, SW-1573, induced by gamma-irradiation. *Oncol Rep* 2006; 16(4): 901-905. (VUmc)
337. Heddema ER, Ter Sluis S, Buys JA, Vandenbroucke-Grauls CMJE, van Wijnen JH, Visser CE. Prevalence of *Chlamydia psittaci* in fecal droppings from feral pigeons in Amsterdam, The Netherlands. *Appl Environ Microbiol* 2006; 72(6): 4423-4425. (VUmc)
338. Heddema ER, van Hannen EJ, Duim B, de Jongh BM, Kaan JA, van Kessel R, Lumeij JT, Visser CE, Vandenbroucke-Grauls CMJE. An outbreak of psittacosis due to *Chlamydia psittaci* genotype

- A in a veterinary teaching hospital. *J Med Microbiol* 2006; 55(Pt 11): 1571-1575. (VUmc)
339. Heemsbergen WD, Peeters STH, Koper PCM, Hoogeman MS, Lebesque JV. Acute and late gastrointestinal toxicity after radiotherapy in prostate cancer patients: Consequential late damage. *Int J Radiat Oncol Biol Phys* 2006; 66: 3-10. (NKI)
340. Helgason HH, Kruijtzter CMF, Huitema ADR, Marcus SG, ten Bokkel Huinink WW, Schot ME, Schornagel JH, Beijnen JH, Schellens JHM. Phase II and pharmacological study of oral paclitaxel (Paxoral) plus ciclosporin in anthracycline-pretreated metastatic breast cancer. *Br J Cancer* 2006; 95: 794-800. (NKI)
341. Hennard C, Pfuhl T, Buettner M, Becker KF, Knofel T, Middeldorp JM, Kremmer E, Niedobitek G, Grasser F. The antibody 2B4 directed against the Epstein-Barr virus (EBV)-encoded nuclear antigen 1 (EBNA1) detects MAGE-4: implications for studies on the EBV association of human cancers. *J Pathol* 2006; 209(4): 430-435. (VUmc)
342. Herberths CA, Neijssen JJ, De Haan J, Janssen L, Drijfhout JW, Reits EA, Neefjes JJ. Cutting edge: HLA-B27 acquires many N-terminal dibasic peptides: Coupling cytosolic peptide stability to antigen presentation. *J Immunol* 2006; 176: 2697-701. (NKI)
343. Herder GJM, Kramer H, Hoekstra OS, Smit EF, Pruim J, van Tinteren H, Comans EFI, Verboom P, Uyl-de Groot CA, Welling A, Paul MA, Boers M, Postmus PE, Teule GJ, Groen HJ. Traditional versus up-front [18F] fluorodeoxyglucose-positron emission tomography staging of non-small-cell lung cancer: a Dutch cooperative randomized study. *J Clin Oncol* 2006; 24(12): 1800-1806. (VUmc)
344. Hermsen BB, van Diest PJ, Berkhof J, Menko FH, Gille JJ, Piek JM, Meijer S, Winters HA, Kenemans P, Mensdorff-Pouilly S, Verheijen RHM. Low prevalence of (pre) malignant lesions in the breast and high prevalence in the ovary and Fallopian tube in women at hereditary high risk of breast and ovarian cancer. *Int J Cancer* 2006; 119(6): 1412-1418. (VUmc)
345. Hess DA, Klomp HM. The role of surgery for pulmonary metastases in breast cancer patients. *Breast Cancer Online* 2006; 9:.. (NKI)
346. Hesselink AT, Bulkman NW, Berkhof J, Lorincz AT, Meijer CJLM, Snijders PJF. Cross-sectional comparison of an automated hybrid capture 2 assay and the consensus GP5+/6+ PCR method in a population-based cervical screening program. *J Clin Microbiol* 2006; 44(10): 3680-3685. (VUmc)
347. Hiel JAP, Van Engelen BGM, Weemaes CMR, Broeks A, Verrips A, ter Laak H, Vingerhoets HM, Van Den Heuvel LPW, Lammens M, Gabreels FJM, Last JI, Taylor AMR. Distal spinal muscular atrophy as a major feature in adult-onset ataxia telangiectasia. *Neurology* 2006; 67: 346-9. (NKI)
348. Hilgers FJM, Ackerstaff AH. Development and evaluation of a novel tracheostoma button and fixation system (Provox LaryButton and LaryClip adhesive) to facilitate hands-free tracheoesophageal speech. *Acta Otolaryngol* 2006; 126: 1218-24. (NKI)
349. Hilgers FJM, van As-Brooks CJ, Polak RMF, Tan IB. Surgical improvement of hypotonicity in tracheoesophageal speech. *Laryngoscope* 2006; 116: 345-8. (NKI)
350. Hilkens J. Recent translational research: oncogene discovery by insertional mutagenesis gets a new boost. *Breast Cancer Res* 2006; 8: 102. (NKI)
351. Hoebbers FJP, Pluim D, Verheij M, Balm AJM, Bartelink H, Schellens JHM, Begg AC. Prediction of treatment outcome by cisplatin-DNA adduct formation in patients with stage III/IV head and neck squamous cell carcinoma, treated by concurrent cisplatin-radiation (RADPLAT). *Int J Cancer* 2006; 119: 750-6. (NKI)
352. Hoefnagel JJ, Mulder MMS, Dreef E, Jansen PM, Pals ST, Meijer CJLM, Willemze R, Vermeer MH. Expression of B-cell transcription factors in primary cutaneous B-cell lymphoma. *Modern Pathol* 2006; 19(9): 1270-1276. (AMC/VUmc)
353. Hoep LS, Merkus P, van Schie A, Rinkel RN, Smit CF. The value of nuclear scans in cochlear implant infections. *Eur Arch Otorhinolaryngol* 2006; 263(10): 895-899. (VUmc)
354. Hogen Esch AJ, van der Heide S, van den Brink W, van Ree JM, Bruynzeel DP, Coenraads PJ. Contact allergy and respiratory/mucosal complaints from heroin (diacetylmorphine). *Contact Dermatitis* 2006; 54(1): 42-49. (VUmc)
355. Hol E, Fischer D, Ovaas H, Scheper W. Ubiquitin proteasome system as a pharmacological target in neurodegeneration. *Expert Rev Neurother* 2006; 6: 1337-47. (NKI)
356. Holling TM, van Eggermond MC, Jager MJ, van den Elsen PJ. Epigenetic silencing of MHC2TA transcription in cancer. *Biochem Pharmacol* 2006; 72(11): 1570-1576. (VUmc)
357. Honeywell R, van Groeningen CJ, Laan AC, Strocchi E, Ruiter R, Giaccone G, Peters GJ. Analysis of deoxycytidine accumulation in gemcitabine treated patients. *Nucleos Nucleot Nucl Acids* 2006; 25(9-11): 1225-1232. (VUmc)
358. Hooijberg JH, de Vries NA, Kaspers GJL, Pieters R, Jansen G, Peters GJ. Multidrug resistance proteins and folate supplementation: therapeutic implications for antifolates and other classes of drugs in cancer treatment. *Cancer Chemother Pharmacol* 2006; 58(1): 1-12. (VUmc)
359. Hooning MJ, Aleman BMP, van Rosmalen AJ, Kuenen MA, Klijn JG, van Leeuwen FE. Cause-specific mortality in long-term survivors of breast cancer: A 25-year follow-up study. *Int J Radiat Oncol Biol Phys* 2006; 64: 1081-91. (NKI)
360. Hooning MJ, Dorresteijn LD, Aleman BMP, Kappelle AC, Klijn JG, Boogerd W, van Leeuwen

- FE. Decreased risk of stroke among 10-year survivors of breast cancer. *J Clin Oncol* 2006; 24: 5388-94. (NKI)
361. Hoopman R, Muller MJ, Terwee CB, Aaronson NK. Translation and validation of the EORTC QLQ-C30 for use among Turkish and Moroccan ethnic minority cancer patients in the Netherlands. *Eur J Cancer* 2006; 42: 1839-47. (NKI)
362. Hopman EG, le Cessie S, von Blomberg BME, Mearin ML. Nutritional management of the gluten-free diet in young people with celiac disease in The Netherlands. *J Pediatr Gastroenterol Nutr* 2006; 43(1): 102-108. (VUmc)
363. Hornberg JJ, Bruggeman FJ, Westerhoff HV, Lankelma J. Cancer: a Systems Biology disease. *Biosystems* 2006; 83(2-3): 81-90. (VUmc)
364. Hornberg JJ, Dekker H, Peters PH, Langerak P, Westerhoff HV, Lankelma J, van Zoelen EJ. Epidermal growth factor receptor-induced activator protein 1 activity controls density-dependent growth inhibition in normal rat kidney fibroblasts. *Mol Biotechnol* 2006; 34(2): 101-108. (VUmc)
365. Horsman MR, Bohm L, Margison GP, Milas L, Rosier JF, Safrany G, Selzer E, Verheij M, Hendry JH. Tumor radiosensitizers - Current status of development of various approaches: Report of an International Atomic Energy Agency meeting. *Int J Radiat Oncol Biol Phys* 2006; 64: 551-61. (NKI)
366. Hosokawa H, Kimura MY, Shinnakasu R, Suzuki A, Miki T, Koseki H, Van Lohuizen M, Yamashita M, Nakayama T. Regulation of Th2 cell development by Polycomb group gene bmi-1 through the stabilization of GATA3. *J Immunol* 2006; 177: 7656-64. (NKI)
367. Houben MP, Aben KK, Teepen JL, Schouten-van Meeteren AY, Tijssen CC, Van Duijn CM, Coebergh JW. Stable incidence of childhood and adult glioma in The Netherlands, 1989-2003. *Acta Oncol* 2006; 45(3): 272-279. (VUmc)
368. Houtenbos I, Westers TM, Ossenkuppele GJ, van de Loosdrecht AA. Feasibility of clinical dendritic cell vaccination in acute myeloid leukemia. *Immunobiology* 2006; 211(6-8): 677-685. (VUmc)
369. Houtenbos I, Westers TM, Ossenkuppele GJ, van de Loosdrecht AA. Leukemia-derived dendritic cells: towards clinical vaccination protocols in acute myeloid leukemia. *Haematologica* 2006; 91(3): 348-355. (VUmc)
370. Huang TT, Nijman SMB, Mirchandani KD, Galardy PJ, Cohn MA, Haas W, Gygi SP, Ploegh HL, Bernardis R, D'Andrea AD. Regulation of monoubiquitinated PCNA by DUB autocleavage. *Nat Cell Biol* 2006; 8: 339-47. (NKI)
371. Hubeek I, Peters GJ, Broekhuizen R, Zwaan CM, Kaaijk P, van Wering ES, Gibson BE, Creutzig U, Janka-Schaub GE, den Boer ML, Pieters R, Kaspers GJL. In vitro sensitivity and cross-resistance to deoxynucleoside analogs in childhood acute leukemia. *Haematologica* 2006; 91(1): 17-23. (VUmc)
372. Huijbers IJ, Krimpenfort P, Chomez P, Van Der Valk MA, Song JY, Inderberg-Suso EM, Schmitt-Verhulst AM, Berns A, Van Den Eynde BJ. An inducible mouse model of melanoma expressing a defined tumor antigen. *Cancer Res* 2006; 66: 3278-86. (NKI)
373. Huitink JM, Buitelaar DR, Schutte PFE. Awake fibrecapnic intubation: A novel technique for intubation in head and neck cancer patients with a difficult airway. *Anaesthesia* 2006; 61: 449-52. (NKI)
374. Hurkmans CW, Meijer GJ, Vliet-Vroegindeweij C, van der Sangen MJ, Cassee J. High-dose simultaneously integrated radiotherapy breast boost using intensity-modulated radiotherapy and inverse optimization. *Int J Radiat Oncol Biol Phys* 2006; 66: 923-30. (NKI)
375. Hussain S, Wilson JB, Blom E, Thompson LH, Sung P, Gordon SM, Kupfer GM, Joenje H, Mathew CG, Jones NJ. Tetratricopeptide-motif-mediated interaction of FANCG with recombination proteins XRCC3 and BRCA2. *DNA Repair (Amst)* 2006; 5(5): 629-640. (VUmc)
376. Imhof SM, Moll AC, Schouten-van Meeteren AY. Stage of presentation and visual outcome of patients screened for familial retinoblastoma: nationwide registration in the Netherlands. *Br J Ophthalmol* 2006; 90(7): 875-878. (VUmc)
377. Isabelle M, Teodorovic I, Morente MM, Jaminé D, Passiukov A, Lejeune S, Therasse P, Dinjens WNM, Oosterhuis JW, Lam KH, Oomen MHA, Spatz A, Ratcliffe C, Knox K, Mager R, Kerr D, Pezzella F, van de Vijver M, van Boven H, Alonso S, Kerjaschki D, Pammer J, Lopez-Guerrero JA, Llombart Bosch A, Carbone A, Gloghini A, van Veen EB, van Damme B, Riegman PHJ. TuBaFrost 5: Multifunctional central database application for a European tumor bank. *Eur J Cancer* 2006; 42: 3103-9. (NKI)
378. Jakubzick C, Tacke F, Llodra J, van Rooijen N, Randolph GJ. Modulation of dendritic cell trafficking to and from the airways. *J Immunol* 2006; 176(6): 3578-3584. (VUmc)
379. Jalink K. Spying on cGMP with FRET. *Nat Meth* 2006; 3: 11-2. (NKI)
380. Jalving M, de Jong S, Koornstra J, Boersma-van Ek W, Zwart N, Wesseling J, de Vries E, Kleibeuker J. TRAIL Induces Apoptosis in Human Colorectal Adenoma Cell Lines and Human Colorectal Adenomas. *Clin Cancer Res* 2006; 12: 4350-6. (NKI)
381. Jalving M, Koornstra J, Wesseling J, Boezen HM, de Jong S, Kleibeuker JH. Increased risk of fundic gland polyps during long-term proton pump inhibitor therapy. *Aliment Pharmacol Ther* 2006; 24: 1341-8. (NKI)
382. Janmaat ML, Gallegos-Ruiz M, Rodriguez JA, Meijer GA, Vervenne WL, Richel DJ, van

- Groeningen CJ, Giaccone G. Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. *J Clin Oncol* 2006; 24(10): 1612-1619. (AMC/VUmc)
383. Janmaat ML, Rodriguez JA, Gallegos-Ruiz M, Kruyt FAE, Giaccone G. Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidylinositol-3 kinase pathways in non-small cell lung cancer cells. *Int J Cancer* 2006; 118(1): 209-214. (VUmc)
384. Jansen JG, Langerak P, Tsaalbi-Shtylik A, Van Den Berk P, Jacobs H, De Wind N. Strand-biased defect in C/G transversions in hypermutating immunoglobulin genes in Rev1-deficient mice. *J Exp Med* 2006; 203: 319-23. (NKI)
385. Jansen NC, Kingma A, Schuitema A, Bouma A, Huisman J, Veerman AJP, Kamps WA. Post-treatment intellectual functioning in children treated for acute lymphoblastic leukaemia (ALL) with chemotherapy-only: a prospective, sibling-controlled study. *Eur J Cancer* 2006; 42(16): 2765-2772. (VUmc)
386. Jellema AP, Slotman BJ, Muller MJ, Leemans CR, Smeele LE, Hoekman K, Aaronson NK, Langendijk JA. Radiotherapy alone, versus radiotherapy with amifostine 3 times weekly, versus radiotherapy with amifostine 5 times weekly: A prospective randomized study in squamous cell head and neck cancer. *Cancer* 2006; 107(3): 544-553. (NKI/VUmc)
387. Jimenez CR, Li KW, Smit AB, Janse C. Auto-inhibitory control of peptidergic molluscan neurons and reproductive senescence. *Neurobiol Aging* 2006; 27(5): 763-769. (VUmc)
388. Jimenez CR, Spijker S, de Schipper S, Lodder JC, Janse CK, Geraerts WP, van Minnen J, Syed NI, Burlingame AL, Smit AB, Li KW. Peptidomics of a single identified neuron reveals diversity of multiple neuropeptides with convergent actions on cellular excitability. *J Neurosci* 2006; 26(2): 518-529. (VUmc)
389. Joerger M, Bosch TM, Doodeman VD, Beijnen JH, Smits PHM, Schellens JHM. Novel deoxycytidine kinase gene polymorphisms: A population screening study in Caucasian healthy volunteers. *Eur J Clin Pharmacol* 2006; 62: 681-4. (NKI)
390. Joerger M, Huitema ADR, Boogerd W, Van Der Sande JJ, Schellens JHM, Beijnen JH. Interactions of serum albumin, valproic acid and carbamazepine with the pharmacokinetics of phenytoin in cancer patients. *Basic Clin Pharmacol Toxicol* 2006; 99: 133-40. (NKI)
391. Joerger M, Huitema ADR, Van Den Bongard DHJG, Schellens JHM, Beijnen JH. Quantitative effect of gender, age, liver function, and body size on the population pharmacokinetics of paclitaxel in patients with solid tumors. *Clin Cancer Res* 2006; 12: 2150-7. (NKI)
392. Joerger M, Huitema ADR, Van Den Bongard HJGD, Baas P, Schornagel JH, Schellens JHM, Beijnen JH. Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients. *Br J Clin Pharmacol* 2006; 62: 71-80. (NKI)
393. Jones D, Bultsma Y, Keune W, Halstead J, Elouarrat D, Mohammed S, Heck A, D'Santos C, Divecha N. Nuclear PtdIns5P as a Transducer of Stress Signaling: An In Vivo Role for PIP4Kbeta. *Mol Cell* 2006; 23: 685-95. (NKI)
394. Jongmans P, Hilgers FJM, Pols LCW, van As-Brooks CJ. The intelligibility of tracheoesophageal speech, with an emphasis on the voiced-voiceless distinction. *Lopop Phoniatr Vocol* 2006; 31: 172-81. (NKI)
395. Jordens I, Westbroek W, Marsman M, Rocha N, Mommaas M, Huizing M, Lambert J, Naeyaert JM, Neefjes J. Rab7 and Rab27a control two motor protein activities involved in melanosomal transport. *Pigment Cell Res* 2006; 19: 412-23. (NKI)
396. Junankar SR, Eichten A, Kramer A, De Visser KE, Coussens LM. Analysis of immune cell infiltrates during squamous carcinoma development. *J Invest Dermatol Symp Proc* 2006; 11: 36-43. (NKI)
397. Kaas R, Kroger R, Peterse JL, Hart AAM, Muller SH. The correlation of mammographic-and histologic patterns of breast cancers in BRCA1 gene mutation carriers, compared to age-matched sporadic controls. *Eur Radiol* 2006; 16: 2842-8. (NKI)
398. Kapiteijn K, de Bruijn CS, de Boer E, de Craen AJM, Burger CW, van Leeuwen FE, Helmerhorst FM. Does subfertility explain the risk of poor perinatal outcome after IVF and ovarian hyperstimulation? *Hum Reprod* 2006; 21: 3228-34. (NKI)
399. Kara MA, Bergman JJGHM. Autofluorescence imaging and narrow-band imaging for the detection of early neoplasia in patients with Barrett's esophagus. *Endoscopy* 2006; 38(6): 627-631. (AMC)
400. Kara MA, Ennahachi M, Fockens P, ten Kate FJW, Bergman JJGHM. Detection and classification of the mucosal and vascular patterns (mucosal morphology) in Barrett's esophagus by using narrow band imaging. *Gastrointest Endosc* 2006; 64(2): 155-166. (AMC)
401. Kara MA, Peters FP, Fockens P, ten Kate FJW, Bergman JJGHM. Endoscopic video-autofluorescence imaging followed by narrow band imaging for detecting early neoplasia in Barrett's esophagus. *Gastrointest Endosc* 2006; 64(2): 176-185. (AMC)
402. Karim R, Brito B, Dutrieux R, Lassance F, Hage JJ. MMP-2 Assessment as an Indicator of Wound Healing: A Feasibility Study. [Report]. *Adv Skin Wound Care* 2006; 19: 324-7. (NKI)
403. Karim RB, Hage JJ, van Rozelaar L, Lange CAH, Raaijmakers J. Complications of polyalkylimide 4% injections (Bio-Alcamid): a

- report of 18 cases. *J Plast Reconstr Aesthet Surg* 2006; 59: 1409-14. (NKI)
404. Kartachova MS, Valdés Olmos R, Haas RLM, Hoebbers FJP, Van Den Brekel MW, Van Zandwijk N, Van Herk M, Verheij M. Mapping of treatment-induced apoptosis in normal structures: ^{99m}Tc-Hynic-rh-annexin V SPECT and CT image fusion. *Eur J Nucl Med Mol Imaging* 2006; 33: 893-9. (NKI)
405. Kaspers GJL, Reinhardt D, Fleischhack G, Armendariz H, Stark B, Zwaan CM, Zimmermann M, Creutzig U. Low efficacy of methotrexate in childhood acute myeloid leukemia (AML): single-agent therapeutic window study in relapsed AML. *Pediatr Blood Cancer* 2006; 47(5): 539-542. (VUmc)
406. Kasperts N, Slotman BJ, Leemans CR, de Bree R, Doornaert PA, Langendijk JA. Results of postoperative reirradiation for recurrent or second primary head and neck carcinoma. *Cancer* 2006; 106(7): 1536-1547. (VUmc)
407. Kaufman Y, Ifergan I, Rothen L, Jansen G, Assaraf YG. Coexistence of multiple mechanisms of PT523 resistance in human leukemia cells harboring 3 reduced folate carrier alleles: transcriptional silencing, inactivating mutations, and allele loss. *Blood* 2006; 107(8): 3288-3294. (VUmc)
408. Keall PJ, Mageras GS, Balter JM, Emery RS, Forster KM, Jiang SB, Kapatoes JM, Low DA, Murphy MJ, Murray BR, Ramsey CR, Van Herk MB, Vedam SS, Wong JW, Yorke E. The management of respiratory motion in radiation oncology report of AAPM Task Group 76. *Med Phys* 2006; 33: 3874-900. (NKI)
409. Keating E, Lemos C, Azevedo I, Martel F. Characteristics of thiamine uptake by the BeWo human trophoblast cell line. *J Biochem Mol Biol* 2006; 39(4): 383-393. (VUmc)
410. Keating E, Lemos C, Azevedo I, Martel F. Comparison of folic acid uptake characteristics by human placental choriocarcinoma cells at acidic and physiological pH. *Can J Physiol Pharmacol* 2006; 84(2): 247-255. (VUmc)
411. Kedde M, le Sage C, Duursma A, Zlotorynski E, Van Leeuwen B, Nijkamp W, Beijersbergen R, Agami R. Telomerase-independent Regulation of ATR by Human Telomerase RNA. *J Biol Chem* 2006; 281: 40503-14. (NKI)
412. Keijser S, de Keizer RJ, Prins FA, Tanke HJ, van Rooijen N, Vrensen GF, Jager MJ. A new model for limbal transplantation using E-GFP for follow-up of transplant survival. *Exp Eye Res* 2006; 83(5): 1188-1195. (VUmc)
413. Keijser S, Missotten GS, Bonfrer JM, Wolff-Rouendaal D, Jager MJ, De Keizer RJW. Immunophenotypic markers to differentiate between benign and malignant melanocytic lesions. *Br J Ophthalmol* 2006; 90: 213-7. (NKI)
414. Keller AM, Borst J. Control of Peripheral T Cell Survival: A Delicate Division of Labor between Cytokines and Costimulatory Molecules. *Hum Immunol* 2006; 67: 469-77. (NKI)
415. Kemper EM, Leenders W, Küsters B, Lyons S, Buckle T, Heerschap A, Boogerd W, Beijnen JH, van Tellingen O. Development of luciferase tagged brain tumour models in mice for chemotherapy intervention studies. *Eur J Cancer* 2006; 42: 3294-303. (NKI)
416. Keryer-Bibens C, Pioche-Durieu C, Villemant C, Souquere S, Nishi N, Hirashima M, Middeldorp JM, Busson P. Exosomes released by EBV-infected nasopharyngeal carcinoma cells convey the viral latent membrane protein 1 and the immunomodulatory protein galectin 9. *BMC Cancer* 2006; 6: 283. (VUmc)
417. Kessels HWHG, Schepers K, Van Den Boom MD, Topham DJ, Schumacher TNM. Generation of T cell help through a MHC class I-restricted TCR. *J Immunol* 2006; 177: 976-82. (NKI)
418. Kester MHA, Kuiper GGJM, Versteeg R, Visser TJ. Regulation of type III iodothyronine deiodinase expression in human cell lines. *Endocrinology* 2006; 147(12): 5845-5854. (AMC)
419. Kijvikai K, van Dijk M, Pes PL, Lertsithichai P, Wijkstra H, de la Rosette JJMCH. Clinical utility of "blind placement" prostatic stent in patients with benign prostatic obstruction: A prospective study. *Urology* 2006; 68(5): 1025-1030. (AMC)
420. Kjaer S, Hogdall E, Frederiksen K, Munk C, van den Brule AJC, Svare E, Meijer CJLM, Lorincz AT, Iftner T. The absolute risk of cervical abnormalities in high-risk human papillomavirus-positive, cytologically normal women over a 10-year period. *Cancer Res* 2006; 66(21): 10630-10636. (VUmc)
421. Klein S, Hage JJ. Measurement, calculation, and normal range of the ankle-arm index: A bibliometric analysis and recommendation for standardization. *Ann Vasc Surg* 2006; 20: 282-92. (NKI)
422. Klingenstein R, Löber S, Kujala P, Godsava S, Leliveld SR, Gmeiner P, Peters PJ, Korth C. Tricyclic antidepressants, quinacrine and a novel, synthetic chimera thereof clear prions by destabilizing detergent-resistant membrane compartments. *J Neurochem* 2006; 98: 748-59. (NKI)
423. Klok RP, Windhorst AD. A general GC analysis method for the determination of residual solvents in PET tracer formulations. *Nucl Med & Biol* 2006; 33: 935-938. (VUmc)
424. Klomp HM, Steyerberg EW, van Urk H, Habbema JDF, for the ESES Study Group. Spinal Cord Stimulation is not Cost-effective for Non-surgical Management of Critical Limb Ischaemia. *Eur J Vasc Endovasc Surg* 2006; 31: 500-8. (NKI)
425. Kluytmans-van den Bergh MF, Kluytmans JAJW. Community-acquired methicillin-resistant *Staphylococcus aureus*: current perspectives. *Clin Microbiol Infect* 2006; 12 Suppl 1: 9-15. (VUmc)

426. Knijnenburg TA, Reinders MJT, Wessels LFA. Artifacts of Markov blanket filtering based on discretized features in small sample size applications. *Pattern Recogn Lett* 2006; 27: 709-14. (NKI)
427. Knipscheer P, Sixma TK. Divide and conquer: The E2 active site. *Nat Struct Mol Biol* 2006; 13: 474-6. (NKI)
428. Kok HP, van Haaren PMA, van de Kamer JB, zum Vorde Sive Vording PJ, Wiersma J, Hulshof MCCM, Geijsen ED, Lanschot JJB van, Crezee J. Prospective treatment planning to improve locoregional hyperthermia for oesophageal cancer. *Int J Hyperther* 2006; 22(5): 375-389. (AMC)
429. Kolaczowska E, Scisłowska-Czarnecka A, Chadzinska M, Plytycz B, van Rooijen N, Opdenakker G, Arnold B. Enhanced early vascular permeability in gelatinase B (MMP-9)-deficient mice: putative contribution of COX-1-derived PGE2 of macrophage origin. *J Leukoc Biol* 2006; 80(1): 125-132. (VUmc)
430. Koopman M, Antonini NF, Douma J, Wals J, Honkoop AH, Erdkamp FLG, de Jong RS, Rodenburg CJ, Vreugdenhil G, Akkermans-Vogelaar JM, Punt CJA. Randomised study of sequential versus combination chemotherapy with capecitabine, irinotecan and oxaliplatin in advanced colorectal cancer, an interim safety analysis. A Dutch Colorectal Cancer Group (DCCG) phase III study. *Ann Oncol* 2006; 17: 1523-8. (NKI)
431. Korth C, Peters PJ. Emerging pharmacotherapies for Creutzfeldt-Jakob disease. *Arch Neurol* 2006; 63: 497-501. (NKI)
432. Kortlever RM, Bernardis R. Senescence, wound healing and cancer: The PAI-1 connection. *Cell Cycle* 2006; 5: 2697-703. (NKI)
433. Kortlever RM, Higgins PJ, Bernardis R. Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence. *Nat Cell Biol* 2006; 8: 878-84. (NKI)
434. Koshani R, Balter JM, Hayman JA, Henning GT, Van Herk M. Short-term and long-term reproducibility of lung tumor position using active breathing control (ABC). *Int J Radiat Oncol Biol Phys* 2006; 65: 1553-9. (NKI)
435. Kraal G, Mebius RE. New insights into the cell biology of the marginal zone of the spleen. *Int Rev Cytol* 2006; 250: 175-215. (VUmc)
436. Kraal G, Samsom JN, Mebius RE. The importance of regional lymph nodes for mucosal tolerance. *Immunol Rev* 2006; 213: 119-130. (VUmc)
437. Kramer GW, Legrand CL, van Schil P, Uitterhoeve L, Smit EF, Schramel FM, Biesma B, Tjan-Heijnen V, van Zandwijk N, Splinter T, Giaccone G, van Meerbeeck JP. Quality assurance of thoracic radiotherapy in EORTC 08941: a randomised trial of surgery versus thoracic radiotherapy in patients with stage IIIA non-small-cell lung cancer (NSCLC) after response to induction chemotherapy. *Eur J Cancer* 2006; 42(10): 1391-1398. (NKI/VUmc)
438. Kreike B, Halfwerk H, Kristel P, Glas A, Peterse H, Bartelink H, Van De Vijver MJ. Gene expression profiles of primary breast carcinomas from patients at high risk for local recurrence after breast-conserving therapy. *Clin Cancer Res* 2006; 12: 5705-12. (NKI)
439. Kreukels BPC, Schagen SB, Ridderinkhof KR, Boogerd W, Hamburger HL, Muller MJ, van Dam FSAM, Schagen SB. Effects of high-dose and conventional-dose adjuvant chemotherapy on long-term cognitive sequelae in patients with breast cancer: An electrophysiologic study. *Clin Breast Cancer* 2006; 7: 67-78. (NKI)
440. Kreulen M, Smeulders MJC, Veeger HEJ, Hage JJ. Movement patterns of the upper extremity and trunk before and after corrective surgery of impaired forearm rotation in patients with cerebral palsy. *Dev Med Child Neurol* 2006; 48: 436-41. (NKI)
441. Kriege M, Brekelmans CT, Obdeijn IM, Boetes C, Zonderland HM, Muller SH, Kok T, Manoliu RA, Besnard AP, Tilanus-Linthorst MM, Seynaeve C, Bartels CC, Kaas R, Meijer S, Oosterwijk JC, Hoogerbrugge N, Tollenaar RA, Rutgers EJ, de Koning HJ, Klijn JG. Factors affecting sensitivity and specificity of screening mammography and MRI in women with an inherited risk for breast cancer. *Breast Cancer Res Treat* 2006; 100(1): 109-119. (NKI/VUmc)
442. Kriege M, Brekelmans CTM, Boetes C, Muller SH, Zonderland HM, Obdeijn IM, Manoliu RA, Kok T, Rutgers EJ, De Koning HJ, Klijn JGM, Bartels CCM, Besnard APE, Hoogerbrugge N, Meijer S, Oosterwijk JC, Seynaeve C, Tilanus-Linthorst MMA, Tollenaar RAEM. Differences between first and subsequent rounds of the MRISC breast cancer screening program for women with a familial or genetic predisposition. *Cancer* 2006; 106: 2318-26. (NKI)
443. Kroep JR, Smit EF, Giaccone G, van der Born K, Beijnen JH, van Groeningen CJ, Van der Vijgh WJ, Postmus PE, Pinedo HM, Peters GJ. Pharmacology of the paclitaxel-cisplatin, gemcitabine-cisplatin, and paclitaxel-gemcitabine combinations in patients with advanced non-small cell lung cancer. *Cancer Chemother Pharmacol* 2006; 58(4): 509-516. (NKI/VUmc)
444. Kroon BK, Nieweg OE, van Boven H, Horenblas S. Size of Metastasis in the Sentinel Node Predicts Additional Nodal Involvement in Penile Carcinoma. *J Urol* 2006; 176: 105-8. (NKI)
445. Kuhlmann K, de Castro S, van Heek T, Busch O, van Gulik T, Obertop H, Gouma D. Microscopically incomplete resection offers acceptable palliation in pancreatic cancer. *Surgery* 2006; 139(2): 188-196. (AMC)
446. Kuipers HF, Rappert AA, Mommaas AM, van Haastert ES, van der Valk P, Boddeke HW, Biber KP, van den Elsen PJ. Simvastatin affects cell

- motility and actin cytoskeleton distribution of microglia. *Glia* 2006; 53(2): 115-123. (VUmc)
447. Kuipers HF, van den Elsen PJ. Putative immunoregulatory role of statins. *Current Immunology Reviews* 2006; 2: 55-64. (VUmc)
448. Kummer W, Wiegand S, Akinci S, Wessler I, Schinkel AH, Wess J, Koepsell H, Haberberger RV, Lips KS. Role of acetylcholine and polyspecific cation transporters in serotonin-induced bronchoconstriction in the mouse. *Respir Res* 2006; 7: 65. (NKI)
449. Kuppens IELM, Dansin E, Boot H, Feger C, Assadourian S, Bonnetterre ME, Beijnen JH, Schellens JHM, Bonnetterre J. Dose-finding phase I clinical and pharmacokinetic study of orally administered irinotecan in patients with advanced solid tumors. *Clin Cancer Res* 2006; 12: 3774-81. (NKI)
450. Lagarde SM, ten Kate FJW, de Boer DJ de, Busch ORC, Obertop H, van Lanschot JJB. Extracapsular lymph node involvement in node-positive patients with adenocarcinoma of the distal esophagus or gastroesophageal junction. *Am J Surg Pathol* 2006; 30(2): 171-176. (AMC)
451. Lagarde SM, ten Kate FW, Reitsma JB, Busch ORC, van Lanschot JJB. Prognostic factors in adenocarcinoma of the esophagus or gastroesophageal junction. *J Clin Oncol* 2006; 24(26), 4347-4355. (AMC)
452. Lagas JS, Vlaming ML, van Tellingen O, Wagenaar E, Jansen RS, Rosing H, Beijnen JH, Schinkel AH. Multidrug resistance protein 2 is an important determinant of paclitaxel pharmacokinetics. *Clin Cancer Res* 2006; 12: 6125-32. (NKI)
453. Laguna MP, Arce-Alcazar A, Mochtar CA, van Velthoven R, Peltier A, de la Rosette JJMCH. Construct validity of the chicken model in the simulation of laparoscopic radical prostatectomy suture. *J Endourol* 2006; 20(1), 69-73. (AMC)
454. Lai C, Reinders M, van 't Veer L, Wessels L. A comparison of univariate and multivariate gene selection techniques for classification of cancer datasets. *BMC Bioinformatics* 2006; 7: 235. (NKI)
455. Laine ML, Leonhardt A, Roos-Jansaker AM, Pena AS, van Winkelhoff AJ, Winkel EG, Renvert S. IL-1RN gene polymorphism is associated with peri-implantitis. *Clin Oral Implants Res* 2006; 17(4): 380-385. (VUmc)
456. Lakhani SR, Audretsch W, Cleton-Jensen AM, Cutuli B, Ellis I, Eusebi V, Greco M, Houlston RS, Kuhl CK, Kurtz J, Palacios J, Peterse H, Rochard F, Rutgers E, on behalf of EUSOMA. The management of lobular carcinoma in situ (LCIS). Is LCIS the same as ductal carcinoma in situ (DCIS)? *Eur J Cancer* 2006; 42: 2205-11. (NKI)
457. Lamfers MLM, Fulci G, Gianni D, Tang Y, Kurozumi K, Kaur B, Moeniralm S, Saeki Y, Carette JE, Weissleder R, Vandertop WP, van Beusechem VW, Dirven CMF, Chiocca EA. Cyclophosphamide increases transgene expression mediated by an oncolytic adenovirus in glioma-bearing mice monitored by bioluminescence imaging. *Mol Ther* 2006; 14(6): 779-788. (VUmc)
458. Lammertsma AA, Hoekstra CJ, Giaccone G, Hoekstra OS. How should we analyse FDG PET studies for monitoring tumour response?. *Eur J Nucl Med Mol Imaging* 2006; 33 Suppl 13: 16-21. (VUmc)
459. Langendijk JA, Kasperts N, Leemans CR, Doornaert PA, Slotman BJ. A phase II study of primary reirradiation in squamous cell carcinoma of head and neck. *Radiother Oncol* 2006; 78(3): 306-312. (VUmc)
460. Le Borgne M, Etchart N, Goubier A, Lira SA, Sirard JC, van Rooijen N, Caux C, Ait-Yahia S, Vicari A, Kaiserlian D, Dubois B. Dendritic cells rapidly recruited into epithelial tissues via CCR6/CCL20 are responsible for CD8+ T cell crosspriming in vivo. *Immunity* 2006; 24(2): 191-201. (VUmc)
461. le Sage C, Agami R. Immense promises for tiny molecules: Uncovering miRNA functions. *Cell Cycle* 2006; 5: 1415-21. (NKI)
462. Lebbink JHG, Georgijevic D, Natrajan G, Fish A, Winterwerp HHK, Sixma TK, De Wind N. Dual role of MutS glutamate 38 in DNA mismatch discrimination and in the authorization of repair. *EMBO J* 2006; 25: 409-19. (NKI)
463. Lebbink RJ, De Ruiter T, Adelmeijer J, Brenkman AB, Van Helvoort JM, Koch M, Farndale RW, Lisman T, Sonnenberg A, Lenting PJ, Meyaard L. Collagens are functional, high affinity ligands for the inhibitory immune receptor LAIR-1. *J Exp Med* 2006; 203: 1419-25. (NKI)
464. Legrand N, Weijer K, Spits H. Experimental models to study development and function of the human immune system in vivo. *J Immunol* 2006; 176: 2053-8. (NKI)
465. Leijte JAP, Valdés Olmos R, Mens JWM, Horenblas S. Use of positron emission tomography in spindle cell carcinoma of the penis. *Urology* 2006; 68: . (NKI)
466. Lekkerkerker AN, van Kooyk Y, Geijtenbeek TBH. Viral piracy: HIV-1 targets dendritic cells for transmission. *Curr HIV Res* 2006; 4(2): 169-176. (VUmc)
467. Lems WF, Lodder MC, Lips P, Bijlsma JW, Geusens PPMM, Schrameijer N, van de Ven CM, Dijkmans BAC. Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial. *Osteoporos Int* 2006; 17(5): 716-723. (VUmc)
468. Lens SM, Rodriguez JA, Vader G, Span SW, Giaccone G, Medema RH. Uncoupling the central spindle-associated function of the chromosomal passenger complex from its role at centromeres. *Mol Biol Cell* 2006; 17(4): 1897-1909. (VUmc)

469. Leveille F, Ferrer M, Medhurst AL, Laghmani eH, Roimans MA, Bier P, Steltenpool J, Titus TA, Postlethwait JH, Hoatlin ME, Joenje H, de Winter JP. The nuclear accumulation of the Fanconi anemia protein FANCD1 depends on FANCC. DNA Repair (Amst) 2006; 5(5): 556-565. (VUmc)
470. Levitus M, Joenje H, de Winter JP. The Fanconi anemia pathway of genomic maintenance. Cell Oncol 2006; 28(1-2): 3-29. (VUmc)
471. Li KW, Jimenez CR, van der Schors RC, Hornshaw MP, Schoffelmeer AN, Smit AB. Intermittent administration of morphine alters protein expression in rat nucleus accumbens. Proteomics 2006; 6(6): 2003-2008. (VUmc)
472. Li LK, Dai M, Clifford GM, Yao WQ, Arslan A, Li N, Shi JF, Snijders PJF, Meijer CJLM, Qiao YL, Franceschi S. Human papillomavirus infection in Shenyang City, People's Republic of China. A population-based study. Br J Cancer 2006; 95(11): 1593-1597. (VUmc)
473. Liedert B, Pluim D, Schellens J, Thomale J. Adduct-specific monoclonal antibodies for the measurement of cisplatin-induced DNA lesions in individual cell nuclei. Nucleic Acids Res 2006; 34: e47. (NKI)
474. Liem MSL, Nieweg OE, Liefers GJ. Isolated tumor cells in lymph nodes are not a prognostic marker for patients with stage I and stage II colorectal cancer: Commentary. J Surg Oncol 2006; 93: 18-9. (NKI)
475. Linet MS, Hauptmann M, Freedman DM, Alexander BH, Miller J, Sigurdson AJ, Morin Doody M. Interventional radiography and mortality risks in U.S. radiologic technologists. Pediatr Radiol 2006; 36 Suppl 14: 113-20. (NKI)
476. Litjens SHM, de Pereda JM, Sonnenberg A. Current insights into the formation and breakdown of hemidesmosomes. Trends Cell Biol 2006; 16: 376-83. (NKI)
477. Ljumanovic R, Langendijk JA, Hoekstra OS, Leemans CR, Castelijns JA. Distant metastases in head and neck carcinoma: identification of prognostic groups with MR imaging. Eur J Radiol 2006; 60(1): 58-66. (VUmc)
478. Llamas MA, Bitter W. Iron gate: the translocation system. J Bacteriol 2006; 188(9): 3172-3174. (VUmc)
479. Llamas MA, Sparrius M, Kloet R, Jimenez CR, Vandenbroucke-Grauls CMJE, Bitter W. The heterologous siderophores ferrioxamine B and ferrichrome activate signaling pathways in Pseudomonas aeruginosa. J Bacteriol 2006; 188(5): 1882-1891. (VUmc)
480. Lok CA, Ansink AC, Grootfaam D, Verheijen RHM, Kate-Booij MJ. Treatment and prognosis of post term choriocarcinoma in The Netherlands. Gynecol Oncol 2006; 103(2): 698-702. (VUmc)
481. Lont AP, Gallee MPW, Meinhardt W, Van Tinteren H, Horenblas S. Penis Conserving Treatment for T1 and T2 Penile Carcinoma: Clinical Implications of a Local Recurrence. J Urol 2006; 176: 575-80. (NKI)
482. Lont AP, Kroon BK, Horenblas S, Gallee MP, Berkhof J, Meijer CJLM, Snijders PJF. Presence of high-risk human papillomavirus DNA in penile carcinoma predicts favorable outcome in survival. Int J Cancer 2006; 119(5): 1078-1081. (NKI/VUmc)
483. Lopez-Guerrero JA, Riegman PHJ, Oosterhuis JW, Lam KH, Oomen MHA, Spatz A, Ratcliffe C, Knox K, Mager R, Kerr D, Pezzella F, van Damme B, van de Vijver M, van Boven H, Morente MM, Alonso S, Kerjaschki D, Pammer J, Carbone A, Gloghini A, Teodorovic I, Isabelle M, Passioukov A, Lejeune S, Therasse P, van Veen EB, Dinjens WNM, Llombart-Bosch A. TuBaFrost 4: Access rules and incentives for a European tumour bank. Eur J Cancer 2006; 42: 2924-9. (NKI)
484. Los A, Vinke F, de Widt J, Topham M, van Blitterswijk W, Divecha N. The Retinoblastoma Family Proteins Bind to and Activate Diacylglycerol Kinase{zeta}. J Biol Chem 2006; 281: 858-66. (NKI)
485. Lotz HT, Pos FJ, Hulshof MCM, Van Herk M, Lebesque JV, Duppen JC, Remeijer P. Tumor motion and deformation during external radiotherapy of bladder cancer. Int J Radiat Oncol Biol Phys 2006; 64: 1551-8. (NKI)
486. Louten J, van Rooijen N, Biron CA. Type 1 IFN deficiency in the absence of normal splenic architecture during lymphocytic choriomeningitis virus infection. J Immunol 2006; 177(5): 3266-3272. (VUmc)
487. Lubberink M, van Schie A, de Jong HW, van Dongen GAMS, Teule GJ. Acquisition settings for PET of 124I administered simultaneously with therapeutic amounts of 131I. J Nucl Med 2006; 47(8): 1375-1381. (VUmc)
488. Ludwig IS, Geijtenbeek TBH, van Kooyk Y. Two way communication between neutrophils and dendritic cells. Curr Opin Pharmacol 2006; 6(4): 408-413. (VUmc)
489. Lukens MV, Claassen EAW, de Graaff PMA, van Dijk MEA, Hoogerhout P, Toebes M, Schumacher TN, van der Most RG, Kimpen JLL, van Bleek GM. Characterization of the CD8+ T cell responses directed against respiratory syncytial virus during primary and secondary infection in C57BL/6 mice. Virology 2006; 352: 157-68. (NKI)
490. Luttjeboer M, Kaspers GJL. Medulloblastoma: need for targeted treatment. Expert Rev Anticancer Ther 2006; 6(5): 649-652. (VUmc)
491. Lyons JM, Ito JI, Morre SA. Efficacy of an Immune Modulator in Experimental Chlamydia trachomatis Infection of the Female Genital Tract. Infect Dis Obstet Gynecol 2006; 14(2): 61265. (VUmc)
492. MacLeod M, Kwakkenbos MJ, Crawford A, Brown S, Stockinger B, Schepers K, Schumacher T, Gray D. CD4 memory T cells survive and proliferate

- but fail to differentiate in the absence of CD40. *J Exp Med* 2006; 203: 897-906. (NKI)
493. Madalinska JB, van Beurden M, Bleiker EM, Valdimarsdottir HB, Hollenstein J, Massuger LF, Gaarenstroom KN, Mourits MJ, Verheijen RHM, van Dorst EB, van der Putten H, Boonstra H, Aaronson NK. The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy. *J Clin Oncol* 2006; 24(22): 3576-3582. (NKI/VUmc)
494. Maher JM, Cheng X, Tanaka Y, Scheffer GL, Klaassen CD. Hormonal regulation of renal multidrug resistance-associated proteins 3 and 4 (Mrp3 and Mrp4) in mice. *Biochem Pharmacol* 2006; 71(10): 1470-1478. (VUmc)
495. Mahieu HF. Practical applications of laryngeal framework surgery. *Otolaryngol Clin North Am* 2006; 39(1): 55-75. (VUmc)
496. Mallant-Hent RC, von Blomberg BME, Yuksel Z, Wahab PJ, Gundy CM, Meyer GA, Mulder CJ. Disappearance of anti-Saccharomyces cerevisiae antibodies in coeliac disease during a gluten-free diet. *Eur J Gastroenterol Hepatol* 2006; 18(1): 75-78. (VUmc)
497. Mallant-Hent RC, Mooij M, von Blomberg BME, Linskens RK, van Bodegraven AA, Savelkoul PHM. Correlation between Saccharomyces cerevisiae DNA in intestinal mucosal samples and anti-Saccharomyces cerevisiae antibodies in serum of patients with IBD. *World J Gastroenterol* 2006; 12(2): 292-297. (VUmc)
498. Malliri A, Rygiel TP, Van Der Kammen RA, Song JY, Engers R, Hurlstone AFL, Clevers H, Collard JG. The Rac activator Tiam1 is a Wnt-responsive gene that modifies intestinal tumor development. *J Biol Chem* 2006; 281: 543-8. (NKI)
499. Mamey I, van Vugt MA, Smits VA, Semple JI, Lemmens B, Perrakis A, Medema RH, Freire R. Polo-like Kinase-1 Controls Proteasome-Dependent Degradation of Claspin during Checkpoint Recovery. *Curr Biol* 2006; 16: 1950-5. (NKI)
500. Mangan NE, van Rooijen N, McKenzie AN, Fallon PG. Helminth-modified pulmonary immune response protects mice from allergen-induced airway hyperresponsiveness. *J Immunol* 2006; 176(1): 138-147. (VUmc)
501. Marin-Jimenez I, Pena AS. Budesonide for ulcerative colitis. *Rev Esp Enferm Dig* 2006; 98(5): 362-373. (VUmc)
502. Marsman M, Jordens I, Rocha N, Kuijl C, Janssen L, Neefjes J. A splice variant of RILP induces lysosomal clustering independent of dynein recruitment. *Biochem Biophys Res Commun* 2006; 344: 747-56. (NKI)
503. Marsman WA, Brink MA, Bergman JJGHM, Tytgat GNJ, ten Kate FJW, van Lanschot JJB, Fockens P. Potential impact of EUS-FNA staging of proximal lymph nodes in patients with distal esophageal carcinoma. *Endoscopy* 2006; 38(8): 825-829. (AMC)
504. Masnikosa R, Baricevic I, Jones DR, Nedic O. Characterisation of insulin-like growth factor receptors and insulin receptors in the human placenta using lectin affinity methods. *Growth Horm IGF Res* 2006; 16: 174-84. (NKI)
505. Mauritz R, Peters GJ. Pharmacogenetics of colon cancer and potential implications for 5-fluorouracil-based chemotherapy. *Current Pharmacogenomics* 2006; 4: 57-67. (VUmc)
506. Maussang D, Verzijl D, van Walsum M, Leurs R, Holl J, Pleskoff O, Michel D, van Dongen GAMS, Smit MJ. Human cytomegalovirus-encoded chemokine receptor US28 promotes tumorigenesis. *Proc Natl Acad Sci U S A* 2006; 103(35): 13068-13073. (VUmc)
507. McDermott LN, Nijsten SMJJ, Sonke JJ, Partridge M, Van Herk M, Mijnheer BJ. Comparison of ghosting effects for three commercial a-Si EPIDs. *Med Phys* 2006; 33: 2448-51. (NKI)
508. McDermott LN, Wendling M, Sonke JJ, Van Herk M, Mijnheer BJ. Anatomy changes in radiotherapy detected using portal imaging. *Radiother Oncol* 2006; 79: 211-7. (NKI)
509. McDermott LN, Wendling M, Van Asselen B, Stroom J, Sonke JJ, Van Herk M, Mijnheer BJ. Clinical experience with EPID dosimetry for prostate IMRT pre-treatment dose verification. *Med Phys* 2006; 33: 3921-30. (NKI)
510. Mearin ML, Catassi C, Brousse N, Brand R, Collin P, Fabiani E, Schweizer JJ, Abuzakouk M, Szajewska H, Hallert C, Farre MC, Holmes GK. European multi-centre study on coeliac disease and non-Hodgkin lymphoma. *Eur J Gastroenterol Hepatol* 2006; 18(2): 187-194. (VUmc)
511. Medhurst AL, Laghmani eH, Steltenpool J, Ferrer M, Fontaine C, de Groot J, Rooimans MA, Scheper RJ, Meetei AR, Wang W, Joenje H, de Winter JP. Evidence for subcomplexes in the Fanconi anemia pathway. *Blood* 2006; 108(6): 2072-2080. (VUmc)
512. Meijer CJLM, Snijders PJF, Castle PE. Clinical utility of HPV genotyping. *Gynecol Oncol* 2006; 103(1): 12-17. (VUmc)
513. Meijer J, Zeelenberg IS, Sipos B, Roos E. The CXCR5 chemokine receptor is expressed by carcinoma cells and promotes growth of colon carcinoma in the liver. *Cancer Res* 2006; 66: 9576-82. (NKI)
514. Meijerman I, Beijnen JH, Schellens JHM. Herb-drug interactions in oncology: Focus on mechanisms of induction. *Oncologist* 2006; 11: 742-52. (NKI)
515. Meleti M, Mooi WJ, van der Waal I. Oral malignant melanoma associated with pseudoepitheliomatous hyperplasia. Report of a case. *J Cutan Pathol* 2006; 33(4): 331-3.. (VUmc)
516. Mendes RA, van der Waal I. An unusual clinicoradiographic presentation of a lateral periodontal cyst--report of two cases. *Med Oral*

- Patol Oral Cir Bucal 2006; 11(2): E185-E187. (VUmc)
517. Merino G, Ivarez AI, Pulido MM, Molina AJ, Schinkel AH, Prieto JG. Breast cancer resistance protein (BCRP/ABCG2) transports fluoroquinolone antibiotics and affects their oral availability, pharmacokinetics, and milk secretion. *Drug Metab Dispos* 2006; 34: 690-5. (NKI)
518. Merks JHM, Özgen HM, Cluitmans TLM, Van Der Burg-Van Rijn JM, Cobben JM, van Leeuwen FE, Hennekam RCM. Normal values for morphological abnormalities in school children. *Am J Med Genet A* 2006; 140: 2091-109. (NKI)
519. Mertens AEE, Pegtel DM, Collard JG. Tiam1 takes PART in cell polarity. *Trends Cell Biol* 2006; 16: 308-16. (NKI)
520. Meshinchi S, Alonzo TA, Stirewalt DL, Zwaan CM, Zimmerman M, Reinhardt D, Kaspers GJL, Heerema NA, Gerbing R, Lange BJ, Radich JP. Clinical implications of FLT3 mutations in pediatric AML. *Blood* 2006; 108(12): 3654-3661. (VUmc)
521. Mey V, Giovannetti E, De Braud F, Nannizzi S, Curigliano G, Verweij F, De Cobelli O, Pece S, Del Tacca M, Danesi R. In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients. *Br J Cancer* 2006; 95(3): 289-297. (VUmc)
522. Meyer S, Barber LM, White DJ, Will AM, Birch JM, Kohler JA, Ersfeld K, Blom E, Joenje H, Eden TO, Malcolm TG. Spectrum and significance of variants and mutations in the Fanconi anaemia group G gene in children with sporadic acute myeloid leukaemia. *Br J Haematol* 2006; 133(3): 284-292. (VUmc)
523. Mieog JSD, van der Hage JA, Van De Vijver MJ, Van De Velde CJH. Tumour response to preoperative anthracycline-based chemotherapy in operable breast cancer: the predictive role of p53 expression. *Eur J Cancer* 2006; 42: 1369-79. (NKI)
524. Milton A, Luoto K, Ingram L, Munro S, Logan N, Graham AL, Brummelkamp TR, Hijmans EM, Bernards R, La Thangue NB. A functionally distinct member of the DP family of E2F subunits. *Oncogene* 2006; 25: 3212-8. (NKI)
525. Minich T, Riemer J, Schulz JB, Wielinga P, Wijnholds J, Dringen R. The multidrug resistance protein 1 (Mrp1), but not Mrp5, mediates export of glutathione and glutathione disulfide from brain astrocytes. *J Neurochem* 2006; 97: 373-84. (NKI)
526. Mochtar CA, Kiemenev LALM, Laguna MP, Debruyne FMJ, de la Rosette JJMCH. PSA velocity in conservatively managed BPH: Can it predict the need for BPH-related invasive therapy? *Prostate* 2006; 66(13): 1407-1412. (AMC)
527. Mochtar CA, Kiemenev LALM, van Riemsdijk MM, Laguna MP, Debruyne FMJ, de la Rosette. Post-void residual urine volume is not a good predictor of the need for invasive therapy among patients with benign prostatic hyperplasia. *J Urology* 2006; 175(1): 213-216. (AMC)
528. Mochtar CA, Laan W, van Houwelingen KP, Franke B, de la Rosette JJMCH, Schalken JA, Kiemenev LALM. Polymorphisms in the alpha(1A)-adrenoceptor gene do not modify the short- and long-term efficacy of alpha(1)-adrenoceptor antagonists in the treatment of benign prostatic hyperplasia. *BJU Int* 2006; 97(4): 852-855. (AMC)
529. Moffit JS, Aleksunes LM, Maher JM, Scheffer GL, Klaassen CD, Manautou JE. Induction of hepatic transporters multidrug resistance-associated proteins (Mrp) 3 and 4 by clofibrate is regulated by peroxisome proliferator-activated receptor alpha. *J Pharmacol Exp Ther* 2006; 317(2): 537-545. (VUmc)
530. Mohammadi T, Savelkoul PHM, Pietersz RN, Reesink HW. Applications of real-time PCR in the screening of platelet concentrates for bacterial contamination. *Expert Rev Mol Diagn* 2006; 6(6): 865-872. (VUmc)
531. Molenkamp BG, van Leeuwen PAM, van den Eertwegh AJM, Sluijter BJ, Scheper RJ, Meijer S, de Gruijl TD. Immunomodulation of the melanoma sentinel lymph node: a novel adjuvant therapeutic option. *Immunobiology* 2006; 211(6-8): 651-661. (VUmc)
532. Mollinedo F, Calafat J, Janssen H, Martin-Martin B, Canchado J, Nabokina SM, Gajate C. Combinatorial SNARE complexes modulate the secretion of cytoplasmic granules in human neutrophils. *J Immunol* 2006; 177: 2831-41. (NKI)
533. Mols F, Poll-Franse LV, Vingerhoets AJJM, Hendriks A, Aaronson NK, Houterman S, Coebergh JWW, Essink-Bot ML. Long-term quality of life among Dutch prostate cancer survivors: Results of a population-based study. *Cancer* 2006; 107: 2186-96. (NKI)
534. Mols F, Vingerhoets AJJM, Coebergh JW, Vreugdenhil G, Aaronson NK, Lybeert MLM, Poll-Franse LV. Better quality of life among 10-15 year survivors of Hodgkin's lymphoma compared to 5-9 year survivors: A population-based study. *Eur J Cancer* 2006; 42: 2794-801. (NKI)
535. Mooi WJ, Peeper DS. Oncogene-induced cell senescence - Halting on the road to cancer. *N Engl J Med* 2006; 355: 1037-46. (NKI)
536. Moorman C, Sun LV, Wang J, de Wit E, Talhout W, Ward LD, Greil F, Lu XJ, White KP, Bussemaker HJ, van Steensel B. Hotspots of transcription factor colocalization in the genome of *Drosophila melanogaster*. *Proc Natl Acad Sci U S A* 2006; 103: 12027-32. (NKI)
537. Moreno A, Ferrer E, Arahetes S, Eguiluz C, van Rooijen N, Benito A. The course of infections and pathology in immunomodulated NOD/LtSz-SCID mice inoculated with *Plasmodium falciparum* laboratory lines and clinical isolates. *Int J Parasitol* 2006; 36(3): 361-369. (VUmc)

538. Morente MM, Mager R, Alonso S, Pezzella F, Spatz A, Knox K, Kerr D, Dinjens WNM, Oosterhuis JW, Lam KH, Oomen MHA, van Damme B, van de Vijver M, van Boven H, Kerjaschki D, Pammer J, Lopez-Guerrero JA, Llombart Bosch A, Carbone A, Gloghini A, Teodorovic I, Isabelle M, Passiukov A, Lejeune S, Therasse P, van Veen EB, Ratcliffe C, Riegman PHJ. TuBaFrost 2: Standardising tissue collection and quality control procedures for a European virtual frozen tissue bank network. *Eur J Cancer* 2006; 42: 2684-91. (NKI)
539. Morosan S, Hez-Deroubaix S, Lunel F, Renia L, Giannini C, van Rooijen N, Battaglia S, Blanc C, Eling W, Sauerwein R, Hannoun L, Belghiti J, Brechot C, Kremsdorf D, Druilhe P. Liver-stage development of *Plasmodium falciparum*, in a humanized mouse model. *J Infect Dis* 2006; 193(7): 996-1004. (VUmc)
540. Morre SA, Pannekoek Y, Ossewaarde JM. More than 25 years of urogenital Chlamydia trachomatis research in the Netherlands. *Drugs Today (Barc)* 2006; 42 Suppl A: 5-24. (VUmc)
541. Morre SA, Spaargaren J, Ossewaarde JM, Land JA, Bax CJ, Dorr PJ, Oostvogel PM, Vanrompay D, Savelkoul PHM, Pannekoek Y, van Bergen JE, Fennema HS, de Vries HJ, Crusius JBA, Pena AS, Ito JI, Lyons JM. Description of the ICTI consortium: an integrated approach to the study of Chlamydia trachomatis infection. *Drugs Today (Barc)* 2006; 42 Suppl A: 107-114. (VUmc)
542. Morre SA, Spaargaren J, Veldhuijzen IK, Postma MJ, van Bergen JE, van Bergen JE, Broer J, Coenen AJ, Gotz HM, de Groot F, Hoebe CJ, Richardus JH, van Schaik DT, Veldhuijzen IK, Verhooren M. Evaluation of the leukocyte esterase test (LET) as pre-screening test to reduce costs for national population-based Chlamydia trachomatis screening programs. *J Adolesc Health* 2006; 38(4): 332-333. (VUmc)
543. Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Elashoff R, Essner R, Nieweg OE, Roses DF, Hoekstra HJ, Karakousis CP, Reintgen DS, Coventry BJ, Glass EC, Wang HJ. Sentinel-node biopsy or nodal observation in melanoma. *N Engl J Med* 2006; 355: 1307-17. (NKI)
544. Moser EC, Kluin-Nelemans HC, Carde P, Meerwaldt JH, Tirelli U, Aleman BMP, Baars J, Thomas J, van Glabbeke M, Noordijk EM. Impact of involved field radiotherapy in partial response after doxorubicin-based chemotherapy for advanced aggressive non-Hodgkin's lymphoma. *Int J Radiat Oncol Biol Phys* 2006; 66: 1168-77. (NKI)
545. Moser EC, Noordijk EM, van Leeuwen FE, Baars JW, Thomas J, Carde P, Meerwaldt JH, van Glabbeke M, Kluin-Nelemans HC. Risk of second cancer after treatment of aggressive non-Hodgkin's lymphoma; an EORTC cohort study. *Haematologica* 2006; 91: 1481-8. (NKI)
546. Moser EC, Noordijk EM, van Leeuwen FE, le Cessie S, Baars JW, Thomas J, Carde P, Meerwaldt JH, van Glabbeke M, Kluin-Nelemans HC. Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma. *Blood* 2006; 107: 2912-9. (NKI)
547. Mostert SM, Sitaesmi MN, Gundy CM, Sutaryo, Veerman AJP. Influence of socioeconomic status on childhood acute lymphoblastic leukemia treatment in Indonesia. *Pediatrics* 2006; 118(6): e1600-e1606. (VUmc)
548. Mous R, Savage P, Remmerswaal EBM, van Lier RAW, Eldering E, van Oers MHJ. Redirection of CMV-specific CTL towards B-CLL via CD20-targeted HLA/CMV complexes. *Leukemia* 2006; 20(6): 1096-1102. (AMC)
549. Mukhopadhyay S, Chen Y, Sankala M, Peiser L, Pikkarainen T, Kraal G, Tryggvason K, Gordon S. MARCO, an innate activation marker of macrophages, is a class A scavenger receptor for *Neisseria meningitidis*. *Eur J Immunol* 2006; 36(4): 940-949. (VUmc)
550. Mulder MMS, Heddema ER, Pannekoek Y, Fairidpooya K, Oud MECM, Schilder-Tol E, Saeed P, Pals ST. No evidence for an association of ocular adnexal lymphoma with Chlamydia psittaci in a cohort of patients from the Netherlands. *Leukemia Res* 2006; 30(10): 1305-1307. (AMC)
551. Müller M, Weigand JE, Weichenrieder O, Suess B. Thermodynamic characterization of an engineered tetracycline-binding riboswitch. *Nucleic Acids Res* 2006; 34: 2607-17. (NKI)
552. Muris JJ, Meijer CJ, Ossenkuppele GJ, Vos W, Oudejans JJ. Apoptosis resistance and response to chemotherapy in primary nodal diffuse large B-cell lymphoma. *Hematol Oncol* 2006; 24: 97-104. (VUmc)
553. Muris JJ, Meijer CJ, Vos W, van Krieken JH, Jiwa NM, Ossenkuppele GJ, Oudejans JJ. Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma. *J Pathol* 2006; 208: 714-723. (VUmc)
554. Muris JJ, Ylstra B, Cillessen SA, Ossenkuppele GJ, Kluin-Nelemans JC, Eijk PP, Nota B, Tijssen M, de Boer WP, van de Wiel M, van den Ijssel PR, Jansen P, de Bruin PC, van Krieken JH, Meijer GA, Meijer CJ, Oudejans JJ. Profiling of apoptosis genes allows for clinical stratification of primary nodal diffuse large B-cell lymphomas. *Br J Haematol* 2006; 136: 38-47. (VUmc)
555. Muris JJF, Meijer CJLM, Ossenkuppele GJ, Vos W, Oudejans JJ. Apoptosis resistance and response to chemotherapy in primary nodal diffuse large B-cell lymphoma. *Hematol Oncol* 2006; 24(3): 97-104. (VUmc)
556. Naarding MA, Dirac AM, Ludwig IS, Speijer D, Lindquist S, Vestman EL, Stax MJ, Geijtenbeek TBH, Pollakis G, Hernel O, Paxton WA. Bile salt-stimulated lipase from human milk binds DC-SIGN and inhibits human immunodeficiency virus type 1 transfer to CD4+ T cells. *Antimicrob Agents Chemother* 2006; 50(10): 3367-3374. (NKI/VUmc)

557. Nabatov AA, van Montfort T, Geijtenbeek TBH, Pollakis G, Paxton WA. Interaction of HIV-1 with dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin-expressing cells is influenced by gp120 envelope modifications associated with disease progression. *FEBS J* 2006; 273(21): 4944-4958. (VUmc)
558. Neve S, Kirtschig G. Elastotic striae associated with striae distensae after application of very potent topical corticosteroids. *Clin Exp Dermatol* 2006; 31(3): 461-462. (VUmc)
559. Nielen MM, van Schaardenburg D, Lems WF, van de Stadt RJ, de Koning MH, Reesink HW, Habibuw MR, van der Horst-Bruinsma IE, Twisk JW, Dijkmans BAC. Vitamin D deficiency does not increase the risk of rheumatoid arthritis: comment on the article by Merlino et al. *Arthritis Rheum* 2006; 54(11): 3719-3720. (VUmc)
560. Nielsen M, Poley JW, Verhoef S, Van Puijtenbroek M, Weiss MM, Burger GT, Dommering CJ, Vasen HFA, Kuipers EJ, Wagner A, Morreau H, Hes FJ. Duodenal carcinoma in MUTYH-associated polyposis. *J Clin Pathol* 2006; 59: 1212-5. (NKI)
561. Niessen RC, Sijmons RH, Ou J, Olthof SGM, Osinga J, Ligtenberg MJ, Hogervorst FBL, Weiss MM, Tops CMJ, Hes FJ, de Bock GH, Buys CHCM, Kleibeuker JH, Hofstra RMW. MUTYH and the mismatch repair system: Partners in crime? *Hum Genet* 2006; 119: 206-11. (NKI)
562. Nieuwenhuijsen K, Bos-Randsorp B, Uitterhoeve LLJ, Sprangers MAG, Verbeek JHAM. Enhanced provider communication and patient education regarding return to work in cancer survivors following curative treatment: A pilot study. *J Occup Rehabil* 2006; 16(4): 647-657. (AMC)
563. Nieweg OE, Kroon BBR. The conundrum of follow-up: should it be abandoned? *Surg Oncol Clin N Am* 2006; 15: 319-30. (NKI)
564. Nijman SMB, Hijmans EM, El Messaoudi S, Van Dongen MMW, Sardet C, Bernards R. A functional genetic screen identifies TFE3 as a gene that confers resistance to the anti-proliferative effects of the retinoblastoma protein and transforming growth factor- β ? *J Biol Chem* 2006; 281: 21582-7. (NKI)
565. Nindl I, Koehler A, Meyer T, Forschner T, Meijer CJLM, Snijders PJF, Sterry W, Stockfleth E. Detection of human papillomavirus DNA in primary squamous cell carcinoma and metastases. *Br J Dermatol* 2006; 154(4): 797-799. (VUmc)
566. Noda D, Itoh S, Watanabe Y, Inamitsu M, Dennler S, Itoh F, Koike S, Danielpour D, Ten Dijke P, Kato M. ELAC2, a putative prostate cancer susceptibility gene product, potentiates TGF- β /Smad-induced growth arrest of prostate cells. *Oncogene* 2006; 25: 5591-600. (NKI)
567. Noorda EM, Vrouwenraets BC, Nieweg OE, Kroon BBR. Isolated Limb Perfusion in Regional Melanoma. *Surg Oncol Clin N Am* 2006; 15: 373-84. (NKI)
568. Noorda EM, Vrouwenraets BC, Nieweg OE, van Geel AN, Eggermont AMM, Kroon BBR. Repeat isolated limb perfusion with TNF α and melphalan for recurrent limb melanoma after failure of previous perfusion. *Eur J Surg Oncol* 2006; 32: 318-24. (NKI)
569. Nuyten DSA, Kreike B, Hart AAM, Chi JTA, Sneddon JB, Wessels LFA, Peterse HJ, Bartelink H, Brown PO, Chang HY, Van De Vijver MJ. Predicting a local recurrence after breast-conserving therapy by gene expression profiling. *Breast Cancer Res* 2006; 8: R62. (NKI)
570. Oerlemans R, van der Heijden JW, Vink J, Dijkmans BAC, Kaspers GJL, Lems WF, Scheffer GL, Ifergan I, Scheper RJ, Cloos J, Assaraf YG, Jansen G. Acquired resistance to chloroquine in human CEM T cells is mediated by multidrug resistance-associated protein 1 and provokes high levels of cross-resistance to glucocorticoids. *Arthritis Rheum* 2006; 54(2): 557-568. (VUmc)
571. Oetke C, Kraal G, Crocker PR. The antigen recognized by MOMA-1 is sialoadhesin. *Immunol Lett* 2006; 106(1): 96-98. (VUmc)
572. Ogasawara M, Yamauchi K, Satoh YI, Yamaji R, Inui K, Jonker JW, Schinkel AH, Maeyama K. Recent advances in molecular pharmacology of the histamine systems: Organic cation transporters as a histamine transporter and histamine metabolism. *J Pharmacol Sci* 2006; 101: 24-30. (NKI)
573. Oguro H, Iwama A, Morita Y, Kamijo T, Van Lohuizen M, Nakauchi H. Differential impact of Ink4a and Arf on hematopoietic stem cells and their bone marrow microenvironment in Bmi1-deficient mice. *J Exp Med* 2006; 203: 2247-53. (NKI)
574. Olivier RI, Lubsen-Brandsma MAC, Verhoef S, van Beurden M. CA125 and transvaginal ultrasound monitoring in high-risk women cannot prevent the diagnosis of advanced ovarian cancer. *Gynecol Oncol* 2006; 100: 20-6. (NKI)
575. Olivier RI, van Beurden M, van 't Veer LJ. The role of gene expression profiling in the clinical management of ovarian cancer. *Eur J Cancer* 2006; 42: 2930-8. (NKI)
576. Omloo JM, Westerterp M, Boellaard R, Hoekstra OS, Sloof GW, Jan BvL. Relation between 18FDG-PET standardised uptake values and prognosis in oesophageal cancer patients. *J Clin Gastroenterol* 2006; 40: S167. (VUmc)
577. Omloo JMT, Lagarde SM, Vrouwenraets BC, Busch ORC, van Lanschot JJB. Compartmentalization for chylothorax originating from the abdomen after extended esophagectomy - Report of two cases and review of the literature. *Digest Surg* 2006; 23(1-2): 86-92. (AMC)
578. Oosterkamp HM, Neering H, Nijman SMB, Dirac AMG, Mooi WJ, Bernards R, Brummelkamp TR. An evaluation of the efficacy of topical application of salicylic acid for the treatment of familial cylindromatosis. *Br J Dermatol* 2006; 155: 182-5. (NKI)

579. Oosterling SJ, Mels AK, Geijtenbeek TBH, van der Bij GJ, Tuk CW, Vuylsteke RJ, van Leeuwen PAM, Meijer GA, Meijer S, Beelen RHJ, van Egmond M. Preoperative granulocyte/macrophage colony-stimulating factor (GM-CSF) increases hepatic dendritic cell numbers and clustering with lymphocytes in colorectal cancer patients. *Immunobiology* 2006; 211(6-8): 641-649. (VUmc)
580. Oosterling SJ, van der Bij GJ, Bogels M, van der Sijp JRM, Beelen RHJ, Meijer S, van Egmond M. Insufficient ability of omental milky spots to prevent peritoneal tumor outgrowth supports omentectomy in minimal residual disease. *Cancer Immunol Immunother* 2006; 55(9): 1043-1051. (VUmc)
581. Oosterling SJ, van der Bij GJ, Mels AK, Beelen RHJ, Meijer S, van Egmond M, van Leeuwen PAM. Perioperative IFN-alpha to avoid surgically induced immune suppression in colorectal cancer patients. *Histol Histopathol* 2006; 21(7): 753-760. (VUmc)
582. Opocher E, Kremer LCM, da Dalt L, van de Wetering MD, Viscardi E, Caron HN, Perilongo G. Prognostic factors for progression of childhood optic pathway glioma: A systematic review. *Eur J Cancer* 2006; 42(12): 1807-1816. (AMC)
583. Ortiz-Ferron G, Tait SW, Robledo G, de Vries E, Borst J, López-Rivas A. The mitogen-activated protein kinase pathway can inhibit TRAIL-induced apoptosis by prohibiting association of truncated Bid with mitochondria. *Cell Death Differ* 2006; 13: 1857-65. (NKI)
584. Otten MA, Groenveld I, van de Winkel JG, van Egmond M. Inefficient antigen presentation via the IgA Fc receptor (FcalphaRI) on dendritic cells. *Immunobiology* 2006; 211(6-8): 503-510. (VUmc)
585. Overwijk WW, De Visser KE, Tirion FH, De Jong LA, Pols TWH, Van Der Velden YU, Van Den Boorn JG, Keller AM, Buurman WA, Theoret MR, Blom B, Restifo NP, Kruisbeek AM, Kastelein RA, Haanen JBAG. Immunological and antitumor effects of IL-23 as a cancer vaccine adjuvant. *J Immunol* 2006; 176: 5213-22. (NKI)
586. Padron JM, Peters GJ. Cytotoxicity of sphingoid marine compound analogs in mono- and multilayered solid tumor cell cultures. *Invest New Drugs* 2006; 24(3): 195-202. (VUmc)
587. Pauwels B, Korst AE, Pattyn GG, Lambrechts HA, Kamphuis JA, De Pooter CM, Peters GJ, Lardon F, Vermorken JB. The relation between deoxycytidine kinase activity and the radiosensitising effect of gemcitabine in eight different human tumour cell lines. *BMC Cancer* 2006; 6: 142. (VUmc)
588. Paz-Ares L, Douillard JY, Koralewski P, Manegold C, Smit EF, Reyes JM, Chang GC, John WJ, Peterson PM, Obasaju CK, Lahn M, Gandara DR. Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-alpha antisense oligonucleotide, in patients with advanced-stage non-small-cell lung cancer. *J Clin Oncol* 2006; 24(9): 1428-1434. (VUmc)
589. Peeper D, Berns A. Cross-Species Oncogenomics in Cancer Gene Identification. *Cell* 2006; 125: 1230-3. (NKI)
590. Peeters STH, Heemsbergen WD, Koper PC, van Putten WL, Slot A, Dielwart MF, Bonfrer JM, Incrocci L, Lebesque JV. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. *J Clin Oncol* 2006; 24: 1990-6. (NKI)
591. Peeters STH, Hoogeman MS, Heemsbergen WD, Hart AAM, Koper PCM, Lebesque JV. Rectal bleeding, fecal incontinence, and high stool frequency after conformal radiotherapy for prostate cancer: Normal tissue complication probability modeling. *Int J Radiat Oncol Biol Phys* 2006; 66: 11-9. (NKI)
592. Peeters STH, Lebesque JV, Heemsbergen WD, Van Putten WLJ, Slot A, Dielwart MFH, Koper PCM. Localized volume effects for late rectal and anal toxicity after radiotherapy for prostate cancer. *Int J Radiat Oncol Biol Phys* 2006; 64: 1151-61. (NKI)
593. Peeva GP, Angelova SK, Guntinas-Lichius O, Streppel M, Irintchev A, Schütz U, Popratiloff A, Savaskan NE, Bräuer AU, Alvanou A, Nitsch R, Angelov DN. Improved outcome of facial nerve repair in rats is associated with enhanced regenerative response of motoneurons and augmented neocortical plasticity. *Eur J Neurosci* 2006; 24: 2152-62. (NKI)
594. Pellitteri PK, Ferlito A, Rinaldo A, Shah JP, Weber RS, Lowry J, Medina JE, Gourin CG, Robbins KT, Suarez C, Shaha AR, Genden EM, Leemans CR, Lefebvre JL, Kowalski LP, Wei WI. Planned neck dissection following chemoradiotherapy for advanced head and neck cancer: is it necessary for all?. *Head Neck* 2006; 28(2): 166-175. (VUmc)
595. Pena AS. Contribution of genetics to a new vision in the understanding of inflammatory bowel disease. *World J Gastroenterol* 2006; 12(30): 4784-4787. (VUmc)
596. Perk LR, Visser OJ, Stigter-van Walsum M, Vosjan MJ, Visser GWM, Zijlstra JM, Huijgens PC, van Dongen GAMS. Preparation and evaluation of (89)Zr-Zevalin for monitoring of (90)Y-Zevalin biodistribution with positron emission tomography. *Eur J Nucl Med Mol Imaging* 2006; 33(11): 1337-1345. (VUmc)
597. Peters FP, Kara MA, Rosmolen WD, ten Kate FJW, Krishnadath KK, van Lanschot JJB, Fockens P, Bergman JJGHM. Stepwise radical endoscopic resection is effective for complete removal of Barrett's esophagus with early neoplasia: A prospective study. *Am J Gastroenterol* 2006; 101(7): 1449-1457. (AMC)
598. Peters GJ, Carrey EA, Sebesta I. Purine and pyrimidine metabolism: a firm basis for a

- transformed society. *Nucleos Nucleot Nucl Acids* 2006; 25(9-11): 971-974. (VUmc)
599. Peters GJ, Van Moorsel CJ, Lakerveld B, Smid K, Noordhuis P, Comijn EC, Weaver D, Willey JC, Voorn D, Van der Vijgh WJ, Pinedo HM. Effects of gemcitabine on cis-platinum-DNA adduct formation and repair in a panel of gemcitabine and cisplatin-sensitive or -resistant human ovarian cancer cell lines. *Int J Oncol* 2006; 28(1): 237-244. (VUmc)
600. Peters JH, Craanen ME, van der Peet DL, Cuesta MA, Mulder CJ. Self-expanding metal stents for the treatment of intrathoracic esophageal anastomotic leaks following esophagectomy. *Am J Gastroenterol* 2006; 101(6): 1393-1395. (VUmc)
601. Peters RPH, Savelkoul PHM, Simoons-Smit AM, Danner SA, Vandenbroucke-Grauls CMJE, van Agtmael MA. Faster identification of pathogens in positive blood cultures by fluorescence in situ hybridization in routine practice. *J Clin Microbiol* 2006; 44(1): 119-123. (VUmc)
602. Peters RPH, van Agtmael MA, Simoons-Smit AM, Danner SA, Vandenbroucke-Grauls CMJE, Savelkoul PHM. Rapid identification of pathogens in blood cultures with a modified fluorescence in situ hybridization assay. *J Clin Microbiol* 2006; 44(11): 4186-4188. (VUmc)
603. Petersen MA, Groenvold M, Aaronson N, Blazeby J, Brandberg Y, de Graeff A, Fayers P, Hammerlid E, Sprangers M, Velikova G, Bjorner JB. Item response theory was used to shorten EORTC QLQ-C30 scales for use in palliative care. *J Clin Epidemiol* 2006; 59(1): 36-44. (AMC/NKI)
604. Petersen MA, Groenvold M, Aaronson N, Fayers P, Sprangers M, Bjorner J.. Multidimensional computerized adaptive testing of the EORTC QLQ-C30: Basic developments and evaluations. *Qual Life Res* 2006; 15(3): 315-329. (AMC)
605. Petersen MA, Groenvold M, Aaronson N, Fayers P, Sprangers M, Bjorner JB. Multidimensional computerized adaptive testing of the EORTC QLQ-C30: Basic developments and evaluations. *Qual Life Res* 2006; 15: 315-29. (NKI)
606. Pham TV, Landewe RB, van der Linden S, Dougados M, Sieper J, Braun J, Davis J, Rudwaleit M, Collantes E, Burgos-Vargas R, Edmonds J, Olivieri I, van der Horst-Bruinsma IE, Mielants H, Stone M, Emery P, van der Heijde DM. An international study on starting tumour necrosis factor-blocking agents in ankylosing spondylitis. *Ann Rheum Dis* 2006; 65(12): 1620-1625. (VUmc)
607. Pham TV, Smeulders AW. Learning spatial relations for object recognition. *Pattern Recognition Letters* 2006; 27(14): 1673-1684. (VUmc)
608. Pham TV, Smeulders AW. Metric tree partitioning and Taylor approximation for fast support vector classification. *ICPR* 2006; 4: 132-135. (VUmc)
609. Pham TV, Smeulders AW. Sparse representation for coarse and fine object recognition. *IEEE Trans Pattern Anal Mach Intell* 2006; 28(4): 555-567. (VUmc)
610. Phernambucq EC, Biesma B, Smit EF, Paul MA, vd Tol A, Schramel FM, Bolhuis RJ, Postmus PE. Multicenter phase II trial of accelerated cisplatin and high-dose epirubicin followed by surgery or radiotherapy in patients with stage IIIa non-small-cell lung cancer with mediastinal lymph node involvement (N2-disease). *Br J Cancer* 2006; 95(4): 470-474. (VUmc)
611. Pickersgill H, Kalverda B, de Wit E, Talhout W, Fornerod M, van Steensel B. Characterization of the *Drosophila melanogaster* genome at the nuclear lamina. *Nat Genet* 2006; 38: 1005-14. (NKI)
612. Piek JM, Dorsman JC, Massuger LF, Ansink AC, Weegenaar J, Shvarts A, Kenemans P, Verheijen RHM. BRCA1 and p53 protein expression in cultured ovarian surface epithelial cells derived from women with and without a BRCA1 germline mutation. *Arch Gynecol Obstet* 2006; 274(6): 327-331. (VUmc)
613. Piriou ERWAN, van Dort K, Weel JFL, Bemelman FJ, Gamadia LE, van Oers MHJ, van Baarle D. Detailed kinetics of EBV-specific CD4(+) and CD8(+) T cells during primary EBV infection in a kidney transplant patient. *Clin Immunol* 2006; 119(1): 16-20. (AMC)
614. Pirrotta V, Van Lohuizen M. Differentiation and gene regulation. *Curr Opin Genet Dev* 2006; 16: 443-6. (NKI)
615. Polfliet MM, Fabriek BO, Daniels WP, Dijkstra CD, van den Berg TK. The rat macrophage scavenger receptor CD163: expression, regulation and role in inflammatory mediator production. *Immunobiology* 2006; 211(6-8): 419-425. (VUmc)
616. Pos FJ, Hart G, Schneider C, Sminia P. Radical radiotherapy for invasive bladder cancer: what dose and fractionation schedule to choose?. *Int J Radiat Oncol Biol Phys* 2006; 64: 1168-1171. (NKI/VUmc)
617. Pos FJ, Hulshof M, Lebesque J, Lotz H, van Tienhoven G, Moonen L, Remeijer P. Adaptive radiotherapy for invasive bladder cancer: A feasibility study. *Int J Radiat Oncol Biol Phys* 2006; 64: 862-8. (NKI)
618. Pos FJ, Nuver TT, Smitsmans MPH, Nijkamp JA, de Jong R, Remeijer P, Van Herk M, Lebesque JV. First Clinical Results of an Adaptive Off-Line Image Guidance Strategy Using Cone-Beam CT Scans for Prostate Cancer [abstract nr 137]. *Int J Radiat Oncol Biol Phys* 2006; 66: S76-S77. (NKI)
619. Post PN, Kuipers EJ, Meijer GA. Declining incidence of peptic ulcer but not of its complications: a nation-wide study in The Netherlands. *Aliment Pharmacol Ther* 2006; 23(11): 1587-1593. (VUmc)

620. Press RR, Buckle T, Beijnen JH, van Tellinghen O. The effect of P-glycoprotein and cytochrome P450 3a on the oral bioavailability of vinorelbine in mice. *Cancer Chemother Pharmacol* 2006; 57: 819-25. (NKI)
621. Puri R, Palit V, Loadman P, Flannigan M, Shah T, Choudry G, Basu S, Double J, Lenaz G, Chawla S, Beer M, Van Kalken C, de Boer R, Beijnen J, Twelves C, Phillips R. Phase I/II Pilot Study of Intravesical Apaziquone (EO9) for Superficial Bladder Cancer. [Miscellaneous Article]. *J Urol* 2006; 176: 1344-8. (NKI)
622. Qian SB, Reits E, Neefjes J, Deslich JM, Bennink JR, Yewdell JW. Tight linkage between translation and MHC class I peptide ligand generation implies specialized antigen processing for defective ribosomal products. *J Immunol* 2006; 177: 227-33. (NKI)
623. Qualls JE, Kaplan AM, van Rooijen N, Cohen DA. Suppression of experimental colitis by intestinal mononuclear phagocytes. *J Leukoc Biol* 2006; 80(4): 802-815. (VUmc)
624. Rademaker-Lakhai JM, Crul M, Zuur L, Baas P, Beijnen JH, Simis YJ, Van Zandwijk N, Schellens JHM. Relationship between cisplatin administration and the development of ototoxicity. *J Clin Oncol* 2006; 24: 918-24. (NKI)
625. Rades D, Dahm-Daphi J, Rudat V, Schulte R, Stalpers LJA, Veninga T, Hoskin PJ. Is short-course radiotherapy with high doses per fraction the appropriate regimen for metastatic spinal cord compression in colorectal cancer patients? *Strahlenther Onkol* 2006; 182(12): 708-712. (AMC)
626. Rades D, Fehlaue F, Schulte R, Veninga T, Stalpers LJA, Basic H, Bajrovic A, Hoskin PJ, Tribius S, Wildfang I, Rudat V, Engenhart-Cabilic R, Karstens JH, Dunst J, Schild SE. Prognostic factors for local control and survival after radiotherapy of metastatic spinal cord compression. *J Clin Oncol* 2006; 24(21): 3388-3393. (AMC)
627. Rades D, Hoskin PJ, Stalpers LJA, Schulte R, Poortmans P, Veninga T, Dahm-Daphi J, Obralic N, Wildfang I, Bahrehand R, Engenhart-Cabilic R, Schild SE. Short-course radiotherapy is not optimal for spinal cord compression due to myeloma. *Int J Radiat Biol* 2006; 64(5): 1452-1457. (AMC)
628. Rades D, Stalpers LJA, Schulte R, Veninga T, Basic H, Engenhart-Cabilic R, Schild SE, Hoskin PJ. Defining the appropriate radiotherapy regimen for metastatic spinal cord compression in non-small cell lung cancer patients. *Eur J Cancer* 2006; 42(8): 1052-1056. (AMC)
629. Rades D, Stalpers LJA, Veninga T, Rudat V, Schulte R, Engenhart-Cabilic R, Hoskin PJ. Evaluation of functional outcome and local control after radiotherapy for metastatic spinal cord compression in patients with prostate cancer. *J Urology* 2006; 175(2): 552-556. (AMC)
630. Rades D, Veninga T, Stalpers LJA, Schulte R, Hoskin PJ, Poortmans P, Schild SE, Rudat V. Prognostic factors predicting functional outcomes, recurrence-free survival, and overall survival after radiotherapy for metastatic spinal cord compression in breast cancer patients. *Int J Radiat Oncol* 2006; 64(1): 182-188. (AMC)
631. Rades D, Walz J, Stalpers LJA, Veninga T, Schulte R, Obralic N, Wildfang I, Engenhart-Cabilic R, Hoskin PJ, Schild SE. Short-course radiotherapy (RT) for metastatic spinal cord compression (MSCC) due to renal cell carcinoma: Results of a retrospective multi-center study. *Eur Urol* 2006; 49(5): 846-852. (AMC)
632. Ramadhani MK, Koomen I, Grobbee DE, van Donselaar CA, van Furth AM, Uiterwaal CS. Increased occurrence of left-handedness after severe childhood bacterial meningitis: support for the pathological left-handedness hypothesis. *Neuropsychologia* 2006; 44(12): 2526-2532. (VUmc)
633. Rassweiler J, Teber D, de la Rosette J, Laguna P, Pansodoro V, Frede T. Laparoscopic pelvic surgery. Where do we stand in the year 2006? *Urology* 2006; 45(9): 1135. (AMC)
634. Rehmann H, Das J, Knipscheer P, Wittinghofer A, Bos JL. Structure of the cyclic-AMP-responsive exchange factor Epac2 in its auto-inhibited state. *Nature* 2006; 439: 625-8. (NKI)
635. Reits EA, Hodge JW, Herberts CA, Groothuis TA, Chakraborty M, Wansley EK, Camphausen K, Luiten RM, de Ru AH, Neijssen J, Griekspoor A, Mesman E, Verreck FA, Spits H, Schlom J, van Veelen P van, Neefjes JJ. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. *J Exp Med* 2006; 203(5): 1259-1271. (AMC/NKI)
636. Revicki DA, Cella D, Hays RD, Sloan JA, Lenderking WR, Aaronson NK. Responsiveness and minimal important differences for patient reported outcomes. *Health Qual Life Outcomes* 2006; 4: 70-5. (NKI)
637. Richters CD, Paauw NJ, Mayen I, van Bloois L, Metselaer JM, Storm G, du Pont JS, Hoekstra MJ, Kreis RW, Kamperdijk EWA. Administration of prednisolone phosphate-liposomes reduces wound contraction in a rat partial-thickness wound model. *Wound Repair Regen* 2006; 14(5): 602-607. (VUmc)
638. Riegman PHJ, Dinjens WNM, Oomen MHA, Spatz A, Ratcliffe C, Knox K, Mager R, Kerr D, Pezzella F, van Damme B, van de Vijver M, van Boven H, Morente MM, Alonso S, Kerjaschki D, Pammer J, Lopez-Guerrero JA, Llombart Bosch A, Carbone A, Gloghini A, Teodorovic I, Isabelle M, Jaminé D, Passiukov A, Lejeune S, Therasse P, van Veen EB, Lam KH, Oosterhuis JW. TuBaFrost 1: Uniting local Frozen Tumour Banks into a European Network: an overview. *Eur J Cancer* 2006; 42: 2678-83. (NKI)
639. Rindi G, Klöppel G, Alhman H, Caplin M, Couvelard A, De Herder WW, Eriksson B, Falchetti A, Falconi M, Komminoth P, Körner M, Lopes JM, McNicol AM, Nilsson O, Perren A, Scarpa A, Scoazec JY, Wiedenmann B, Arnold R, Bechstein WO, Cadiot

- G, Christ E, Chung D, Delle Fave G, Ferone D, Goretzki P, Gross D, Hochhauser D, Hyrdel R, Jensen R, Kaltsas G, Keletimur F, Kianmanesh R, Knapp W, Knigge UP, Kos-Kuda B, Kvols L, Kwekkeboom D, Lewington V, Manfredi R, Mitry E, Niederle B, Nikou G, Öberg K, O'Connor J, O'Toole D, Pauwels S, Pavel M, Plöckinger U, Ramage J, Ricke J, Ruzniewski P, Salazar R, Sauvanet A, Sevilla Garcia MI, Steinmüller TA, Sundin A, Taal B, Van Cutsem E, Vullierme MP, Wildi S, Yao JC. TNM staging of foregut (neuro)endocrine tumors: A consensus proposal including a grading system. *Virchows Arch* 2006; 449: 395-401. (NKI)
640. Risseuw M, Berkers C, Ploegh H, Ovaa H. Synthesis of tritium labeled KRN7000. *Tetrahedron Lett* 2006; 47: 3677-9. (NKI)
641. Rodenhuis S, Bontenbal M, Van Hoesel QGCM, Smit WM, Nooij MA, Voest EE, Van Der Wall E, Hupperets P, Van Tinteren H, Peterse JL, Van De Vijver MJ, De Vries EGE. Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer. *Ann Oncol* 2006; 17: 588-96. (NKI)
642. Rodenhuis S, Rutgers EJT. Adjuvant therapy for breast cancer. *Br J Surg* 2006; 93: 1443-5. (NKI)
643. Rodenko B, Toebes M, Hadrup S, van Esch W, Molenaar A, Schumacher T, Ovaa H. Generation of peptide-MHC class I complexes through UV-mediated ligand exchange. *Nat Protoc* 2006; 1: 1120-32. (NKI)
644. Rodriguez JA, Giaccone G. Keynote comment: are large-scale cancer-genomics projects ready to use?. *Lancet Oncol* 2006; 7(3): 190-191. (VUmc)
645. Rodriguez JA, Lens SM, Span SW, Vader G, Medema RH, Kruyt FAE, Giaccone G. Subcellular localization and nucleocytoplasmic transport of the chromosomal passenger proteins before nuclear envelope breakdown. *Oncogene* 2006; 25(35): 4867-4879. (NKI/VUmc)
646. Roepman P, Kemmeren P, Wessels LFA, Slootweg PJ, Holstege FCP. Multiple robust signatures for detecting lymph node metastasis in head and neck cancer. *Cancer Res* 2006; 66: 2361-6. (NKI)
647. Roj, n U, Kobzeva V, Gasparjan N, Ovaa H, Winberg G, Kisseljov F, Masucci MG. Activity profiling of deubiquitinating enzymes in cervical carcinoma biopsies and cell lines. *Mol Carcinog* 2006; 45: 260-9. (NKI)
648. Romier C, Ben Jelloul M, Albeck S, Buchwald G, Busso D, Celie PHN, Christodoulou E, De Marco V, Van Gerwen S, Knipscheer P, Lebbink JH, Notenboom V, Poterszman A, Rochel N, Cohen SX, Unger T, Sussman JL, Moras D, Sixma TK, Perrakis A. Co-expression of protein complexes in prokaryotic and eukaryotic hosts: Experimental procedures, database tracking and case studies. *Acta Crystallogr D Biol Crystallogr* 2006; 62: 1232-42. (NKI)
649. Roozen HG, Van Beers SE, Weevers HJ, Breteler MH, Willemsen MC, Postmus PE, Kerkhof AJ. Effects on smoking cessation: naltrexone combined with a cognitive behavioral treatment based on the community reinforcement approach. *Subst Use Misuse* 2006; 41(1): 45-60. (VUmc)
650. Rouschop KMA, Claessen N, Pals ST, Weening JJ, Florquin S. CD44 disruption prevents degeneration of the capillary network in obstructive nephropathy via reduction of TGF-beta 1-induced apoptosis. *J Am Soc Nephrol* 2006; 17(3): 746-753. (AMC)
651. Rowland BD, Bernards R. Re-Evaluating Cell-Cycle Regulation by E2Fs. *Cell* 2006; 127: 871-4. (NKI)
652. Rowland BD, Peeper DS. KLF4, p21 and context-dependent opposing forces in cancer. *Nat Rev Cancer* 2006; 6: 11-23. (NKI)
653. Ruan D, Fessler JA, Balter JM, Sonke JJ. Exploring breathing pattern irregularity with projection-based method. *Med Phys* 2006; 33: 2491-9. (NKI)
654. Rudkin TM, Hamel N, Galvez M, Hogervorst F, Gille JJP, Moller P, Apold J, Foulkes WD. The frequent BRCA1 mutation 1135insA has multiple origins: A haplotype study in different populations. *BMC Med Genet* 2006; 7:. (NKI)
655. Ruijs M, Schmidt M, Nevanlinna H, Tommiska J, Aittomaki K, Pruntel R, Verhoef S, van 't Veer L. The single-nucleotide polymorphism 309 in the MDM2 gene contributes to the Li-Fraumeni syndrome and related phenotypes. *Eur J Hum Genet* 2006; 15: 110-4. (NKI)
656. Ruijs MWG, Verhoef S, Wigbout G, Pruntel R, Floore AN, de Jong D, van 't Veer LJ, Menko FH. Late-onset common cancers in a kindred with an Arg213Gln TP53 germline mutation. *Fam Cancer* 2006; 5: 169-74. (NKI)
657. Ruiz-Rabelo JF, Monjero A, I, Torregrosa-Gallud A, Delgado PL, Cuesta MA. [Fast-track multimodal rehabilitation programs in laparoscopic colorectal surgery]. *Cir Esp* 2006; 80(6): 361-368. (VUmc)
658. Saboerali MD, Koolen MG, Noorduyn LA, van Delden OM, Bogaard HJ. Pleural thickening in a construction worker: it is not always mesothelioma. *Neth J Med* 2006; 64(3): 88-90. (VUmc)
659. Sachs N, Kreft M, Bergh Weerman MA, Beynon AJ, Peters TA, Weening JJ, Sonnenberg A. Kidney failure in mice lacking the tetraspanin CD151. *J Cell Biol* 2006; 175: 33-9. (NKI)
660. Sakariassen PO, Prestegarden L, Wang J, Skafnesmo KO, Mahesparan R, Molthoff CFM, Sminia P, Sundlisaeter E, Misra A, Tysnes BB, Chekenya M, Peters H, Lende G, Kalland KH, Oyan AM, Petersen K, Jonassen I, van der Kogel A, Feuerstein BG, Terzis AJ, Bjerkvi. Angiogenesis-independent tumor growth mediated by stem-like cancer cells. *Proc Natl Acad Sci U S A* 2006; 103(44): 16466-16471. (VUmc)

661. Santegoets SJAM, Masterson AJ, van der Sluis PC, Lougheed SM, Fluitsma DM, van den Eertwegh AJM, Pinedo HM, Scheper RJ, de Gruijl TD. A CD34(+) human cell line model of myeloid dendritic cell differentiation: evidence for a CD14(+)CD11b(+) Langerhans cell precursor. *J Leukoc Biol* 2006; 80(6): 1337-1344. (VUmc)
662. Santegoets SJAM, Schreurs MWJ, Masterson AJ, Liu YP, Goletz S, Baumeister H, Kueter EW, Lougheed SM, van den Eertwegh AJM, Scheper RJ, Hooijberg E, de Gruijl TD. In vitro priming of tumor-specific cytotoxic T lymphocytes using allogeneic dendritic cells derived from the human MUTZ-3 cell line. *Cancer Immunol Immunother* 2006; 55(12): 1480-1490. (VUmc)
663. Savelkoul PHM, Catsburg A, Mulder S, Oostendorp L, Schirm J, Wilke H, van der Zanden AG, Noordhoek GT. Detection of Mycobacterium tuberculosis complex with Real Time PCR: comparison of different primer-probe sets based on the IS6110 element. *J Microbiol Methods* 2006; 66(1): 177-180. (VUmc)
664. Sayas CL, Ariaens A, Ponsioen B, Moolenaar W. GSK-3 Is Activated by the Tyrosine Kinase Pyk2 during LPA1-mediated Neurite Retraction. *Mol Biol Cell* 2006; 17: 1834-44. (NKI)
665. Scagliotti GV, Szczesna A, Ramlau R, Cardenal F, Mattson K, Van Zandwijk N, Price A, Lebeau B, Debus J, Manegold C. Docetaxel-based induction therapy prior to radiotherapy with or without docetaxel for non-small-cell lung cancer. *Br J Cancer* 2006; 94: 1375-82. (NKI)
666. Schagen FHE, Wensveen FM, Carette JE, Dermody TS, Gerritsen WR, Van Beusechem VW. Genetic targeting of adenovirus vectors using a reovirus sigma1-based attachment protein. *Mol Ther* 2006; 13: 997-1005. (VUmc)
667. Schagen SB, Muller MJ, Boogerd W, Mellenbergh GJ, van Dam FSAM. Change in cognitive function after chemotherapy: a prospective longitudinal study in breast cancer patients. *J Natl Cancer Inst* 2006; 98: 1742-5. (NKI)
668. Scheepers JJ, Mulder CJ, van der Peet DL, Meijer S, Cuesta MA. Minimally invasive oesophageal resection for distal oesophageal cancer: a review of the literature. *Scand J Gastroenterol Suppl* 2006; 243: 123-134. (VUmc)
669. Schmidlin H, Dontje W, Groot F, Ligthart SJ, Colantonio AD, Oud ME, Schilder-Tol EJ, Spaargaren M, Spits H, Uittenbogaart CH, Blom B. Stimulated plasmacytoid dendritic cells impair human T-cell development. *Blood* 2006; 108(12): 3792-3800. (AMC)
670. Schmitt M, Bravo IG, Snijders PJF, Gissmann L, Pawlita M, Waterboer T. Bead-based multiplex genotyping of human papillomaviruses. *J Clin Microbiol* 2006; 44(2): 504-512. (VUmc)
671. Schnell S, Démollière C, Van Den Berk P, Jacobs H. Gimap4 accelerates T-cell death. *Blood* 2006; 108: 591-9. (NKI)
672. Schnell S, Démollière C, Van Den Berk P, Kirberg J, Jacobs H. Constitutive expression of the pre-TCR enables development of mature T cells. *Int Immunol* 2006; 18: 911-20. (NKI)
673. Scholten KB, Kramer D, Kueter EW, Graf M, Schoedl T, Meijer CJ, Schreurs MW, Hooijberg E. Codon modification of T cell receptors allows enhanced functional expression in transgenic human. *Clin Immunol* 2006; 119: 135-145. (VUmc)
674. Schwartz CE, Bode R, Repucci N, Becker J, Sprangers MAG, Fayers PM. The clinical significance of adaptation to changing health: A meta-analysis of response shift. *Qual Life Res* 2006; 15(9): 1533-1550. (AMC)
675. Schwartz GF, Veronesi U, Clough KB, Dixon JM, Fentiman IS, Heywang K, Holland R, Hughes KS, Margoless R, Olivetto IA, Palazzo JP, Solin LJ, Bartelink H, Cataliotti L, O'Ugo DM, Fournier M, Fourquet A, Gentilini O, Lattanzio V, McCormick B, Mansel RE, Masood S, Mendelson EB, Pierce LJ, Poole CJ, Rutgers EJT, Tavassoli F, Terribile DA, Untch M. Proceedings of the Consensus Conference on Breast Conservation, April 28 to May 1, 2005, Milan, Italy. *Cancer* 2006; 107: 242-50. (NKI)
676. Schwarz M, Van der Geer J, Van Herk M, Lebesque JV, Mijnheer BJ, Damen EMF. Impact of geometrical uncertainties on 3D CRT and IMRT dose distributions for lung cancer treatment. *Int J Radiat Oncol Biol Phys* 2006; 65: 1260-9. (NKI)
677. Scott NW, Fayers PM, Bottomley A, Aaronson NK, de Graeff A, Groenvold M, Koller M, Peterson MA, Sprangers MAG. Comparing translations of the EORTC QLQ-C30 using differential item functioning analyses. *Qual Life Res* 2006; 15(6): 1103-1115. (AMC/NKI)
678. Scott NW, Fayers PM, Bottomley A, Aaronson NK, de Graeff A, Groenvold M, Koller M, Petersen MA, Sprangers MAG. Response to Commentary on Comparing translations of the EORTC QLQ-C30 using differential item functioning analyses. *Qual Life Res* 2006; 15(6): 1119-1120. (AMC/NKI)
679. Shakhova O, Leung C, van Montfort E, Berns A, Marino S. Lack of Rb and p53 delays cerebellar development and predisposes to large cell anaplastic medulloblastoma through amplification of N-Myc and Ptch2. *Cancer Res* 2006; 66: 5190-200. (NKI)
680. Shankar LK, Hoffman JM, Bacharach S, Graham MM, Karp J, Lammertsma AA, Larson S, Mankoff DA, Siegel BA, Van den Abbeele A, Yap J, Sullivan D. Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. *J Nucl Med* 2006; 47(6): 1059-1066. (VUmc)
681. Sharma P, Dent J, Armstrong D, Bergman JJGHM, Gossner L, Hoshihara Y, Jankowski JA, Junghard O, Lundell L, Tytgat GNJ, Vieth M. The development and validation of an endoscopic grading system for Barrett's esophagus: The Prague C & M Criteria. *Gastroenterology* 2006; 131(5), 1392-1399. (AMC)

682. Siegel-Lakhai WS, Crul M, De Porre P, Zhang S, Chang I, Boot H, Beijnen JH, Schellens JHM. Clinical and pharmacologic study of the farnesyltransferase inhibitor tipifarnib in cancer patients with normal or mildly or moderately impaired hepatic function. *J Clin Oncol* 2006; 24: 4558-64. (NKI)
683. Sigmond J, Haveman J, Kreder NC, Loves WJ, van Bree C, Franken NA, Peters GJ. Enhanced activity of deoxycytidine kinase after pulsed low dose rate and single dose gamma irradiation. *Nucleos Nucleot Nucl Acids* 2006; 25(9-11): 1177-1180. (VUmc)
684. Simonis M, Klous P, Splinter E, Moshkin Y, Willemsen R, de Wit E, van Steensel B, De Laat W. Nuclear organization of active and inactive chromatin domains uncovered by chromosome conformation capture-on-chip (4C). *Nat Genet* 2006; 38: 1348-54. (NKI)
685. Simoons-Smit AM, Kraan EM, Beishuizen A, Strack van Schijndel RJ, Vandenbroucke-Grauls CMJE. Herpes simplex virus type 1 and respiratory disease in critically-ill patients: Real pathogen or innocent bystander?. *Clin Microbiol Infect* 2006; 12(11): 1050-1059. (VUmc)
686. Simsek S, Lips P, Comans EFI, Netelenbos C. Paradoxical reaction on treatment with 131I. *Thyroid* 2006; 16(12): 1321-1322. (VUmc)
687. Singhal D, de Castro S de, Goyal N, Gouma DJ, Chaudhary A, van Gulik TM. Current role of portosystemic shunt surgery in the management of hepatic venous outflow obstruction. *Digest Surg* 2006; 23(5-6): 358-369. (AMC)
688. Siroen MP, van Bokhorst-de van der Schueren MA, Richir MC, Sauerwein HP, Leemans CR, Quak JJ, van Leeuwen PAM. The prognostic value of severe malnutrition in the development of nonthyroidal illness in head and neck cancer patients. *JPEN J Parenter Enteral Nutr* 2006; 30(5): 415-420. (VUmc)
689. Sisodiya SM, Martinian L, Scheffer GL, Scheper RJ, Harding BN, Thom M. Vascular colocalization of P-glycoprotein, multidrug-resistance associated protein 1, breast cancer resistance protein and major vault protein in human epileptogenic pathologies. *Neuropathol Appl Neurobiol* 2006; 32(1): 51-63. (VUmc)
690. Skrekas T, Mochtar CA, Lagerveld BW, Reijke TM, van Velthoven RF, Peltier A, de la Rosette JJMCH, Laguna MP. Mentor-initiated approach in laparoscopic radical prostatectomy. *J Endourol* 2006; 20(10): 831-835. (AMC)
691. Slitt AL, Cherrington NJ, Dieter MZ, Aleksunes LM, Scheffer GL, Huang W, Moore DD, Klaassen CD. trans-Stilbene oxide induces expression of genes involved in metabolism and transport in mouse liver via CAR and Nrf2 transcription factors. *Mol Pharmacol* 2006; 69(5): 1554-1563. (VUmc)
692. Sloan JA, Frost MH, Berzon R, Dueck A, Guyatt G, Moynour C, Sprangers M, Ferrans C, Cella D. The clinical significance of quality of life assessments in oncology: a summary for clinicians. *Support Care Cancer* 2006; 14(10): 988-998. (AMC)
693. Slotman BJ, Lagerwaard FJ, Senan S. 4D imaging for target definition in stereotactic radiotherapy for lung cancer. *Acta Oncol* 2006; 45(7): 966-972. (VUmc)
694. Smeenk RM, Bex A, Verwaal VJ, Horenblas S, Zoetmulder FAN. Pseudomyxoma peritonei and the urinary tract: Involvement and treatment related complications. *J Surg Oncol* 2006; 93: 20-3. (NKI)
695. Smeenk RM, Verwaal VJ, Zoetmulder FAN. Toxicity and mortality of cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in pseudomyxoma peritonei - A report of 103 procedures. *Eur J Surg Oncol* 2006; 32: 186-90. (NKI)
696. Smeets LC, Becker SC, Barcak GJ, Vandenbroucke-Grauls CMJE, Bitter W, Goosen N. Functional characterization of the competence protein DprA/Smf in *Escherichia coli*. *FEMS Microbiol Lett* 2006; 263(2): 223-228. (VUmc)
697. Smeets SJ, Braakhuis BJM, Abbas S, Snijders PJF, Ylstra B, van de Wiel MA, Meijer GA, Leemans CR, Brakenhoff RH. Genome-wide DNA copy number alterations in head and neck squamous cell carcinomas with or without oncogene-expressing human papillomavirus. *Oncogene* 2006; 25(17): 2558-2564. (VUmc)
698. Smid EJ, Stoter TR, Bloemena E, Lafleur MV, Leemans CR, van der Waal I, Slotman BJ, Langendijk JA. The importance of immunohistochemical expression of EGFR in squamous cell carcinoma of the oral cavity treated with surgery and postoperative radiotherapy. *Int J Radiat Oncol Biol Phys* 2006; 65: 1323-1329. (VUmc)
699. Smid K, Bergman AM, Eijk PP, Veerman G, van Haperen VW, van den Ijssel PR, Ylstra B, Peters GJ. Micro-array analysis of resistance for gemcitabine results in increased expression of ribonucleotide reductase subunits. *Nucleos Nucleot Nucl Acids* 2006; 25(9-11): 1001-1007. (VUmc)
700. Smit LA, van Maldegem F, Langerak AW, van der Schoot CE, de Wit MJ, Bea S, Campo E, Bende RJ, van Noesel CJM. Antigen receptors and somatic hypermutation in B-cell chronic lymphocytic leukemia with Richter's transformation. *Haematol Hematol J* 2006; 91(7): 903-911. (AMC)
701. Smits C, Swen SJ, Theo GS, Moll AC, Imhof SM, Schouten-van Meeteren AY. Assessment of hearing in very young children receiving carboplatin for retinoblastoma. *Eur J Cancer* 2006; 42(4): 492-500. (VUmc)
702. Smorenburg CH, Peters GJ, van Groeningen CJ, Noordhuis P, Smid K, van Riel AM, Dercksen W, Pinedo HM, Giaccone G. Phase II study of tailored chemotherapy for advanced colorectal cancer with either 5-fluoracil and leucovorin or oxaliplatin and irinotecan based on the expression of thymidylate synthase and dihydropyrimidine

- dehydrogenase. *Ann Oncol* 2006; 17(1): 35-42. (VUmc)
703. Smulders SA, van den Bosch HW, Post JC, Vonk-Noordegraaf A, Postmus PE. Where is the Heart after Left-Sided Pneumonectomy?. *J Thor Oncol* 2006; 1: 69-70. (VUmc)
704. Snijders PJF, Hogewoning CJ, Hesselink AT, Berkhof J, Voorhorst FJ, Bleeker MC, Meijer CJLM. Determination of viral load thresholds in cervical scrapings to rule out CIN 3 in HPV 16, 18, 31 and 33-positive women with normal cytology. *Int J Cancer* 2006; 119(5): 1102-1107. (VUmc)
705. Snijders PJF, Steenbergen RDM, Heideman DAM, Meijer CJLM. HPV-mediated cervical carcinogenesis: concepts and clinical implications. *J Pathol* 2006; 208(2): 152-164. (VUmc)
706. Sobek A, Stone S, Costanzo V, de Graaf B, Reuter T, de Winter J, Wallisch M, Akkari Y, Olson S, Wang W, Joenje H, Christian JL, Lupardus PJ, Cimprich KA, Gautier J, Hoatlin ME. Fanconi anemia proteins are required to prevent accumulation of replication-associated DNA double-strand breaks. *Mol Cell Biol* 2006; 26(2): 425-437. (VUmc)
707. Soontornmalai A, Vlaming MLH, Fritschy JM. Differential, strain-specific cellular and subcellular distribution of multidrug transporters in murine choroid plexus and blood-brain barrier. *Neuroscience* 2006; 138: 159-69. (NKI)
708. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, Nordgren H, Farmer P, Praz V, Haibe-Kains B, Desmedt C, Larsimont D, Cardoso F, Peterse H, Nuyten D, Buyse M, Van De Vijver MJ, Bergh J, Piccart M, Delorenzi M. Gene expression profiling in breast cancer: Understanding the molecular basis of histologic grade to improve prognosis. *J Natl Cancer Inst* 2006; 98: 262-72. (NKI)
709. Sparidans RW, Bosch TM, Joerger M, Schellens JHM, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for the analysis of uracil, 5,6-dihydrouracil and ?-ureidopropionic acid in urine for the measurement of the activities of the pyrimidine catabolic enzymes. *J Chromatogr B Analyt Technol Biomed Life Sci* 2006; 839: 45-53. (NKI)
710. Sparidans RW, Dost F, Crommentuyn KML, Huitema ADR, Schellens JHM, Beijnen JH. Liquid chromatographic assay for the non-peptidic protease inhibitor tipranavir in plasma. *Biomed Chromatogr* 2006; 20: 671-3. (NKI)
711. Sparidans RW, Dost F, Crommentuyn KML, Huitema ADR, Schellens JHM, Beijnen JH. Liquid chromatographic assay for the protease inhibitor atazanavir in plasma. *Biomed Chromatogr* 2006; 20: 72-6. (NKI)
712. Sparmann A, Van Lohuizen M. Polycomb silencers control cell fate, development and cancer. *Nat Rev Cancer* 2006; 6: 846-56. (NKI)
713. Sprong D, Janssen HL, Vens C, Begg AC. Resistance of hypoxic cells to ionizing radiation is influenced by homologous recombination status. *Int J Radiat Oncol Biol Phys* 2006; 64: 562-72. (NKI)
714. Sriamporn S, Snijders PJF, Pientong C, Pisani P, Ekalaksananan T, Meijer CJLM, Parkin DM. Human papillomavirus and cervical cancer from a prospective study in Khon Kaen, Northeast Thailand. *Int J Gynecol Cancer* 2006; 16(1): 266-269. (VUmc)
715. Stam H, Grootenhuis MA, Brons PPT, Caron HN, Last BF. Health-related quality of life in children and emotional reactions of parents following completion of cancer treatment. *Pediatr Blood Cancer* 2006; 47(3): 312-319. (AMC)
716. Stam H, Grootenhuis MA, Caron HN, Last BF. Quality of life and current coping in young adult survivors of childhood cancer: Positive expectations about the further course of the disease were correlated with better quality of life. *Psycho-Oncol* 2006; 15(1): 31-43. (AMC)
717. Stam RW, Hubeek I, den Boer ML, Buijs-Gladdines JG, Creutzig U, Kaspers GJL, Pieters R. MLL gene rearrangements have no direct impact on Ara-C sensitivity in infant acute lymphoblastic leukemia and childhood M4/M5 acute myeloid leukemia. *Leukemia* 2006; 20(1): 179-182. (VUmc)
718. Steeghs L, van Vliet SJ, Uronen-Hansson H, van Mourik A, Engering A, Sanchez-Hernandez M, Klein N, Callard R, van Putten JP, van der Lely P, van Kooyk Y, van de Winkel JG. Neisseria meningitidis expressing IgtB lipopolysaccharide targets DC-SIGN and modulates dendritic cell function. *Cell Microbiol* 2006; 8(2): 316-325. (VUmc)
719. Steele JC, Torr EE, Noakes KL, Kalk E, Moss PA, Reynolds GM, Hubscher SG, Van Lohuizen M, Adams DH, Young LS. The polycomb group proteins, BMI-1 and EZH2, are tumour-associated antigens. *Br J Cancer* 2006; 95: 1202-11. (NKI)
720. Steenbakkens RJ, Duppen JC, Fitton I, Deurloo KE, Zijp LJ, Comans EFI, Uitterhoeve AL, Rodrigus PT, Kramer GW, Bussink J, De Jaeger K, Belderbos JS, Nowak PJ, van Herk M, Rasch CR. Reduction of observer variation using matched CT-PET for lung cancer delineation: a three-dimensional analysis. *Int J Radiat Oncol Biol Phys* 2006; 64(2): 435-448. (NKI/VUmc)
721. Sternberg CN, de Mulder P, Schornagel JH, Theodore C, Fossa SD, van Oosterom AT, Witjes JA, Spina M, Van Groeningen CJ, Duclos B, Roberts JT, de Balincourt C, Colette L, EORTC Genito-Urinary Cancer Group. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. *Eur J Cancer* 2006; 42: 50-4. (NKI)
722. Stevens SJC, Verkuijlen SA, Hariwiyanto B, Harijadi A, Paramita DK, Fachiroh J, Adham M, Tan IB, Haryana SM, Middeldorp JM. Noninvasive diagnosis of nasopharyngeal carcinoma:

- nasopharyngeal brushings reveal high Epstein-Barr virus DNA load and carcinoma-specific viral BARF1 mRNA. *Int J Cancer* 2006; 119(3): 608-614. (NKI/VUmc)
723. Stevens SJC, Zwaan CM, Verkuijlen SA, Middeldorp JM. Epstein-Barr virus (EBV) serology for predicting distant metastases in a white juvenile patient with nasopharyngeal carcinoma and no clinical response to EBV lytic induction therapy. *Head Neck* 2006; 28(11): 1040-1045. (VUmc)
724. Stevenson M, Boos E, Herbert C, Hale A, Green N, Lyons M, Chandler L, Ulbrich K, van Rooijen N, Mautner V, Fisher K, Seymour L. Chick embryo lethal orphan virus can be polymer-coated and retargeted to infect mammalian cells. *Gene Ther* 2006; 13(4): 356-368. (VUmc)
725. Stewart FA, Heeneman S, te Poele J, Kruse J, Russell NS, Gijbels M, Daemen M. Ionizing radiation accelerates the development of atherosclerotic lesions in ApoE^{-/-} mice and predisposes to an inflammatory plaque phenotype prone to hemorrhage. *Am J Pathol* 2006; 168: 649-58. (NKI)
726. Stratis A, Pasparakis M, Rupec RA, Markur D, Hartmann K, Scharffetter-Kochanek K, Peters T, van Rooijen N, Krieg T, Haase I. Pathogenic role for skin macrophages in a mouse model of keratinocyte-induced psoriasis-like skin inflammation. *J Clin Invest* 2006; 116(8): 2094-2104. (VUmc)
727. Stroeken PJM, Alvarez B, van Rheenen J, Wijnands YM, Geerts D, Jalink K, Roos E. Integrin cytoplasmic domain-associated protein-1 (ICAP-1) interacts with the ROCK-I kinase at the plasma membrane. *J Cell Physiol* 2006; 208: 620-8. (NKI)
728. Stroom JC, Heijmen BJM. Limitations of the planning organ at risk volume (PRV) concept. *Int J Radiat Oncol Biol Phys* 2006; 66: 279-86. (NKI)
729. Strumane K, Bonnomet A, Stove C, Vandenbroucke R, Nawrocki-Raby B, Bruyneel E, Mareel M, Birembaut P, Berx G, Van Roy F. E-cadherin regulates human Nanos1, which interacts with p120ctn and induces tumor cell migration and invasion. *Cancer Res* 2006; 66: 10007-15. (NKI)
730. Summan M, Warren GL, Mercer RR, Chapman R, Hulderman T, van Rooijen N, Simeonova PP. Macrophages and skeletal muscle regeneration: a clodronate-containing liposome depletion study. *Am J Physiol Regul Integr Comp Physiol* 2006; 290(6): R1488-R1495. (VUmc)
731. Susanto CR, Vonk-Noordegraaf A, Kummer JA, Boonstra A. Nonresolving pneumonia in mycoplasma pneumoniae infection resembling a lung tumor. *Respiration* 2006; 73(2): 247. (VUmc)
732. Svensson JP, Stalpers LJA, Esvelde-Lange REE, Franken NAP, Haveman J, Klein B, Turesson I, Vrieling H, Giphart-Gassler M. Analysis of gene expression using gene sets discriminates cancer patients with and without late radiation toxicity. *Plos Medicine* 2006; 3(10): 1904-1914. (AMC)
733. Synowitz M, Glass R, Farber K, Markovic D, Kronenberg G, Herrmann K, Schnermann J, Nolte C, van Rooijen N, Kiwit J, Kettenmann H. A1 adenosine receptors in microglia control glioblastoma-host interaction. *Cancer Res* 2006; 66(17): 8550-8557. (VUmc)
734. Tack JW, Verkerke GJ, van der Houwen EB, Mahieu HF, Schutte HK. Development of a double-membrane sound generator for application in a voice-producing element for laryngectomized patients. *Ann Biomed Eng* 2006; 34(12): 1896-1907. (VUmc)
735. Tacke F, Ginhoux F, Jakubzick C, van Rooijen N, Merad M, Randolph GJ. Immature monocytes acquire antigens from other cells in the bone marrow and present them to T cells after maturing in the periphery. *J Exp Med* 2006; 203(3): 583-597. (VUmc)
736. Taghavi P, Van Lohuizen M. Developmental biology: Two paths to silence merge. *Nature* 2006; 439: 794-5. (NKI)
737. Tanenbaum ME, Galjart N, Van Vugt MATM, Medema RH. CLIP-170 facilitates the formation of kinetochore-microtubule attachments. *EMBO J* 2006; 25: 45-57. (NKI)
738. Temmink OH, de Bruin M, Laan AC, Turksma AW, Cricca S, Masterson AJ, Noordhuis P, Peters GJ. The role of thymidine phosphorylase and uridine phosphorylase in (fluoro)pyrimidine metabolism in peripheral blood mononuclear cells. *Int J Biochem Cell Biol* 2006; 38(10): 1759-1765. (VUmc)
739. Temmink OH, Hoogeland MF, Fukushima M, Peters GJ. Low folate conditions may enhance the interaction of trifluorothymidine with antifolates in colon cancer cells. *Cancer Chemother Pharmacol* 2006; 57(2): 171-179. (VUmc)
740. ten Kooster JP, Evers EE, Janssen L, Machesky LM, Michiels F, Hordijk P, Collard JG. Interaction between Tiam1 and the Arp2/3 complex links activation of Rac to actin polymerization. *Biochem J* 2006; 397: 39-45. (NKI)
741. Teodorovic I, Isabelle M, Carbone A, Passioukov A, Lejeune S, Jaminé D, Therasse P, Gloghini A, Dinjens WNM, Lam KH, Oomen MHA, Spatz A, Ratcliffe C, Knox K, Mager R, Kerr D, Pezzella F, van Damme B, van de Vijver M, van Boven H, Morente MM, Alonso S, Kerjaschki D, Pammer J, Lopez-Guerrero JA, Llombart Bosch A, van Veen EB, Oosterhuis JW, Riegman PHJ. TuBaFrost 6: Virtual microscopy in virtual tumour banking. *Eur J Cancer* 2006; 42: 3110-6. (NKI)
742. Terhaar sive Droste JS, Heine GDN, Craanen ME, Boot H, Mulder CJJ. On attitudes about colorectal cancer screening among gastrointestinal specialists and general practitioners in the Netherlands. *World J Gastroenterol* 2006; 12: 5201-4. (NKI)
743. Terhaar C, Lubsen H, Tan B, Merckx T, van der Laan B, Baatenburg-de Jong R, Manni H, Knecht P. Facial nerve function in carcinoma of the

- parotid gland. *Eur J Cancer* 2006; 42: 2744-50. (NKI)
744. Terwisscha Van Scheltinga SE, Den Boer FC, Pijpers R, Meijer GA, Engel AF, Silvis R, Meijer S, van der Sijp JRM. Sentinel node staging in colon carcinoma: value of sentinel lymph node biopsy with radiocolloid and blue staining. *Scand J Gastroenterol Suppl* 2006; (243): 153-157. (VUmc)
745. Teunissen SC, de Graeff A, de Haes HC, Voest EE. Prognostic significance of symptoms of hospitalised advanced cancer patients. *Eur J Cancer* 2006; 42(15): 2510-2516. (AMC)
746. Teunissen SC, de Haes HC, Voest EE, de Graeff A. Does age matter in palliative care? *Crit Rev Oncol Hemat* 2006; 60(2): 152-158. (AMC)
747. Thunnissen FB, Kerr KM, Brambilla E, Comin CE, Franklin WA, Guldhammerskov B, Westra WH, Flieder DB. EU-USA pathology panel for uniform diagnosis in randomised controlled trials for HRCT screening in lung cancer. *Eur Respir J* 2006; 28(6): 1186-1189. (VUmc)
748. Thunnissen FB, Schuurbiers OC, den Bakker MA. A critical appraisal of prognostic and predictive factors for common lung cancers. *Histopathology* 2006; 48(7): 779-786. (VUmc)
749. Tijink BM, Buter J, de Bree R, Giaccone G, Lang MS, Staab A, Leemans CR, van Dongen GAMS. A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. *Clin Cancer Res* 2006; 12(20 Pt 1): 6064-6072. (VUmc)
750. Tijink BM, de Bree R, van Dongen GAMS, Leemans CR. How we do it: chemo-electroporation in the head and neck for otherwise untreatable patients. *Clin Otolaryngol* 2006; 31(5): 447-451. (VUmc)
751. Tijink BM, Neri D, Leemans CR, Budde M, Dinkelborg LM, Stigter-van Walsum M, Zardi L, van Dongen GAMS. Radioimmunotherapy of head and neck cancer xenografts using ¹³¹I-labeled antibody L19-SIP for selective targeting of tumor vasculature. *J Nucl Med* 2006; 47(7): 1127-1135. (VUmc)
752. Tjin EPM, Groen RWJ, Vogelzang I, Derksen PWB, Klok MD, Meijer HP, van Eeden S van, Pals ST, Spaargaren M. Functional analysis of HGF/MET signaling and aberrant HGF-activator expression in diffuse large B-cell lymphoma. *Blood* 2006; 107(2): 760-768. (AMC)
753. Toebak MJ, Moed H, von Blomberg BME, Bruynzeel DP, Gibbs S, Scheper RJ, Rustemeyer T. Intrinsic characteristics of contact and respiratory allergens influence production of polarizing cytokines by dendritic cells. *Contact Dermatitis* 2006; 55(4): 238-245. (VUmc)
754. Toebak MJ, Pohlmann PR, Sampat-Sardjoepersad SC, von Blomberg BME, Bruynzeel DP, Scheper RJ, Rustemeyer T, Gibbs S. CXCL8 secretion by dendritic cells predicts contact allergens from irritants. *Toxicol In Vitro* 2006; 20(1): 117-124. (VUmc)
755. Toebes M, Coccoris M, Bins A, Rodenko B, Gomez R, Nieuwkoop NJ, Van De Kastele W, Rimmelzwaan GF, Haanen JBAG, Ovaa H, Schumacher TNM. Design and use of conditional MHC class I ligands. *Nat Med* 2006; 12: 246-51. (NKI)
756. Tofts PS, Steens SC, Cercignani M, Admiraal-Behloul F, Hofman PA, van Osch MJ, Teeuwisse WM, Tozer DJ, van Waesberghe JH, Yeung R, Barker GJ, van Buchem MA. Sources of variation in multi-centre brain MTR histogram studies: body-coil transmission eliminates inter-centre differences. *MAGMA* 2006; 19(4): 209-222. (VUmc)
757. Tolhuis B, Muijters I, de Wit E, Teunissen H, Talhout W, van Steensel B, Van Lohuizen M. Genome-wide profiling of PRC1 and PRC2 Polycomb chromatin binding in *Drosophila melanogaster*. *Nat Genet* 2006; 38: 694-9. (NKI)
758. Tolstrup J, Munk C, Thomsen BL, Svare E, van den Brule AJC, Gronbaek M, Meijer CJLM, Kjaer S. The role of smoking and alcohol intake in the development of high-grade squamous intraepithelial lesions among high-risk HPV-positive women. *Acta Obstet Gynecol Scand* 2006; 85(9): 1114-1119. (VUmc)
759. Toornvliet R, van Berckel BN, Luurtsema G, Lubberink M, Geldof AA, Bosch TM, Oerlemans R, Lammertsma AA, Franssen EJ. Effect of age on functional P-glycoprotein in the blood-brain barrier measured by use of (R)-[¹¹C]verapamil and positron emission tomography. *Clin Pharmacol Ther* 2006; 79(6): 540-548. (VUmc)
760. Toornvliet R, van Berckel BNM, Luurtsema G, Lubberink M, Geldof AA, Bosch TM, Oerlemans R, Lammertsma AA, Franssen EJ. Effect of age on functional P-glycoprotein in the blood-brain barrier measured by use of (R)-[¹¹C]verapamil and positron emission tomography. *Clin Pharmacol Ther* 2006; 79: 540-8. (NKI)
761. Triesscheijn M, Baas P, Schellens JHM, Stewart FA. Photodynamic therapy in oncology. *Oncologist* 2006; 11: 1034-44. (NKI)
762. Triesscheijn M, Ruevekamp M, Antonini N, Neering H, Stewart F, Baas P. Optimizing meso-tetra-hydroxyphenyl-chlorin mediated photodynamic therapy for basal cell carcinoma. *Photochem Photobiol* 2006; 82: 1686-90. (NKI)
763. Tushuizen ME, Bunck MC, Pouwels PJ, van Waesberghe JH, Diamant M, Heine RJ. Incretin mimetics as a novel therapeutic option for hepatic steatosis. *Liver Int* 2006; 26(8): 1015-1017. (VUmc)
764. Ulens C, Hogg RC, Celie PH, Bertrand D, Tsetlin V, Smit AB, Sixma TK. Structural determinants of selective α -conotoxin binding to a nicotinic acetylcholine receptor homolog AChBP. *Proc Natl Acad Sci U S A* 2006; 103: 3615-20. (NKI)
765. Underberg RW, Lagerwaard FJ, van Tinteren H, Cuijpers JP, Slotman BJ, Senan S. Time trends

- in target volumes for stage I non-small-cell lung cancer after stereotactic radiotherapy. *Int J Radiat Oncol Biol Phys* 2006; 64(4): 1221-1228. (VUmc)
766. Underberg RW, van Sornsens de Koste JR, Lagerwaard FJ, Vincent A, Slotman BJ, Senan S. A dosimetric analysis of respiration-gated radiotherapy in patients with stage III lung cancer. *Radiat Oncol* 2006; 1: 8. (NKI/VUmc)
767. Vaccarella S, Franceschi S, Herrero R, Munoz N, Snijders PJF, Clifford GM, Smith JS, Lazcano-Ponce E, Sukvirach S, Shin HR, de Sanjose S, Molano M, Matos E, Ferreccio C, Anh PT, Thomas JO, Meijer CJLM. Sexual behavior, condom use, and human papillomavirus: pooled analysis of the IARC human papillomavirus prevalence surveys. *Cancer Epidemiol Biomarkers Prev* 2006; 15(2): 326-333. (VUmc)
768. Vaccarella S, Herrero R, Dai M, Snijders PJF, Meijer CJLM, Thomas JO, Hoang Anh PT, Ferreccio C, Matos E, Posso H, de Sanjose S, Shin HR, Sukvirach S, Lazcano-Ponce E, Ronco G, Rajkumar R, Qiao YL, Munoz N, Franceschi S. Reproductive factors, oral contraceptive use, and human papillomavirus infection: pooled analysis of the IARC HPV prevalence surveys. *Cancer Epidemiol Biomarkers Prev* 2006; 15(11): 2148-2153. (VUmc)
769. Vader G, Kauw JJW, Medema RH, Lens SMA. Survivin mediates targeting of the chromosomal passenger complex to the centromere and midbody. *EMBO Rep* 2006; 7: 85-92. (NKI)
770. Vainas T, Stassen FR, Bruggeman CA, Welten RJ, van den Akker LH, Kitslaar PJ, Pena AS, Morre SA. Synergistic effect of Toll-like receptor 4 and CD14 polymorphisms on the total atherosclerosis burden in patients with peripheral arterial disease. *J Vasc Surg* 2006; 44(2): 326-332. (VUmc)
771. Vainchtein LD, Rosing H, Mirejovsky D, Huynh V, Lenaz L, Hillebrand MJX, Schellens JHM, Beijnen JH. Quantitative analysis of EO9 (apaziquone) and its metabolite EO5a in human plasma by high-performance liquid chromatography under basic conditions coupled to electrospray tandem mass spectrometry. *J Mass Spectrom* 2006; 41: 1268-76. (NKI)
772. Vainchtein LD, Thijssen B, Stokvis E, Rosing H, Schellens JHM, Beijnen JH. A simple and sensitive assay for the quantitative analysis of paclitaxel and metabolites in human plasma using liquid chromatography/tandem mass spectrometry. *Biomed Chromatogr* 2006; 20: 139-48. (NKI)
773. Valentijn LJ, Koster J, Versteeg R. Read-through transcript from NM23-H1 into the neighboring NM23-H2 gene encodes a novel protein, NM23-LV. *Genomics* 2006; 87(4): 483-489. (AMC)
774. van Agthoven M, Heule-Dieleman HA, Knegt PP, Kaanders JH, Baatenburg de Jong RJ, Kremer B, Leemans CR, Marres HA, Manni JJ, Langendijk JA, Levendag PC, Tjho-Heslinga RE, de Jong JM, de Boer MF, Uyl-de Groot CA. Compliance and efficiency before and after implementation of a clinical practice guideline for laryngeal carcinomas. *Eur Arch Otorhinolaryngol* 2006; 263(8): 729-737. (VUmc)
775. van Amerongen R, Berns A. Knockout mouse models to study Wnt signal transduction. *Trends Genet* 2006; 22: 678-89. (NKI)
776. van Amerongen R, Berns A. TXR1-mediated thrombospondin repression: A novel mechanism of resistance to taxanes? *Genes Dev* 2006; 20: 1975-81. (NKI)
777. van Apeldoorn M, Rustemeijer C, Voerman B, Peterse J. Mesothelioma of the Tunica Vaginalis Complicated by Chyluria. *J Clin Oncol* 2006; 24: 5329-30. (NKI)
778. van As-Brooks CJ, Koopmans-van Beinum FJ, Pols LCW, Hilgers FJM. Acoustic Signal Typing for Evaluation of Voice Quality in Tracheoesophageal Speech. *J Voice* 2006; 20: 355-68. (NKI)
779. Van Asselen B, Schwarz M, Vliet-Vroegindewij C, Lebesque JV, Mijnheer BJ, Damen EMF. Intensity-modulated radiotherapy of breast cancer using direct aperture optimization. *Radiat Oncol* 2006; 79: 162-9. (NKI)
780. van Baal JWPM, Diks SH, Wanders RJA, Rygiel AM, Milano F, Joore J, Bergman JJGHM, Peppelenbosch MP, Krishnadath KK. Comparison of kinome profiles of Barrett's esophagus with normal squamous esophagus and normal gastric cardia. *Cancer Res* 2006; 66(24): 11605-11612. (AMC)
781. van Baarsen LGM, van der Pouw Kraan CTM, Kragt JJ, Baggen JM, Rustenburg F, Hooper T, Meilof JF, Fero MJ, Dijkstra CD, Polman CH, Verweij CL. A subtype of multiple sclerosis defined by an activated immune defense program. *Genes Immun* 2006; 7(6): 522-531. (VUmc)
782. van Baarsen LGM, van der Pouw Kraan CTM, Verweij CL. A genomic view of subtypes in rheumatoid arthritis: towards personalized medicine. *Future Rheumatology* 2006; 1: 311-322. (VUmc)
783. van Beek J, zur Hausen A, Snel SN, Berkhof J, Kranenburg EK, van de Velde CJ, van den Brule AJ, Middeldorp JM, Meijer CJ, Bloemena E. Morphological evidence of an activated cytotoxic T-cell infiltrate in EBV-positive gastric carcinoma preventing lymph node metastases. *Am J Surg Pathol* 2006; 30: 59-65. (VUmc)
784. van Beers EH, Joosse SA, Ligtenberg MJ, Fles R, Hogervorst FBL, Verhoef S, Nederlof PM. A multiplex PCR predictor for aCGH success of FFPE samples. *Br J Cancer* 2006; 94: 333-7. (NKI)
785. van Beers EH, Nederlof PM. Array-CGH and breast cancer. *Breast Cancer Res* 2006; 8: 210. (NKI)
786. van Bodegraven AA, Curley CR, Hunt KA, Monsuur AJ, Linskens RK, Onnie CM, Crusius JBA, Annese V, Latiano A, Silverberg MS, Bitton A, Fisher SA, Steinhart AH, Forbes A, Sanderson J, Prescott NJ, Strachan DP, Playford RJ, Mathew CG, Wijmenga C, Daly MJ, Rio. Genetic variation in

- myosin IXB is associated with ulcerative colitis. *Gastroenterology* 2006; 131(6): 1768-1774. (VUmc)
787. van Dalen EC, van den Brug M, Caron HN, Kremer LCM. Anthracycline-induced cardiotoxicity: Comparison of recommendations for monitoring cardiac function during therapy in paediatric oncology trials. *Eur J Cancer* 2006; 42(18): 3199-3205. (AMC)
788. van Dalen EC, van der Pal HJH, Kok WEM, Caron HN, Kremer LCM. Clinical heart failure in a cohort of children treated with anthracyclines: A long-term follow-up study. *Eur J Cancer* 2006; 42(18): 3191-3198. (AMC)
789. van Dalen EC, van der Pal HJH, van den Bos C, Kok WEM, Caron HN, Kremer LCM. Clinical heart failure during pregnancy and delivery in a cohort of female childhood cancer survivors treated with anthracyclines. *Eur J Cancer* 2006; 42(15): 2549-2553. (AMC)
790. van de Pol SM, Doornaert PA, de Bree R, Leemans CR, Slotman BJ, Langendijk JA. The significance of anemia in squamous cell head and neck cancer treated with surgery and postoperative radiotherapy. *Oral Oncol* 2006; 42(2): 131-138. (VUmc)
791. van de Ven R, de Jong MC, Reurs AW, Schoonderwoerd AJ, Jansen G, Hooijberg JH, Scheffer GL, de Gruijl TD, Scheper RJ. Dendritic cells require multidrug resistance protein 1 (ABCC1) transporter activity for differentiation. *J Immunol* 2006; 176(9): 5191-5198. (VUmc)
792. van den Berg JH, Beijnen JH, Balm AJM, Schellens JHM. Future opportunities in preventing cisplatin induced ototoxicity. *Cancer Treat Rev* 2006; 32: 390-7. (NKI)
793. van den Born J, Pisa B, Bakker MA, Celie JW, Straatman C, Thomas S, Viberti GC, Kjellen L, Berden JH. No change in glomerular heparan sulfate structure in early human and experimental diabetic nephropathy. *J Biol Chem* 2006; 281(40): 29606-29613. (VUmc)
794. van den Broek GB, Balm AJM, van den Brekel MWM, Hauptmann M, Schornagel JH, Rasch CRN. Relationship between clinical factors and the incidence of toxicity after intra-arterial chemoradiation for head and neck cancer. *Radiother Oncol* 2006; 81: 143-50. (NKI)
795. van den Broek GB, Rasch CRN, Pameijer FA, Peter E, van den Brekel MWM, Balm AJM. Response measurement after intraarterial chemoradiation in advanced head and neck carcinoma: Magnetic resonance imaging and evaluation under general anesthesia? *Cancer* 2006; 106: 1722-9. (NKI)
796. van den Oever MC, Spijker S, Li KW, Jimenez CR, Koya E, van der Schors RC, Gouwenberg Y, Binnekade R, De Vries TJ, Schoffelmeer AN, Smit AB. A proteomics approach to identify long-term molecular changes in rat medial prefrontal cortex resulting from sucrose self-administration. *J Proteome Res* 2006; 5(1): 147-154. (VUmc)
797. van Denderen JC, Peters MJL, van Halm VP, van der Horst-Bruinsma IE, Dijkmans BAC, Nurmohamed MT. Statin therapy might be beneficial for patients with ankylosing spondylitis. *Ann Rheum Dis* 2006; 65(5): 695-696. (VUmc)
798. van der Bij AK, Spaargaren J, Morre SA, Fennema HS, Mindel A, Coutinho RA, de Vries HJ. Diagnostic and clinical implications of anorectal lymphogranuloma venereum in men who have sex with men: a retrospective case-control study. *Clin Infect Dis* 2006; 42(2): 186-194. (VUmc)
799. van der Deen M, Marks H, Willemsse BW, Postma DS, Muller MJ, Smit EF, Scheffer GL, Scheper RJ, de Vries EG, Timens W. Diminished expression of multidrug resistance-associated protein 1 (MRP1) in bronchial epithelium of COPD patients. *Virchows Arch* 2006; 449(6): 682-688. (VUmc)
800. van der Donk NWCJ, Kroger N, Hegenbart U, Corradini P, San Miguel JF, Goldschmidt H, Perez-Simon JA, Zijlmans M, Raymakers RA, Montefusco V, Ayuk FA, van Oers MHJ, Nagler A, Verdonck LF, Lokhorst HM. Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma. *Blood* 2006; 107(8): 3415-3416. (AMC)
801. van der Elst A, Oosterling SJ, Paul MA, Vonk AM, Sparidans RW, van der Sijp JRM. Isolated lung perfusion with melphalan: pharmacokinetics and toxicity in a pig model. *J Surg Oncol* 2006; 93(5): 410-416. (VUmc)
802. van der Gaast MH, Eijkemans MJC, van der Net JB, de Boer EJ, Burger CW, van Leeuwen FE, Fauser BCJM, Macklon NS. Optimum number of oocytes for a successful first IVF treatment cycle. *Reprod BioMed Online* 2006; 13: 476-80. (NKI)
803. van der Geld YG, Lagerwaard FJ, van Sornsen de Koste JR, Cuijpers JP, Slotman BJ, Senan S. Reproducibility of target volumes generated using uncoached 4-dimensional CT scans for peripheral lung cancer. *Radiation Oncol* 2006; 1: 43. (VUmc)
804. van der Geld YG, Senan S, van Sornsen de Koste JR, van Tinteren H, Slotman BJ, Underberg RW, Lagerwaard FJ. Evaluating mobility for radiotherapy planning of lung tumors: a comparison of virtual fluoroscopy and 4DCT. *Lung Cancer* 2006; 53(1): 31-37. (VUmc)
805. van der Graaf CA, Netea MG, Morre SA, Den Heijer M, Verweij PE, Van der Meer JW, Kullberg BJ. Toll-like receptor 4 Asp299Gly/Thr399Ile polymorphisms are a risk factor for *Candida* bloodstream infection. *Eur Cytokine Netw* 2006; 17(1): 29-34. (VUmc)
806. van der Groep P, Bouter A, van der Zanden R, Siccama I, Menko FH, Gille JJ, van Kalken C, van der Wall E, Verheijen RHM, van Diest PJ. Distinction between hereditary and sporadic breast

- cancer on the basis of clinicopathological data. *J Clin Pathol* 2006; 59(6): 611-617. (VUmc)
807. van der Heijde DM, Da Silva JC, Dougados M, Geher P, van der Horst-Bruinsma IE, Juanola X, Olivieri I, Raeman F, Settas L, Sieper J, Szechinski J, Walker D, Bousuge MP, Wajdula JS, Paolozzi L, Fatenejad S. Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis. *Ann Rheum Dis* 2006; 65(12): 1572-1577. (VUmc)
808. van der Heijde DM, Kivitz A, Schiff MH, Sieper J, Dijkmans BAC, Braun J, Dougados M, Reveille JD, Wong RL, Kupper H, Davis JC, Jr. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. *Arthritis Rheum* 2006; 54(7): 2136-2146. (VUmc)
809. van der Hout AH, van den Ouweland AMW, van der Lijdt RB, Gille HJP, Bodmer D, Brüggewirth H, Mulder IM, van der Vlies P, Elfferich P, Huisman MT, ten Berge AM, Kromosoeto J, Jansen RPM, van Zon PHA, Vriesman T, Arts N, Boutmy-de Lange N, Oosterwijk JC, Meijers-Heijboer H, Ausems MGEM, Hoogerbrugge N, Verhoef S, Halley DJJ, Vos YJ, Hogervorst F, Ligtenberg M, Hofstra RMW. A DGGE system for comprehensive mutation screening of BRCA1 and BRCA2: application in a Dutch cancer clinic setting. *Hum Mutat* 2006; 27: 654-66. (NKI)
810. van der Meij EH, Becking AG, van der Waal I. Fibrodysplasia ossificans progressiva. An unusual cause of restricted mandibular movement. *Oral Dis* 2006; 12(2): 204-207. (VUmc)
811. van der Plaats A, Schutte HK, van der Eerden FJ, de Vries MP, Mahieu HF, Verkerke GJ. An in-vitro test set-up for evaluation of a voice-producing element under physiologic acoustic conditions. *Ann Biomed Eng* 2006; 34(5): 893-900. (VUmc)
812. van Der Ploeg HP, Streppel KRM, Van Der Beek AJ, Van Der Woude LHV, Vollenbroek-Hutten MMR, Van Harten WH, Van Mechelen W. Counselling increases physical activity behaviour nine weeks after rehabilitation. *Br J Sports Med* 2006; 40: 223-9. (NKI)
813. van der Poel HG, Antonini N, Hoefnagel CA, Horenblas S, Valdés Olmos R. Serum hemoglobin levels predict response to strontium-89 and rhenium-186-HEDP radionuclide treatment for painful osseous metastases in prostate cancer. *Urol Int* 2006; 77: 50-6. (NKI)
814. van der Poel HG. Foreseeing cancer metastases. *Eur Urol* 2006; 50: 648-9. (NKI)
815. van der Putten L, de Bree R, Plukker JT, Langendijk JA, Smits C, Burlage FR, Leemans CR. Permanent unilateral hearing loss after radiotherapy for parotid gland tumors. *Head Neck* 2006; 28(10): 902-908. (VUmc)
816. van der Sar AM, Stockhammer OW, van der Laan C, Spaik HP, Bitter W, Meijer AH. MyD88 innate immune function in a zebrafish embryo infection model. *Infect Immun* 2006; 74(4): 2436-2441. (VUmc)
817. van der Schoot SC, Nuijen B, Sood P, Thurmond II KB, Stewart DR, Rice JR, Beijnen JH. Pharmaceutical development, quality control, stability and compatibility of a parenteral lyophilized formulation of the investigational polymer-conjugated platinum antineoplastic agent AP5346. *Pharmazie* 2006; 61: 835-44. (NKI)
818. van der Sluijs KF, van Elden LJR, Xiao Y, Arens R, Nijhuis M, Schuurman R, Florquin S, Jansen HM, Lutter R, van der Poll T. IL-12 deficiency transiently improves viral clearance during the late phase of respiratory tract infection with influenza A virus in mice. *Antiviral Res* 2006; 70: 75-84. (NKI)
819. van der Steen LPE, Hage JJ, Kon M, Monstrey SJ. Intra-rater repeatability of a structured method of selecting abstracts for the annual Euraps scientific meeting. *Eur J Plast Surg* 2006; 29: 111-4. (NKI)
820. van der Torn M, van Gogh CDL, Verdonck-de Leeuw IM, Festen JM, Mahieu HF. Analysis of failure of voice production by a sound-producing voice prosthesis. *J Laryngol Otol* 2006; 120(6): 455-462. (VUmc)
821. van der Torn M, van Gogh CDL, Verdonck-de Leeuw IM, Festen JM, Verkerke GJ, Mahieu HF. Assessment of alaryngeal speech using a sound-producing voice prosthesis in relation to sex and pharyngoesophageal segment tonicity. *Head Neck* 2006; 28(5): 400-412. (VUmc)
822. van der Veldt AAM, Hooft L, van Diest PJ, Berkhof J, Buist MR, Comans EFI, Hoekstra OS, Molthoff CFM. Microvessel density and p53 in detecting cervical cancer by FDG PET in cases of suspected recurrence. *Eur J Nucl Med Mol Imaging* 2006; 33(12): 1408-1416. (VUmc)
823. van der Vliet HJ, van Vonderen MG, Molling JW, Bontkes HJ, Reijm M, Reiss P, van Agtmael MA, Danner SA, van den Eertwegh AJM, von Blomberg BME, Scheper RJ. Cutting edge: Rapid recovery of NKT cells upon institution of highly active antiretroviral therapy for HIV-1 infection. *J Immunol* 2006; 177(9): 5775-5778. (VUmc)
824. van Die IM, Cummings RD. Glycans modulate immune responses in helminth infections and allergy. *Chem Immunol Allergy* 2006; 90: 91-112. (VUmc)
825. van Dijk MM, de la Rosette JJMCH, Michel MC. Effects of alpha 1-adrenoceptor antagonists on male sexual function. *Drugs* 2006; 66(3): 287-301. (AMC)
826. van Dijk MM, Mochtar CA, Wijkstra H, Laguna MP, de la Rosette JJMCH. The bell-shaped nitinol prostatic stent in the treatment of lower urinary tract symptoms: experience in 108 patients. *Eur Urol* 2006; 49(2): 353-359. (AMC)

827. van Doorn HR, Bruijnesteijn van Coppenraet ES, Duim B, Vandenbroucke-Grauls CMJE, Weel JF, Dankert J, Kuijper EJ, de Jong MD. Silica-guanidinium thiocyanate-based nucleic acid isolation protocol does not improve sensitivity of two commercial tests for detection of *Mycobacterium tuberculosis* in respiratory samples. *Eur J Clin Microbiol Infect Dis* 2006; 25(10): 673-675. (VUmc)
828. van Doorn HR, de Haas PE, Kremer K, Vandenbroucke-Grauls CMJE, Borgdorff MW, van Soolingen D. Public health impact of isoniazid-resistant *Mycobacterium tuberculosis* strains with a mutation at amino-acid position 315 of *katG*: a decade of experience in The Netherlands. *Clin Microbiol Infect* 2006; 12(8): 769-775. (VUmc)
829. van Duijnhoven FH, Jansen MC, Junggeburst JMC, Van Hillegersberg R, Rijken AM, Van Coevorden F, Van Der Sijp JR, Van Gulik TM, Slooter GD, Klaase JM, Putter H, Tollenaar RAEM. Factors influencing the local failure rate of radiofrequency ablation of colorectal liver metastases. *Ann Surg Oncol* 2006; 13: 651-8. (NKI)
830. van Eijk IC, Nielen MM, van Soesbergen RM, Hamburger HL, Kerstens PJ, Dijkmans BAC, van Schaardenburg D. Cervical spine involvement is rare in early arthritis. *Ann Rheum Dis* 2006; 65(7): 973-974. (VUmc)
831. van Elmpt W, Nijsten S, Schiffeleers R, Dekker A, Mijnheer B, Lambin P, Minke A. A Monte Carlo based three-dimensional dose reconstruction method derived from portal dose images. *Med Phys* 2006; 33: 2426-34. (NKI)
832. van Gent WB, Hop WC, van Praag MC, Mackaay AJ, de Boer EM, Wittens CH. Conservative versus surgical treatment of venous leg ulcers: a prospective, randomized, multicenter trial. *J Vasc Surg* 2006; 44(3): 563-571. (VUmc)
833. van Gogh CDL, Verdonck-de Leeuw IM, Boon-Kamma BA, Rinkel RN, de Bruin MD, Langendijk JA, Kuik DJ, Mahieu HF. The efficacy of voice therapy in patients after treatment for early glottic carcinoma. *Cancer* 2006; 106(1): 95-105. (VUmc)
834. van Grotel M, Meijerink JP, Beverloo HB, Langerak AW, Buys-Gladdines JG, Schneider P, Poulsen TS, den Boer ML, Horstmann M, Kamps WA, Veerman AJP, van Wering ER, van Noesel MM, Pieters R. The outcome of molecular-cytogenetic subgroups in pediatric T-cell acute lymphoblastic leukemia: a retrospective study of patients treated according to DCOG or COALL protocols. *Haematologica* 2006; 91(9): 1212-1221. (VUmc)
835. van Haaren PMA, Kok HP, Vording PJZVS, van Dijk JDP, Hulshof MCCM, Fockens P, van Lanschot JJB, Crezee J. Reliability of temperature and SAR measurements at oesophageal tumour locations. *Int J Hyperther* 2006; 22(7): 545-561. (AMC)
836. van Halm VP, Nurmohamed MT, Twisk JW, Dijkmans BAC, Voskuyl AE. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study. *Arthritis Res Ther* 2006; 8(5): R151. (VUmc)
837. van Halm VP, van Denderen JC, Peters MJL, Twisk JW, van der Paardt M, van der Horst-Bruinsma IE, van de Stadt RJ, de Koning MH, Dijkmans BAC, Nurmohamed MT. Increased disease activity is associated with a deteriorated lipid profile in patients with ankylosing spondylitis. *Ann Rheum Dis* 2006; 65(11): 1473-1477. (VUmc)
838. van Herwaarden AE, Schinkel AH. The function of breast cancer resistance protein in epithelial barriers, stem cells and milk secretion of drugs and xenotoxins. *Trends Pharmacol Sci* 2006; 27: 10-6. (NKI)
839. van Herwaarden AE, Wagenaar E, Karnekamp B, Merino G, Jonker JW, Schinkel AH. Breast cancer resistance protein (Bcrp1/Abcg2) reduces systemic exposure of the dietary carcinogens aflatoxin B1, IQ and Trp-P-1 but also mediates their secretion into breast milk. *Carcinogenesis* 2006; 27: 123-30. (NKI)
840. van Houdt WJ, Haviv YS, Lu B, Wang M, Rivera AA, Ulasov IV, Lamfers MLM, Rein D, Lesniak MS, Siegal GP, Dirven CMF, Curjel DT, Zhu ZB. The human survivin promoter: a novel transcriptional targeting strategy for treatment of glioma. *J Neurosurg* 2006; 104(4): 583-592. (VUmc)
841. van Houwelingen HC, Bruinsma T, Hart AAM, van 't Veer LJ, Wessels LFA. Cross-validated Cox regression on microarray gene expression data. *Stat Med* 2006; 25: 3201-16. (NKI)
842. van Kempen LCL, De Visser KE, Coussens LM. Inflammation, proteases and cancer. *Eur J Cancer* 2006; 42: 728-34. (NKI)
843. van Kooyk Y, Geijtenbeek TBH. Toll-like receptors keep antigen sorting on the right track. *Immunity* 2006; 25(4): 525-527. (VUmc)
844. van Kuijk AWR, Reinders-Blankert P, Smeets TJ, Dijkmans BAC, Tak PP. Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment. *Ann Rheum Dis* 2006; 65(12): 1551-1557. (VUmc)
845. van Lanschot JJB. Preface - Oesophageal adenocarcinoma. *Best Pract Res CL GA* 2006; 20(5): 801-802. (AMC)
846. van Liempt E, Bank CM, Mehta P, Garci A-V, Kwar ZS, Geyer R, Alvarez RA, Cummings RD, van Kooyk Y, van Die IM. Specificity of DC-SIGN for mannose- and fucose-containing glycans. *FEBS Lett* 2006; 580(26): 6123-6131. (VUmc)
847. van Luenen HGAM, Van Harten WH. Quality Management and Stimulation of Technology Transfer in a Research Institute. *Creat Innov Manag* 2006; 15: 207-17. (NKI)
848. van Luijn HEM, Aaronson NK, Keus RB, Musschenga AW. The evaluation of the risks and benefits of phase II cancer clinical trials by

- institutional review board (IRB) members: A case study. *J Med Ethics* 2006; 32: 170-6. (NKI)
849. van Meeteren LA, Ruurs P, Stortelers C, Bouwman P, Van Rooijen MA, Pradšre JP, Pettit TR, Wakelam MJO, Saulnier-Blache JS, Mummery CL, Moolenaar WH, Jonkers J. Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development. *Mol Cell Biol* 2006; 26: 5015-22. (NKI)
850. van Nifterik KA, Elkhuizen PH, van Andel RJ, Stalpers LJ, Leenstra S, Lafleur MV, Vandertop WP, Slotman BJ, Hulsebos TJ, Sminia P. Genetic profiling of a distant second glioblastoma multiforme after radiotherapy: Recurrence or second primary tumor?. *J Neurosurg* 2006; 105(5): 739-744. (AMC/VUmc)
851. van Oers MHJ, Klasa R, Marcus RE, Wolf M, Kimby E, Gascoyne RD, Jack A, van 't Veer M, Vranovsky A, Holte H, van Glabbeke M, Teodorovic I, Rozewicz C, Hagenbeek A. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. *Blood* 2006; 108(10): 3295-3301. (AMC)
852. van Rietschoten JG, Verzijlbergen KF, Gringhuis SI, van der Pouw Kraan CTM, Bayley JP, Wierenga EA, Jones PA, Kooter JM, Verweij CL. Differentially methylated alleles in a distinct region of the human interleukin-1alpha promoter are associated with allele-specific expression of IL-1alpha in CD4+ T cells. *Blood* 2006; 108(7): 2143-2149. (VUmc)
853. Van Rijk MC, Deurloo EE, Nieweg OE, Gilhuijs KGA, Peterse JL, Rutgers EJT, Kröger R, Kroon BBR. Ultrasonography and fine-needle aspiration cytology can spare breast cancer patients unnecessary sentinel lymph node biopsy. *Ann Surg Oncol* 2006; 13: 31-5. (NKI)
854. Van Rijk MC, Nieweg OE, Oldenburg HSA, Rutgers EJT, Kroon BBR. The sentinel node biopsy in patients with breast cancer; many controversies remain. *Eur J Gynaecol Oncol* 2006; 27: 321-8. (NKI)
855. Van Rijk MC, Nieweg OE, Rutgers EJT, Oldenburg HSA, Valdés Olmos RA, Hoefnagel CA, Kroon BBR. Sentinel node biopsy before neoadjuvant chemotherapy spares breast cancer patients axillary lymph node dissection. *Ann Surg Oncol* 2006; 13: 475-9. (NKI)
856. Van Rijk MC, Peterse JL, Nieweg OE, Oldenburg HSA, Rutgers EJT, Kroon BBR. Additional axillary metastases and stage migration in breast cancer patients with micrometastases or submicrometastases in sentinel lymph nodes. *Cancer* 2006; 107: 467-71. (NKI)
857. Van Rijk MC, Tanis PJ, Nieweg OE, Valdés Olmos R, Rutgers EJT, Hoefnagel CA, Kroon BBR. Clinical implications of sentinel nodes outside the axilla and internal mammary chain in patients with breast cancer. *J Surg Oncol* 2006; 94: 281-6. (NKI)
858. Van Rijk MC, Teertstra HJ, Peterse JL, Nieweg OE, Valdés Olmos RA, Hoefnagel CA, Kroon BBR. Ultrasonography and fine-needle aspiration cytology in the preoperative evaluation of melanoma patients eligible for sentinel node biopsy. *Ann Surg Oncol* 2006; 13: 1511-6. (NKI)
859. van Rossum A, Moolenaar W, Schuurung E. Cortactin affects cell migration by regulating intercellular adhesion and cell spreading. *Exp Cell Res* 2006; 312: 1658-70. (NKI)
860. Van Rossum AGSH, van Bragt MPA, Schuurung-Scholtes E, van der Ploeg JCM, Van Krieken JHJM, Kluin PM, Schuurung E. Transgenic mice with mammary gland targeted expression of human cortactin do not develop (pre-malignant) breast tumors: Studies in MMTV-cortactin and MMTV-cortactin/-cyclin D1 bitransgenic mice. *BMC Cancer* 2006; 6: . (NKI)
861. van Sornsen de Koste JR, Senan S, Kleynen CE, Slotman BJ, Lagerwaard FJ. Renal mobility during uncoached quiet respiration: an analysis of 4DCT scans. *Int J Radiat Oncol Biol Phys* 2006; 64(3): 799-803. (VUmc)
862. van Tilburg EW, Windhorst AD, Van Der Mey M, Herscheid JDM. One-pot synthesis of [11C]ureas via triphenylphosphinimines. *J Labelled Comp Radiopharm* 2006; 49: 321-30. (NKI)
863. van Tinteren H, Hoekstra OS, Smit EF, Boers M. The implementation of PET in non-small-cell lung cancer in the Netherlands. *Clin Oncol (R Coll Radiol)* 2006; 18(2): 156-157. (VUmc)
864. van Tuyl S, van Noorden J, Timmer R, Stolk M, Kuipers E, Taal B. Detection of small-bowel neuroendocrine tumors by video capsule endoscopy. *Gastrointest Endosc* 2006; 64: 66-72. (NKI)
865. van Veen EB, Riegman PHJ, Dinjens WNM, Lam KH, Oomen MHA, Spatz A, Mager R, Ratcliffe C, Knox K, Kerr D, van Damme B, van de Vijver M, van Boven H, Morente MM, Alonso S, Kerjaschki D, Pammer J, Lopez-Guerrero JA, Llombart Bosch A, Carbone A, Gloghini A, Teodorovic I, Isabelle M, Passioukov A, Lejeune S, Therasse P, Oosterhuis JW. TuBaFrost 3: Regulatory and ethical issues on the exchange of residual tissue for research across Europe. *Eur J Cancer* 2006; 42: 2914-23. (NKI)
866. van Veen RLP, Nyst H, Rai Indrasari S, Adham Yudharto M, Robinson DJ, Tan IB, Meewis C, Peters R, Spaniol S, Stewart FA, Levendag PC, Sterenberg HJCM. In vivo fluence rate measurements during Foscanc-mediated photodynamic therapy of persistent and recurrent nasopharyngeal carcinomas using a dedicated light applicator. *J Biomed Optics* 2006; 11: a041107. (NKI)
867. van Vlierberghe P, van Grotel M, Beverloo HB, Lee C, Helgason T, Buijs-Gladdines J, Passier M, van Wering ER, Veerman AJP, Kamps WA, Meijerink JP, Pieters R. The cryptic chromosomal

- deletion del(11)(p12p13) as a new activation mechanism of LMO2 in pediatric T-cell acute lymphoblastic leukemia. *Blood* 2006; 108(10): 3520-3529. (VUmc)
868. van Vliet SJ, Gringhuis SI, Geijtenbeek TBH, van Kooyk Y. Regulation of effector T cells by antigen-presenting cells via interaction of the C-type lectin MGL with CD45. *Nat Immunol* 2006; 7(11): 1200-1208. (VUmc)
869. van Vliet SJ, van Liempt E, Geijtenbeek TBH, van Kooyk Y. Differential regulation of C-type lectin expression on tolerogenic dendritic cell subsets. *Immunobiology* 2006; 211(6-8): 577-585. (VUmc)
870. van Westrhenen R, Westra WM, van den Born J, Krediet RT, Keuning ED, Hiralall J, Dragt C, Hekking LH. Alpha-2-macroglobulin and albumin are useful serum proteins to detect subclinical peritonitis in the rat. *Perit Dial Int* 2006; 26(1): 101-107. (VUmc)
871. van Wieringen WN, Belien JAM, Vosse SJ, Achame EM, Ylstra B. ACE-it: a tool for genome-wide integration of gene dosage and RNA expression data. *Bioinformatics* 2006; 22(15): 1919-1920. (VUmc)
872. van Zelm MC, Reisli I, van der Burg M, Castano D, van Noesel CJM, van Tol MJD, Woellner C, Grimbacher B, Patino PJ, van Dongen JJM, Franco JL. An antibody-deficiency syndrome due to mutations in the CD19 gene. *New Engl J Med* 2006; 354(18): 1901-1912. (AMC)
873. van Zon A, Mossink MH, Houtsmuller AB, Schoester M, Scheffer GL, Scheper RJ, Sonneveld P, Wiemer EA. Vault mobility depends in part on microtubules and vaults can be recruited to the nuclear envelope. *Exp Cell Res* 2006; 312(3): 245-255. (VUmc)
874. van Dalen EC, Michiels EMC, Caron HN, Kremer LCM. Different anthracycline derivatives for reducing cardiotoxicity in cancer patients. *Cochrane Database Syst Rev* 2006; CD005006. (AMC)
875. van Dalen EC, van der Pal HJH, Caron HN, Kremer LCM. Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy. *Cochrane Database Syst Rev* 2006; CD005008. (AMC)
876. Vanrompay D, Lyons JM, Morre SA. Animal models for the study of Chlamydia trachomatis infections in the female genital infection. *Drugs Today (Barc)* 2006; 42 Suppl A: 55-63. (VUmc)
877. Veltkamp SA, Hillebrand MJX, Rosing H, Jansen RS, Wickremsinhe ER, Perkins EJ, Schellens JHM, Beijnen JH. Quantitative analysis of gemcitabine triphosphate in human peripheral blood mononuclear cells using weak anion-exchange liquid chromatography coupled with tandem mass spectrometry. *J Mass Spectrom* 2006; 41: 1633-42. (NKI)
878. Veltkamp SA, Thijssen B, Garrigue JS, Lambert G, Lallemand F, Binlich F, Huitema ADR, Nuijen B, Nol A, Beijnen JH, Schellens JHM. A novel self-microemulsifying formulation of paclitaxel for oral administration to patients with advanced cancer. *Br J Cancer* 2006; 95: 729-34. (NKI)
879. Vencken PM, Ewing PC, Zweemer RP. Epithelioid trophoblastic tumour: a case report and review of the literature. *J Clin Pathol* 2006; 59(12): 1307-1308. (VUmc)
880. Verbruggen MB, Verheijen RHM, van de Goot FR, van Beurden M, Dorsman JC, van Diest PJ. Serous borderline tumor of the ovary presenting with cervical lymph node involvement: a report of 3 cases. *Am J Surg Pathol* 2006; 30(6): 739-743. (NKI/VUmc)
881. Verdoes M, Florea BI, Menendez-Benito V, Maynard CJ, Witte MD, van der Linden WA, van den Nieuwendijk AMCH, Hofmann T, Berkers CR, van Leeuwen FWB, Groothuis TA, Leeuwenburgh MA, Ovaa H, Neeffjes JJ, Filippov DV, van der Marel GA, Dantuma NP, Overkleef HS. A Fluorescent Broad-Spectrum Proteasome Inhibitor for Labeling Proteasomes In Vitro and In Vivo. *Chem Biol* 2006; 13: 1217-26. (NKI)
882. Vergeer MR, Doornaert PA, Leemans CR, Buter J, Slotman BJ, Langendijk JA. Control of nodal metastases in squamous cell head and neck cancer treated by radiation therapy or chemoradiation. *Radiother Oncol* 2006; 79(1): 39-44. (VUmc)
883. Verhaagh S, de Jong E, Goudsmit J, Lecollinet S, Gillissen G, de Vries M, van Leuven K, Que I, Ouwehand K, Mintardjo R, Weverling GJ, Radosevic K, Richardson J, Eloit M, Lowik CW, Quax P, Havenga MJ. Human CD46-transgenic mice in studies involving replication-incompetent adenoviral type 35 vectors. *J Gen Virol* 2006; 87(Pt 2): 255-265. (VUmc)
884. Verheije MH, Würdinger T, Van Beusechem VW, De Haan CAM, Gerritsen WR, Rottier PJM. Redirecting coronavirus to a non-native receptor through a virus-encoded targeting adapter. *J Virol* 2006; 80: 1250-1260. (VUmc)
885. Verheijen RHM, Massuger LF, Benigno BB, Epenetos AA, Lopes A, Soper JT, Markowska J, Vyzula R, Jobling T, Stamp G, Spiegel G, Thurston D, Falke T, Lambert J, Seiden MV. Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission. *J Clin Oncol* 2006; 24(4): 571-578. (VUmc)
886. Vermeer J, van Leeuwen W, Tobena-Santamaria R, Laxalt A, Jones D, Divecha N, Gadella T, Munnik T. Visualization of PtdIns3P dynamics in living plant cells. *Plant J* 2006; 47: 687-700. (NKI)
887. Vink J, Cloos J, Kaspers GJL. Proteasome inhibition as novel treatment strategy in

- leukaemia. *Br J Haematol* 2006; 134(3): 253-262. (VUmc)
888. Vink SR, Lagerwerf S, Mesman E, Schellens JHM, Begg AC, Van Blitterswijk WJ, Verheij M. Radiosensitization of squamous cell carcinoma by the alkylphospholipid perfosine in cell culture and xenografts. *Clin Cancer Res* 2006; 12: 1615-22. (NKI)
889. Vink SR, Schellens JHM, Beijnen JH, Sindermann H, Engel J, Dubbelman R, Moppi G, Hillebrand MJX, Bartelink H, Verheij M. Phase I and pharmacokinetic study of combined treatment with perfosine and radiation in patients with advanced solid tumours. *Radiother Oncol* 2006; 80: 207-13. (NKI)
890. Vis M, Havaardsholm EA, Haugeberg G, Uhlig T, Voskuyl AE, van de Stadt RJ, Dijkmans BAC, Woolf AD, Kvien TK, Lems WF. Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkappaB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis. *Ann Rheum Dis* 2006; 65(11): 1495-1499. (VUmc)
891. Vischioni B, Oudejans JJ, Vos W, Rodriguez JA, Giaccone G. Frequent overexpression of aurora B kinase, a novel drug target, in non-small cell lung carcinoma patients. *Mol Cancer Ther* 2006; 5(11): 2905-2913. (VUmc)
892. Vischioni B, Span SW, Kruyt FAE, Rodriguez JA, Giaccone G. Expression and localization of inhibitor of apoptosis proteins in normal human tissues. *Hum Pathol* 2006; 37(1): 78-86. (VUmc)
893. Visser MRM, van Lanschot JJB, van der Velden J, Kloek JJ, Gouma DJ, Sprangers MAG. Quality of life in newly diagnosed cancer patients waiting for surgery is seriously impaired. *J Surg Oncol* 2006; 93(7): 571-577. (AMC)
894. Visser OJ, Perk LR, Zijlstra JM, van Dongen GAMS, Huijgens PC, van de Loosdrecht AA. Radioimmunotherapy for indolent B-cell non-Hodgkin lymphoma in relapsed, refractory and transformed disease. *BioDrugs* 2006; 20(4): 201-207. (VUmc)
895. Vlaming MLH, Mohrmann K, Wagenaar E, De Waart DR, Oude Elferink RPJ, Lagas JS, van Tellingem O, Vainchtein LD, Rosing H, Beijnen JH, Schellens JHM, Schinkel AH. Carcinogen and anticancer drug transport by Mrp2 in vivo: Studies using Mrp2 (Abcc2) knockout mice. *J Pharmacol Exp Ther* 2006; 318: 319-27. (NKI)
896. Vogel MJ, Guelen L, de Wit E, Peric-Hupkes D, Lod nM, Talhout W, Feenstra M, Abbas B, Classen AK, van Steensel B. Human heterochromatin proteins form large domains containing KRAB-ZNF genes. *Genome Res* 2006; 16: 1493-504. (NKI)
897. Vonk-Noordegraaf A, Voskuyl AE, Dijkmans BAC. Echocardiography is not sufficient to diagnose pulmonary arterial hypertension in systemic sclerosis: comment on the article by Wigley et al. *Arthritis Rheum* 2006; 54(1): 380-381. (VUmc)
898. Voorhoeve PM, le Sage C, Schrier M, Gillis AJM, Stoop H, Nagel R, Liu YP, van Duijse J, Drost J, Griekspoor A, Zlotorynski E, Yabuta N, De Vita G, Nojima H, Looijenga LHJ, Agami R. A Genetic Screen Implicates miRNA-372 and miRNA-373 As Oncogenes in Testicular Germ Cell Tumors. *Cell* 2006; 124: 1169-81. (NKI)
899. Voortman J, Giaccone G. Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: a case report. *BMC Cancer* 2006; 6: 129. (VUmc)
900. Vos MJ, Berkhof J, Postma TJ, Hoekstra OS, Barkhof F, Heimans JJ. Thallium-201 SPECT: the optimal prediction of response in glioma therapy. *Eur J Nucl Med Mol Imaging* 2006; 33(2): 222-227. (VUmc)
901. Vos PJ, Visser AP, Garssen B, Duivenvoorden HJ, de Haes HCJM. Effects of delayed psychosocial interventions versus early psychosocial interventions for women with early stage breast cancer. *Patient Educ Couns* 2006; 60(2): 212-219. (AMC)
902. Voskuyl AE, Dijkmans BAC. Remission and radiographic progression in rheumatoid arthritis. *Clin Exp Rheumatol* 2006; 24(6 Suppl 43): S037-S040. (VUmc)
903. Vrouwenraets BC, van Lanschot JJB. Extent of surgical resection for esophageal and gastroesophageal junction adenocarcinomas. *Surg Oncol Clin N Am* 2006; 15(4): 781-791. (AMC)
904. Vuylsteke RJ, Molenkamp BG, van Leeuwen PAM, Meijer S, Wijnands PG, Haanen JB, Scheper RJ, de Gruijl TD. Tumor-specific CD8+ T cell reactivity in the sentinel lymph node of GM-CSF-treated stage I melanoma patients is associated with high myeloid dendritic cell content. *Clin Cancer Res* 2006; 12(9): 2826-2833. (NKI/VUmc)
905. Vyth-Dreese FA, Kim YH, DelleMijn TAM, Schrama E, Haanen JBAG, Spierings E, Goulmy E. In situ visualization of antigen-specific T cells in cryopreserved human tissues. *J Immunol Methods* 2006; 310: 78-85. (NKI)
906. Wang H, Peters T, Kess D, Sindrilaru A, Oreshkova T, van Rooijen N, Stratis A, Renkl AC, Sunderkotter C, Wlaschek M, Haase I, Scharffetter-Kochanek K. Activated macrophages are essential in a murine model for T cell-mediated chronic psoriasisform skin inflammation. *J Clin Invest* 2006; 116(8): 2105-2114. (VUmc)
907. Wei WI, Ferlito A, Rinaldo A, Gourin CG, Lowry J, Ho WK, Leemans CR, Shaha AR, Suarez C, Clayman GL, Robbins KT, Bradley PJ, Silver CE. Management of the NO neck--reference or preference. *Oral Oncol* 2006; 42(2): 115-122. (VUmc)
908. Weinkove D, Halstead J, Gems D, Divecha N. Long-term starvation and ageing induce AGE-1/PI 3-kinase-dependent translocation of DAF-16/FOXO to the cytoplasm. *BMC Biol* 2006; 4: 1. (NKI)

909. Wendling M, Louwe RJW, McDermott LN, Sonke JJ, Van Herk M, Mijnheer BJ. Accurate two-dimensional IMRT verification using a back-projection EPID dosimetry method. *Med Phys* 2006; 33: 259-73. (NKI)
910. Wessels JA, Vries-Bouwstra JK, Heijmans BT, Slagboom PE, Goekoop-Ruiterman YP, Allaart CF, Kerstens PJ, van Zeben D, Breedveld FC, Dijkmans BAC, Huizinga TW, Guchelaar HJ. Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes. *Arthritis Rheum* 2006; 54(4): 1087-1095. (VUmc)
911. Westers TM, Houtenbos I, van de Loosdrecht AA, Ossenkoppele GJ. Principles of dendritic cell-based immunotherapy in myeloid leukemia. *Immunobiology* 2006; 211(6-8): 663-676. (VUmc)
912. Westerterp M, Omloo JM, Sloof GW, Hulshof MC, Hoekstra OS, Crezee H, Boellaard R, Vervenne WL, ten Kate FJ, van Lanschot JJ. Monitoring of response to pre-operative chemoradiation in combination with hyperthermia in oesophageal cancer by FDG-PET. *Int J Hyperthermia* 2006; 22(2): 149-160. (AMCVUmc)
913. Westerterp M, Omloo JMT, Sloof GW, Hulshof MCCM, Hoekstra OS, Crezee H, Boellaard R, Vervenne WL, ten Kate FJW, van Lanschot JJB. Monitoring of response to pre-operative chemoradiation in combination with hyperthermia in oesophageal cancer by FDG-PET. *J Clin Gastroenterol* 2006; 40(Suppl 4): S180-ev. (AMC)
914. Westerterp M, van Westreenen HL, Sloof GW, Plukker JTM, van Lanschot JJB. Role of positron emission tomography in the (re-)staging of oesophageal cancer. *Scand J Gastroenterol* 2006; 41(Suppl. 243): 116-122. (AMC)
915. Wiedemann A, Patel JC, Lim J, Tsun A, van Kooyk Y, Caron E. Two distinct cytoplasmic regions of the beta2 integrin chain regulate RhoA function during phagocytosis. *J Cell Biol* 2006; 172(7): 1069-1079. (VUmc)
916. Wieland CW, Kerver ME, Florquin S, Nolte MA, Borst J, van Lier R, van Oers MHJ, van der Poll T. CD27 contributes to the early systemic immune response to Mycobacterium tuberculosis infection but does not affect outcome. *Int Immunol* 2006; 18: 1531-9. (NKI)
917. Wilhelmsen K, Ketema M, Truong H, Sonnenberg A. KASH-domain proteins in nuclear migration, anchorage and other processes. *J Cell Sci* 2006; 119: 5021-9. (NKI)
918. Wilhelmsen K, Litjens SHM, Sonnenberg A. Multiple functions of the integrin $\alpha 6 \beta 4$ in epidermal homeostasis and tumorigenesis. *Mol Cell Biol* 2006; 26: 2877-86. (NKI)
919. Willems AM, Bruynzeel AME, Kedde MA, van Groenigen CJ, Bast A, Van der Vijgh WJ. A phase I study of monohydroxyethylrutoside in healthy volunteers. *Cancer Chemother Pharmacol* 2006; 57(5): 678-684. (VUmc)
920. Willemze R, Meijer CJLM. Classification of cutaneous T-cell lymphoma: from Alibert to WHO-EORTC. *J Cutan Pathol* 2006; 33 Suppl 1: 18-26. (VUmc)
921. Wilting SM, Snijders PJF, Meijer GA, Ylstra B, van den Ijssel PR, Snijders AM, Albertson DG, Coffa J, Schouten JP, van de Wiel MA, Meijer CJLM, Steenbergen RDM. Increased gene copy numbers at chromosome 20q are frequent in both squamous cell carcinomas and adenocarcinomas of the cervix. *J Pathol* 2006; 209(2): 220-230. (VUmc)
922. Wind J, Hofland J, Preckel B, Hollmann MW, Bossuyt PM, Gouma DJ, Berge Henegouwen MI, Fuhring JW, Dejong CH, van Dam RM, Cuesta MA, Noordhuis A, de Jong D, van Zalingen E, Engel AF, Goei TH, de Stoppelaar IE, van Tets WF, van Wagenveld BA, Swart A, van d. Perioperative strategy in colonic surgery. LAParoscopy and/or FAST track multimodal management versus standard care (LAFA trial). *BMC Surg* 2006; 6: 16. (VUmc)
923. Wind J, Polle SW, Fung Kon Jin PHP, Dejong CHC, von Meyenfeldt MF, Ubbink DT, Gouma DJ, Bemelman WA. Systematic review of enhanced recovery programmes in colonic surgery. *Brit J Surg* 2006; 93(7): 800-809. (AMC)
924. Wink MH, Lagerveld BW, Laguna MP, de la Rosette JJMCH, Wijkstra H. Cryotherapy for renal-cell cancer: Diagnosis, treatment, and contrast-enhanced ultrasonography for follow-up. *J Endourol* 2006; 20(7): 456-458. (AMC)
925. Wink MH, Wijkstra H, de la Rosette JJMCH, Grimbergen CA. Ultrasound imaging and contrast agents: A safe alternative to MRI? *Minim Investiv Ther* 2006; 15(2): 93-100. (AMC)
926. Winnepenninckx V, Debiec-Rychter M, Belien JAM, Fiten P, Michiels S, Lazar V, Opdenakker G, Meijer GA, Spatz A, van den Oord JJ. Expression and possible role of hPTTG1/securin in cutaneous malignant melanoma. *Mod Pathol* 2006; 19(9): 1170-1180. (VUmc)
927. Wissink EHJ, Verbrugge I, Vink SR, Schader MB, Schaefer U, Walczak H, Borst J, Verheij M. TRAIL enhances efficacy of radiotherapy in a p53 mutant, Bcl-2 overexpressing lymphoid malignancy. *Radiother Oncol* 2006; 80: 214-22. (NKI)
928. Wittgen BP, Kunst PWA, Perkins WR, Lee JK, Postmus PE. Assessing a system to capture stray aerosol during inhalation of nebulized liposomal cisplatin. *J Aerosol Med* 2006; 19(3): 385-391. (VUmc)
929. Woerdeman LAE, Hage JJ, Smeulders MJC, Rutgers EJT, Van Der Horst CMAM. Skin-sparing mastectomy and immediate breast reconstruction by use of implants: An assessment of risk factors for complications and cancer control in 120 patients. *Plast Reconstr Surg* 2006; 118: 321-30. (NKI)
930. Woerdeman LAE, Kortmann JBJ, Hage JJ. Routine histologic examination of 728 mastectomy

- scars: Did it benefit our patients? *Plast Reconstr Surg* 2006; 118: 1288-92. (NKI)
931. Wolbink GJ, Vis M, Lems WF, Voskuyl AE, de Groot E, Nurmohamed MT, Stapel S, Tak PP, Aarden L, Dijkmans BAC. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. *Arthritis Rheum* 2006; 54(3): 711-715. (VUmc)
932. Wolthaus JWH, Schneider C, Sonke JJ, Van Herk M, Belderbos JSA, Rossi MMG, Lebesque JV, Damen EMF. Mid-ventilation CT scan construction from four-dimensional respiration-correlated CT scans for radiotherapy planning of lung cancer patients. *Int J Radiat Oncol Biol Phys* 2006; 65: 1560-71. (NKI)
933. Wong SL, Morton DL, Thompson JF, Gershenwald JE, Leong SPL, Reintgen DS, Gutman H, Sabel MS, Carlson GW, McMasters KM, Tyler DS, Goydos JS, Eggermont AMM, Nieweg OE, Cosimi AB, Riker AI, Coit DG. Melanoma patients with positive sentinel nodes who did not undergo completion lymphadenectomy: A multi-institutional study. *Ann Surg Oncol* 2006; 13: 809-16. (NKI)
934. Wouters D, Voskuyl AE, Molenaar ET, Dijkmans BAC, Hack CE. Evaluation of classical complement pathway activation in rheumatoid arthritis: measurement of C1q-C4 complexes as novel activation products. *Arthritis Rheum* 2006; 54(4): 1143-1150. (VUmc)
935. Wurdinger T, Verheije MH, van der Aa LM, Bosch BJ, de Haan CA, van Beusechem VW, Gerritsen WR, Rottier PJ. Antibody-mediated targeting of viral vectors to the Fc receptor expressed on acute myeloid leukemia cells. *Leukemia* 2006; 20(12): 2182-2184. (VUmc)
936. Ye H, Gong L, Liu H, Ruskone-Fourmesttraux A, de Jong D, Pileri S, Thiede C, Lavergne A, Boot H, Caletti G, Wundisch T, Molina T, Taal BG, Elena S, Neubauer A, MacLennan KA, Siebert R, Remstein ED, Dogan A, Du MQ. Strong BCL10 nuclear expression identifies gastric MALT lymphomas that do not respond to H pylori eradication [9]. *Gut* 2006; 55: 137-9. (NKI)
937. Ylstra B, Carvalho B, Brakenhoff RH, Meijer GA. BAC to the future! or oligonucleotides: a perspective for micro array comparative genomic hybridization (array CGH). *Nucleic Acids Res* 2006; 34(2): 445-450. (VUmc)
938. Zandvliet AS, Copalu W, Schellens JHM, Beijnen JH, Huitema ADR. Saturable binding of indisulam to plasma proteins and distribution to human erythrocytes. *Drug Metab Dispos* 2006; 34: 1041-6. (NKI)
939. Zandvliet AS, Schellens JHM, Copalu W, Beijnen JH, Huitema ADR. A semi-physiological population pharmacokinetic model describing the non-linear disposition of indisulam. *J Pharmacokinet Pharmacodyn* 2006; 33: 543-70. (NKI)
940. Zandvoort A, van der Geld YM, Jonker MR, Noordhoek JA, Vos JTWM, Wesseling J, Kauffman HF, Timens W, Postma DS. High ICAM-1 gene expression in pulmonary fibroblasts of COPD patients: a reflection of an enhanced immunological function. *Eur Respir J* 2006; 28: 113-22. (NKI)
941. Zareie M, Fabbrini P, Hekking LH, Keuning ED, Ter Wee PM, Beelen RHJ, van den Born J. Novel role for mast cells in omental tissue remodeling and cell recruitment in experimental peritoneal dialysis. *J Am Soc Nephrol* 2006; 17(12): 3447-3457. (VUmc)
942. Zareie M, Keuning ED, Ter Wee PM, Schalkwijk CG, Beelen RHJ, van den Born J. Improved biocompatibility of bicarbonate/lactate-buffered PDF is not related to pH. *Nephrol Dial Transplant* 2006; 21(1): 208-216. (VUmc)
943. Zelcer N, van de Wetering K, de Waart R, Scheffer GL, Marschall HU, Wielinga PR, Kuil A, Kunne C, Smith A, Valk M, Wijnholds J, Elferink RO, Borst P. Mice lacking Mrp3 (Abcc3) have normal bile salt transport, but altered hepatic transport of endogenous glucuronides. *J Hepatol* 2006; 44(4): 768-775. (AMC/NKI)
944. Zhang W, Shannon WD, Duncan J, Scheffer GL, Scheper RJ, McLeod HL. Expression of drug pathway proteins is independent of tumour type. *J Pathol* 2006; 209(2): 213-219. (VUmc)
945. Zienolddiny S, Ryberg D, Svendsrud DH, Eilertsen E, Skaug V, Hewer A, Phillips DH, te Riele H, Haugen A. Msh2 deficiency increases susceptibility to benzo[a]pyrene-induced lymphomagenesis. *Int J Cancer* 2006; 118: 2899-902. (NKI)
946. Zijlstra JM, Lindauer-van der Werf G, Hoekstra OS, Hooft L, Riphagen II, Huijgens PC. 18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: a systematic review. *Haematologica* 2006; 91(4): 522-529. (VUmc)
947. Zuur CL, Simis YJW, Lansdaal PEM, Rasch CRN, Tange RA, Balm AJM, Dreschler WA. Audiometric patterns in ototoxicity of intra-arterial cisplatin chemoradiation in patients with locally advanced head and neck cancer. *Audiol Neurootol* 2006; 11: 318-30. (NKI)
948. Zuur JK, Muller SH, De Jongh FHC, Van Zandwijk N, Hilgers FJM. The physiological rationale of heat and moisture exchangers in post-laryngectomy pulmonary rehabilitation: A review. *Eur Arch Otorhinolaryngol* 2006; 263: 1-8. (NKI)
949. Zwaan CM, den Boer ML, Kazemier KM, Hahlen K, Loonen AH, Reinhardt D, Creutzig U, Kaspers GJL, Pieters R. Does modulation of P-glycoprotein have clinical relevance in pediatric acute myeloid leukemia?. *Blood* 2006; 107(12): 4975-4976. (VUmc)
950. Zwijnenburg PJG, van der Poll T, Roord JJ, van Furth AM. Chemotactic factors in cerebrospinal

